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Résume 
 
Contexte - La prévalence de la maladie de Crohn (MC), une maladie inflammatoire chronique du tube 
digestif, chez les enfants canadiens se situe parmi les plus élevées au monde. Les interactions entre les 
réponses immunes innées et acquises aux microbes de l'hôte pourraient être à la base de la transition de 
l’inflammation physiologique à une inflammation pathologique. Le leucotriène B4 (LTB4) est un modulateur 
clé de l'inflammation et a été associé à la MC. Nous avons postulé que les principaux gènes impliqués dans 
la voie métabolique du LTB4 pourrait conférer une susceptibilité accrue à l'apparition précoce de la MC. 
Dans cette étude, nous avons exploré les associations potentielles entre les variantes de l'ADN des gènes 
ALOX5 et CYP4F2 et la survenue précoce de la MC. Nous avons également examiné si les gènes 
sélectionnés montraient des effets parent-d'origine, influençaient les phénotypes cliniques de la MC et s'il 
existait des interactions gène-gène qui modifieraient la susceptibilité à développer la MC chez l’enfant.  
Méthodes – Dans le cadre d’une étude de cas-parents et de cas-témoins, des cas confirmés, leurs parents 
et des contrôles ont été recrutés à partir de trois cliniques de gastro-entérologie à travers le Canada. Les 
associations entre les polymorphismes de remplacement d'un nucléotide simple (SNP) dans les gènes 
CYP4F2 et ALOX5 ont été examinées. Les associations allélique et génotypiques ont été examinées à  
partir d’une analyse du génotype conditionnel à la parenté (CPG) pour le résultats cas-parents et à l’aide de 
table de contingence et de régression logistique pour les données de cas-contrôles. Les interactions gène-
gène ont été explorées à l'aide de méthodes de réduction multi-factorielles de dimensionnalité (MDR).  
Résultats – L’étude de cas-parents a été menée sur 160 trios. L’analyse CPG pour 14 tag-SNP (10 dans la 
CYP4F2 et 4 dans le gène ALOX5) a révélé la présence d’associations alléliques ou génotypique 
significatives entre 3 tag-SNP dans le gène CYP4F2 (rs1272, p = 0,04, rs3093158, p = 0.00003, et 
rs3093145, p = 0,02). Aucune association avec les SNPs de ALOX5 n’a pu être démontrée. L’analyse de 
l’haplotype de CYP4F2 a montré d'importantes associations avec la MC (test omnibus p = 0,035). Deux 
haplotypes (GAGTTCGTAA, p = 0,05; GGCCTCGTCG, p = 0,001) montraient des signes d'association avec 
la MC. Aucun effet parent-d'origine n’a été observé. Les tentatives de réplication pour trois SNPs du gene 
CYP4F2 dans l'étude cas-témoins comportant 225 cas de MC et 330 contrôles suggèrent l’association dans 
un de ceux-ci (rs3093158, valeur non-corrigée de p du test unilatéral = 0,03 ; valeur corrigée de p = 0.09). 
La combinaison des ces deux études a révélé des interactions significatives entre les gènes CYP4F2, ALOX 
et NOD2. Nous n’avons pu mettre en évidence aucune interaction gène-sexe, de même qu’aucun  gène 
associé aux phénotypes cliniques de la MC n’a pu être identifié. 
Conclusions - Notre étude suggère que la CYP4F2, un membre clé de la voie métabolique LTB4 est un 
gène candidat potentiel pour MC. Nous avons également pu mettre en évidence que les interactions entre 
les gènes de l'immunité adaptative (CYP4F2 et ALOX5) et les gènes de l'immunité innée (NOD2)  modifient 
les risques de MC chez les enfants. D'autres études sur des cohortes plus importantes sont nécessaires 
pour confirmer ces conclusions.  
 
Mots-clés: Maladie de Crohn (MC), survenue précoce, gène candidat, CYP4F2, ALOX5, voie de la 5-
lipoxygénase (5-LO), leucotriène B4 (LTB4), polymorphismes de remplacement d'un nucléotide simple 
(SNP). 
 
Abstract 
Background - The rates of Crohn’s disease (CD) a chronic inflammatory disease of the gastrointestinal 
tract, among Canadian children are the world’s highest. Interactions between the host microbial–
innate-immune-responses are thought to underplay transition from physiological to pathological 
inflammation. Leukotriene B4 (LTB4) is a key modulator of inflammation and has been shown to be 
associated with CD. We postulated that key genes involved in the LTB4 metabolic pathway could 
confer susceptibility for early-onset CD. In this study we implemented a candidate gene approach to 
test for associations between DNA variants in the ALOX5 and CYP4F2 genes and early-onset of CD. 
We also explored whether the selected genes demonstrated parent-of-origin effects, influenced CD 
clinical phenotypes and whether there were gender-gene and gene-gene interactions that determined 
CD susceptibility.  Methods – The study consisted of an exploratory phase (case-parent design) 
followed by a replication phase (case-control design). Confirmed cases, parents and controls were 
recruited from three tertiary gastroenterology clinics across Canada. Associations between tag-single 
nucleotide polymorphisms in the CYP4F2 and ALOX5 genes were examined. Allelic and/or genotype 
associations were examined using conditional on parental genotype (CPG) analysis for the case-
parent data and contingency table and logistic regression for the case-control data. Gene-gene 
interactions were explored using multi-factor dimensionality reduction (MDR) methods. Results – The 
first phase of the study was based on 160 trios (case-parent design). CPG analysis for 14 tag-SNPs 
(i.e. 10 in the CYP4F2 and 4 in the ALOX5 gene, respectively) revealed significant allelic or genotypic 
associations between 3 tag-SNPs in the CYP4F2 gene (rs1272, p=0.04, rs3093158, p=0.00003, and 
rs3093145, p=0.02). No associations with ALOX5 tag-SNPs were evident. CYP4F2-haplotype analysis 
showed significant associations with CD (omnibus test p-value=0.035). Two specific haplotypes 
(GAGTTCGTAA, p=0.05; GGCCTCGTCG, p=0.001) showed evidence for association with CD. No 
parent-of-origin effects were observed. The second phase of the study retested the three CYP4F2 
SNPs that showed association in the first stage and was based on 223 CD cases and 330 controls. 
Some indications of association with one SNP i.e. rs3093158 were present (genotypic uncorrected 1-
sided p-value=0.03); however this genotype association did not withstand correction. Combining cases 
from the two phases of the study revealed significant interactions between the CYP4F2, ALOX and 
NOD2 genes. No gene-gender interactions were obvious nor were the study genes associated with 
specific clinical phenotypes of CD. Conclusions - Our study suggests that the CYP4F2, a key member 
of the LTB4 metabolic pathway is a potential candidate gene for CD. Furthermore there was evidence 
that interactions between adaptive immunity genes (CYP4F2 and ALOX5) and innate immunity genes 
(NOD2) genes modify risk for CD in children. Further studies on larger cohorts are required to confirm 
these findings.  
 
Keywords: Crohn’s Disease (CD), early-onset, candidate gene, CYP4F2, ALOX5, 5-lipoxygenase (5-
LO) pathway, leukotriene B4 (LTB4), tag-SNP, case-parent design, case-control design. 
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Section A. Introduction and Background 
 
The chronic inflammatory bowel diseases (IBD) are now common causes of 
gastrointestinal illness in developed countries. Recent population-based studies of disease 
prevalence suggest that as many as 0.5% of the Canadian population may be affected by 
chronic IBD [1]. Although mortality associated with IBD is uncommon, the diseases 
continue to have a high morbidity, particularly in children, in whom growth, psychosocial 
wellbeing and implicitly, quality of life are adversely influenced. 
A.1. Crohn’s Disease (CD)  
Crohn's disease (CD) is a type of IBD characterized by chronic, relapsing 
inflammation of the gastrointestinal tract (GIT). First termed “regional ileitis” due to its 
predilection for the terminal small bowel [2], it is now well known that CD can affect any 
part of the GIT – Figure 1*. 
A.1.1. Epidemiology of CD 
Epidemiologic studies show that the incidence and prevalence of CD varies 
significantly depending on geographic location and racial or ethnic background. Over the 
past few decades, incidence of CD has increased in the Western populations, especially in 
North-Americans as well as in populations of Northern European and Anglo-Saxon 
ethnic derivation, and seems to be on the rise in populations of developing countries, such 
as African populations [3]. Within North-America, as well as within Europe, a North-to-
South gradient in the distribution of CD has been observed [4, 5]. Other studies however 
do not support this north-to-south gradient [6]. Although still a rare disease outside 
Europe and North-America, the incidence of CD in developing countries is also on the 
rise, e.g. Asia [7]. CD occurs about equally in both sexes and is more common among 
Ashkenazi Jews [8].  
Till recently, CD was considered an adult-age condition characterized by 2 peaks: 
one between 25-40 years of age and a second one after 55 years of age [9]. In the last 
                                                 
* Figures and tables are presented at the end of each section. 
decade, however, it is becoming more and more apparent that CD incidence and 
prevalence among children and young adults is on the rise.  
As for the social determinants of adult-onset CD, it has been shown that there is 
an increased risk for developing CD in urban compared to rural areas, in higher 
socioeconomic classes, and in populations migrating from low-risk to high-risk 
geographical areas. Interestingly, the observed geographical trends seem thus, to point at 
environmental factors probably associated with adoption of a Western lifestyle and 
improved socioeconomic circumstances [10]. However, in the case of early-onset of 
disease, socio-economic factors (such as parental education and family income) have not 
been shown to be associated with  CD [11]. 
Two population-based studies (i.e. one provincial and one nation-wide) conducted 
by Bernstein et al. revealed that over the last two decades Canada has one of the highest 
CD incidence and prevalence rates, i.e. an estimated 13.4/100,000 incident cases across 
Canada and 234/100,000 prevalent cases (year 2000), equivalent to a total of 170,000 
existing cases (or approximately 1 in 180) (0.5% of the Canadian population). In 
addition, regional, age- and gender-specific differences have been noted. While the first 
study, restricted to the province of Manitoba, estimated the overall incidence and point 
prevalence (year 1994) for CD at around 14.6/105 and 198.5/105, respectively; the nation-
wide study reveals, in addition to a slight increase in these rates in Manitoba (15.4/105 
and 271.4/105 - year 2000, respectively), also a east-west gradient, with the highest rates 
recorded in Nova Scotia, 20.2/105 and 318.5/105 (year 2000), respectively (Figures 
2a,b). These regional differences were maintained by sex, age group, and urban/rural 
residence. In both studies, there was a sharp peak in the incidence rate among those aged 
20-29 years (28.4/105), followed by those aged 30-39 (17.6/105) (Figure 2a). The peak 
prevalence was noted in the age group 30-39 years (around 310/105), which is one decade 
later than the peak incidence (Figure 2b). The overall incidence rate for CD for children 
less than 20 years of age was 8.3/105. Overall, the incidence of CD was higher among 
females for all ages, except for those less than 20 years, than among males, by a factor of 
20-30% with roughly equal distribution in the urban versus the rural areas.   
In a pediatric population, similar incidence rates among girls (i.e. 8.0/105) 
compared with boys (i.e. 7.5/105) were noted; however, with a higher CD prevalence rate 
among boys (i.e. 49.6/105) when compared with girls (i.e. 43.8/105). The overall urban to 
rural incidence ratio, adjusted for age, gender, and province was 1.05 [1, 9]. 
Overall these findings reveal: (i) an increase of CD burden over the past two 
decades, and especially among children and teenagers, with incidence rates approaching 
that in adults; (ii) a geographic gradient; and, (iii) a female preponderance in the adult 
population versus a smaller male preponderance in the pediatric population.   
A.1.2. Demographics of CD in children 
As indicated above, CD incidence and prevalence among children and young 
adults appears to be on the rise. In addition to the Canadian studies, ages at diagnosis and 
gender of children with CD have been characterized in a number of recent population-
based epidemiologic studies. A recent study notes that 4% of the pediatric cases of CD 
are presenting before the age of 5 [12]. Another population-based study from Denmark 
approximates the mean age at diagnosis at around 12 years (range 0-14 years), indicating 
a steep increase in incidence around puberty [13]. However, further evidence linking 
factors implicated in pubertal changes to inflammation and CD development is still 
lacking. Unlike the adult cases, recent studies conducted in the United States, Canada, 
and the UK and restricted to pediatric-onset CD, document a male-to-female 
preponderance [1, 14, 15]. Although currently there is no convincing evidence that 
gender plays a role in the etiology or clinical outcome in CD [16], this contrasting higher 
male-to-female incidence of CD in the pediatric age group with a reversal of incidence 
and prevalence of CD in adults is intriguing.  
A.1.3. Clinical features of CD in children  
Early-onset CD is of important concern, because it presents numerous challenges 
and represents a particular burden. In comparison to adult patients, pediatric CD patients 
are more often closer to disease initiation and earlier in the process of chronic intestinal 
inflammation. More importantly, during the disease course affected children experience 
growth failure, the severity of the disease is greater and the frequency of complications is 
higher vis-à-vis adults. In particular, children with CD are more susceptible to relapses, 
undergo more frequent surgeries, are at high risk for growth retardation and pubertal 
delay, and thus suffer significant psychological morbidity [17]. 
A.1.3.1. Localization  
Overall CD is characterized by a pan-enteric inflammatory process. All the gut 
wall layers can be inflamed and strictures and/or fistulae or abscesses can develop. 
Recent reports have shown that patients with early-onset CD may have specific 
phenotypes that differ from adult onset CD, thus suggesting that the pathogenesis of 
pediatric CD and adult CD may differ [18]. The most consistent difference in phenotype 
in children versus adults is in disease distribution. These reports suggest that compared to 
adult CD, first-decade pediatric onset CD is associated with more colitis and less ileitis 
[19-23]. Of particular interest is the subset of patients with a very early onset IBD (onset 
before the age of 8 year). These patients often present with rectal bleeding and have more 
isolated colonic involvement [18, 21, 24]. In a large study of nearly 1,400 North 
American early-onset patients, Heyman et al.  demonstrated that a colonic predominant 
phenotype exists in CD diagnosed under the age of 8 years [21]. Paul et al. studied 413 
pediatric IBD patients and also demonstrated a greater tendency for very young patients 
to present with colonic disease [24]. Finally, a recent study by van Limbergen et al on 
276 patients with childhood-onset CD also points out the colonic predisposition in very 
young children [18]. Children with CD also have less ileal involvement as compared to 
adult-onset CD. The reasons for these phenotype differences are presently unclear but 
may be a reflection of differing genetic susceptibilities. Evidence for the latter comes 
from investigations that have shown that in early onset CD, those children who do not 
possess the NOD2/CARD15 disease conferring variants are more likely to have colonic 
disease [25]. Certainly genotype-phenotype investigations need to be further explored. 
A.1.3.2. Symptoms and signs 
The clinical presentation of CD is largely dependent on disease location and can 
include diarrhea, abdominal pain, fever, clinical signs of bowel obstruction, as well as 
passage of blood or mucus or both. The constellation of abdominal pain, diarrhea, poor 
appetite, and weight loss constitutes the classic presentation of CD in any age group [26]. 
Certain features however are unique to pediatric CD, as compared with adult onset of 
disease [16]. For instance, one important characteristic in children with CD is growth 
failure that can precede the development of intestinal symptoms and dominate the clinical 
presentation [27]. Impairment of linear growth can be present at diagnosis in up to 10-
40% of affected children with CD. Several interrelated factors may contribute to growth 
failure in CD and some of these factors may underlie important pathogenesis 
mechanisms, as shown by the fact that further growth development is best achieved 
through control of intestinal inflammation [28]. Another more recent hypothesis suggests 
that immunity dysregulation directly determined by gut inflammation may affect growth. 
In particular, the direct growth-inhibiting effects of pro-inflammatory cytokines (i.e. 
small signalling proteins which mediate and regulate immunity), which are released from 
the inflamed intestine are incriminated [29].  
A.1.3.3. Disease course 
The natural history of CD is characterized by remission and relapses and 
occurrence of complications such as fistulas, abscesses, and strictures, the pathological 
process oft requiring surgical intervention. Furthermore, disease behaviour often changes 
during disease course. At diagnosis most patients have inflammatory disease (ranging 
from 70-90%) that can progress to stricturing (17%) and/or penetrating disease 
(characterized by fistulas and/or abscesses) (13%) [30] during disease course. 
A.1.3.4. Disease classification 
Patients with CD may show great variability in their disease phenotype (i.e. 
phenotypic heterogeneity) and response to treatment. It has been hypothesized that the 
phenotypic differences may reflect underlying differences in immunological processes 
between the different clinical entities [31]. In order to standardize the classification of the 
varying clinical phenotypes, the Vienna classification [32], and a more recent and refined 
classification, the Montreal Classification [33], have been promulgated. In brief, the 
Vienna classification of CD considered age of onset, disease location, and disease 
behaviour as the predominant phenotypic elements. The Montreal revision of the Vienna 
classification has not changed the three predominant parameters of age at diagnosis, 
location, and behaviour, but refinements based on epidemiologic and genetic 
observations within each of these categories have been made – Table I†. 
                                                 
† Figures and tables are presented at the end of each section. 
Despite important advances in diagnosis and treatment in recent years, the underlying 
cause of the disease remains unclear. As a result, the available therapies are not curative 
and may pose a substantial risk of side effects. Furthermore, because of the increasing 
burden of disease, demographic and clinical specificities, limited knowledge on whether 
potential risk factors contributing to adult-onset CD similarly predisposes to early-onset 
CD, investigating the etiopathogenesis of pediatric onset of CD is a public health priority.   
A.2. Genetic epidemiology of CD 
It is generally accepted that CD results from a complex interplay between 
environmental and genetic risk factors. Observations that CD incidence has increased 
markedly over the past half century, argues in favor of recent, unidentified, 
environmental contributions. Equally important, regional differences, twin studies and the 
familial aggregations of CD strongly point towards genetic risks. Furthermore, recent 
data suggests now that not only susceptibility, but also disease location, behavior and 
response to therapy may have a strong genetic influence [34]. Given the complex nature 
of the disease, i.e. the presence of phenomena such as incomplete penetrance, 
phenocopies, and genetic heterogeneity, it is more than likely that multiple genes acting 
in combination with environmental factors would enhance susceptibility for CD. CD is 
thus considered a multifactorial disease, with genetic, immunologic and environmental 
factors playing important roles in the development of the disease. This also means that 
CD is less likely to be due to a major gene effect, but rather due to multiple genes 
contributing modest risks to disease development.  
Observations such as familial aggregation patterns, concordance rates in twin 
pairs and sibling pairs as well as ethnic differences have provided the impetus to study 
the genetic contribution in CD. More so, recent studies suggest that genetic factors may 
be of more importance in early-onset CD vis-à-vis the adult form [35].  
A.2.1. Familial aggregation and ethnic differences 
In pediatric CD the greatest risk factor for developing the disease is having other 
affected family members [12]. This observation was illustrated for the first time in a 
cohort study by Orholm et al. who showed that when compared with the general 
population, the first-degree relatives of a CD patient had a 10-fold increase in the risk of 
having the same disease as the proband [36]. This translates into an estimate of 5.2% of  
first degree relatives of non-Jewish probands to develop CD during their life time [37]. In 
addition, it seems that up to 75% of multiply affected families with CD are concordant 
for disease type [12].  
In terms of ethnicity, it appears that while the highest prevalence is undoubtedly 
associated with Jewish ancestry [4, 37, 38], Asian Americans, Americans of Hispanic 
background, and aboriginal North Americans are less likely to develop CD [39]. The 
latter is confirmed by a study that reveals that aboriginals residing in Manitoba, Canada, 
are less likely to develop CD [40]. Nonetheless, other studies of migrant populations 
suggest that ethnic and racial differences may be more related to lifestyle and 
environmental influences than true genetic differences. For instance, until recently, CD 
occurrence was thought to be rare in the Indian subcontinent. Once these populations 
become exposed to a different environment and lifestyle, such as moving to the United 
Kingdom or Singapore, South Asians and their offspring are at increased risk of CD 
relative to British Caucasians [41] or to ethnic Chinese, respectively [42].  
A.2.2. Twin studies 
Twin studies have been a powerful tool in the identification of the different 
contributions of genes and environment to CD pathogenesis. This is because twins are 
generally brought up in the same environment, so differences in disease incidence 
between mono- (MZ) and dizygotic (DZ) pairs are used to estimate the genetic 
contribution to a phenotype. Although the true rate of twin concordance could only be 
estimated by large population studies, the early literature contained many case series 
reports of CD concordance in MZ twin pairs. These reports however were probably 
subject to reporting bias, with concordant pairs more likely to be documented, reported 
and published and thus likely to overestimate the genetic contribution to CD. A summary 
of all these early CD case reports found 85% of pairs concordant for CD [43].  
In Europe, Tysk et al. [44] published the first population survey of twins and 
concordance for CD in 1988. The cases were selected from the Swedish twin registry (i.e. 
about 25,000 pairs of twins) and matched with hospital inpatient records; and 80 twin 
pairs suffering from IBD were identified (18 MZ twin pairs in the CD disease group). 
The original cohort of twins were followed up 15 years later and three further cases of 
CD were diagnosed [45]. All of these ‘new’ cases had been symptomatic at the time of 
the original survey but did not fulfil the diagnostic criteria. In the MZ - CD concordant 
pairs the authors were able to demonstrate, using the Vienna classification that 77% of 
pairs were concordant for disease location and that 67% of pairs were concordant for age 
at diagnosis within 2 years of each other. There was no significant concordance for 
disease behaviour or extent. A second population study was performed in Denmark with 
similar results to the Swedish study.  Orholm et al studied 103 twin pairs—again from a 
national registry—using a postal questionnaire to identify affected twin pairs. Two-fifths 
of CD-concordant pairs were concordant for disease location and two-fifths were 
diagnosed within 2 years of each other. The authors were able to calculate relative risks 
in this study and accordingly, a MZ twin of a CD proband has a relative risk for 
developing CD of 667 [46]. The third large published study was undertaken in the UK by 
Thompson et al. and examined 143 twin pairs. In this study, patients from a CD support 
group—the National Association for Colitis and Crohn's Disease—were sent a 
questionnaire to identify CD twin pairs. Unlike the other two studies, the concordance 
rate for CD was much lower (i.e. 20%, possible due to the selective nature of the study) 
than that of the two population studies [47]. However, a later extension of this study 
population to a total of 249 twin pairs did show similar concordance rates to the two 
population studies [48].  
The individual concordance rates for the twin pairs from all three studies are 
shown in Table II. The combined results of the three studies reveal a MZ twin CD 
concordance rate of approximately 50% and less than 10% among DZ twins [49].  
 In addition, closer examination of the phenotypic characteristics of the Swedish 
cohort provided some evidence that in CD even the disease phenotype may be genetically 
determined. Thus, in the monozygotic CD concordant pairs 7/9 were concordant for 
disease location, as determined by Vienna classification, and 6/9 were diagnosed within 2  
years of each other. There was no significant concordance for disease behaviour, i.e. 
fistulizing or stricturing type, or extent of the disease [45]. 
Overall the markedly higher MZ twin concordance rates, as compared with the 
DZ twins, demonstrates that susceptibility to IBD, particularly CD, is determined to a 
significant degree by genetic factors. Nonetheless, these values also show that MZ 
concordance was incomplete as the majority of MZ twins did not both have CD.  
This suggests that significant non-genetic factors, primarily environmental, are 
required to “trigger” CD in a genetically susceptible host. 
A.2.3. Parent-of-origin effects in CD 
Observed phenomena in CD patients, such as familial aggregation [12, 36], 
increased prevalence among certain ethnic groups (e.g. Ashkenazi Jews) [4, 37, 38], and 
high concordance rate among identical twins [49], are highly suggestive of a genetic 
contribution to this disease. However, no simple genetic models are able to account for 
the familial patterns of disease. In addition to mutant genes and a hazardous environment, 
an interesting hypothesis that may be of relevancy in understanding the etiopathogenesis 
of CD is based on a phenomenon called genomic imprinting. Genomic imprinting can be 
viewed as an epigenetic system‡, in which the activity of a gene is reversibly modified 
(“silenced”) depending on the gender of the parent that transmits it [50]. This may lead 
further to unequal expression from the maternal and paternal alleles of a diploid locus. 
The mechanisms for imprinting are still incompletely defined, but they involve epigenetic 
modifications that are laid down in the parental germ cells and consist in reversible 
changes in DNA methylation and/or chromatin structure [51]. In addition to genetic and 
non-genetic studies, there is accumulating evidence that genomic imprinting (or parent-
of-origin effects) may play a role in the ethiopathogenesis of many complex diseases. 
Specifically, the preferential transmission of disease from parents of one sex to children 
has been previously observed in a number of diseases, such as Prader-Willi/Angelman 
syndromes, Alzheimer disease, autism, bipolar disorder, diabetes, obesity; as well as a 
number of cancers: bladder, breast, cervical, colorectal, esophageal, hepatocellular, lung, 
mesothelioma, ovarian, prostate, testicular, and leukemia [52, 53]. While the epigenetic 
system that is causing the genetic imprinting is difficult to study, it is generally accepted 
that epigenetic phenomena are at play in the following instances: (i) there is evidence for 
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significant heritability, (ii) most genetic linkage and association studies are negative, (iii) 
there is evidence of environmental determinism, and (iv) there is evidence for change in 
incidence over time [54].  
As it applies to CD, the parent-of-origin hypothesis has been put forward based on 
a number of clinical and molecular findings in CD studies such as: (i) the maternal effect 
in transmission of CD from affected parent to offspring; (ii) parental differences in the 
degree of genetic anticipation; and, (iii) discordance of monozygotic twins affected by 
CD.  This evidence is suggestive that inherited and/or acquired epigenetic defects, or 
epimutations, may be of aetiological and pathogenic importance in CD [55].  
Clinical evidence for a parent-of-origin effect was recently shown in the analysis 
of 135 families in which both a parent and an offspring had CD. In the majority of 
families the transmission of susceptibility to disease occurred from mother to child, and 
the difference between maternal versus paternal transmissions was highly significant 
(p=0.00001) [56]. Interestingly, the maternal effect was observed only among non-Jewish 
pairs with CD in which affected mother-offspring pairs comprised 85% of the sample. 
This maternal effect is suggestive of several possibilities, such as mitochondrial 
transmission, X linked effects, and genomic imprinting. However, in the context of CD – 
viz. delayed onset (i.e. post-neonatal), remissions and relapses of this disease, a defect in 
mitochondrial genome is not likely to be the main cause of the maternal effect. X linked 
factors are of interest as an association of IBD with Turner’s syndrome (i.e. a X 
monosomy) has been identified [57, 58], and evidence of CD linkage to markers on the X 
chromosome was recently detected [59]. The third possibility is genomic imprinting, or, 
as it has been explained, the differential expression of homologous genes depending on 
their parental origin.  
Parent-of-origin effects were also detected in genetic anticipation studies of CD. 
Genetic anticipation is a biological phenomenon that exhibits an earlier age of disease 
onset and increased severity in affected offspring in comparison with their affected 
parents [60]. Anticipation studies, however, are not straightforward because a number of 
ascertainment biases may occur, and it has been shown that the rate of false positives can 
be very high if inappropriate sample collection criteria are used [61, 62]. One way for 
differentiating between artefactual anticipation and a genuine effect uses the comparison 
of parental effects on the degree of anticipation [63]. The rationale behind this idea is that 
if anticipation occurs as a consequence of ascertainment bias, it would be equally 
apparent in father-offspring and mother-offspring pairs, while anticipation confined to 
parents of one sex indicates some specific genetic or epigenetic event. This approach was 
applied in a sample of 61 parent-offspring pairs, both with CD, and it was found that the 
degree of anticipation was significantly greater for father-child pairs [20.6 (3.2) years, 
n=17] than for mother-child pairs [11.7 (2.1) years, n=44] [64]. Parental effects were also 
detected for severity where disease was more severe in the younger generation when the 
affected parent was the father (13 of 16 pairs) and not the mother (two of 11 pairs) [65]. 
Several other studies of genetic anticipation were less conclusive, with the trend towards 
higher degrees of anticipation in transmitting fathers [66] and transmitting mothers [67]. 
Discrepancies between the studies are not surprising given the differences in 
ascertainment criteria, ethnic background of CD, and the high degree of heterogeneity of 
CD.  
As mentioned previously, twin studies detected a significantly higher concordance 
rate among MZ twins for CD compared with DZ twins [47]. Nonetheless, the combined 
concordance rate for monozygotic twins was relatively low (less than 50%) [49]. It is 
thought that environmental factors may cause phenotypic discordance of MZ twins as 
these twins are considered to be genetically identical. However, it would be very difficult 
to assess the large variety of environmental factors that may play a role in the 
pathogenesis of CD for each specific twin affected with CD. In this situation, epigenetic 
developments may be of interest to study. To some extent the epigenetic status of a gene 
represents an interface between the DNA sequence and the intra- and extracellular 
environment. DNA modification is subject to change due to the influence of cellular-
environmental factors, and therefore epigenetic status represents a combination of both 
inherited and acquired traits. Thus, MZ twins, although carrying identical or very similar 
DNA sequences, may be very different from an epigenetic point of view [68]. 
Taken together, these findings suggest that parent-of-origin effects may be at play 
in CD. Exploring such effects in CD may further our understanding of the pathogenesis 
of this complex disease. 
 
Considerable progress has been made in in the last decade in the identification 
and characterization of genes, as well as in understanding their functional role that 
implicates these genes in the etiology and pathophysiology of CD. Several approaches 
are presently used in the search for genetic susceptibility genes in CD: linkage studies, 
candidate gene association studies and genome-wide association studies (GWAS). In the 
next section we highlight the major findings based on these approaches. 
A.2.4. Linkage studies 
The principle of genetic linkage studies is to analyze families containing more 
than one affected member for the purposes of identifying chromosomal regions shared in 
excess of statistical expectation. A measurement of familial disease clustering, often used 
to estimate the number of families required to identify genes by linkage mapping, is 
lambda, the ratio of recurrence risk in siblings compared with population disease 
prevalence. For CD, a British report estimated lambda as high as 36.5; a high value when 
compared to other complex diseases (e.g. type II diabetes – 15) [69]. This observation 
suggests that CD may be controlled by relatively stronger genetic factors then other 
complex entities.  
Of particular relevance are the genetic linkage studies that led to the identification 
of  NOD2/CARD15 gene on chromosome 16q12 (IBD1) [70]. In brief, Hugot and 
colleagues conducted a linkage study of affected sibling pairs and identified an area of 
interest located in the peri-centromeric region of chromosome 16 (i.e. 16cen). Significant 
linkage to this chromosomic region, further designated as IBD1, translates into 62% of 
CD sibling pairs co-inheriting the same grandparental copy of IBD1 [71]. This also 
correlates with a relative sibling risk of 1.7 [72]. This degree of sharing was significantly 
greater than that expected, and therefore this finding was suggestive that the IBD1 region 
contained one or more CD predisposing genes. Further replication studies in Australia 
[73] and recommendations from the International IBD Genetics Consortium [71] made 
IBD1 a promising region for potential CD predisposing genes. This further led to the 
discovery, by both linkage disequilibrium fine mapping [70] and a focused candidate 
gene approach [74], of CD predisposing mutations within the NOD2/CARD15 gene 
located at chromosome 16, i.e. 16q12. The sequence of genetic discoveries from 
identifying an otherwise unknown CD predisposing locus, IBD1, to identifying 
NOD2/CARD15 CD predisposing mutations represented a major landmark for 
establishing an initial etiopathogenesis for an otherwise enigmatic immune mediated 
disease, as well as one of the first successes demonstrating the feasibility of positional 
identification of disease genes for a common complex genetic disorder. Identification and 
confirmation of the IBD1 locus has provided a strong impetus to search for other CD 
susceptibility loci by means of linkage analyses. In summary, genome wide linkage 
studies have now identified nine IBD designated loci (IBD1-9) on chromosomes 16q 
[72], 12 [72], 6p [59, 75], 14q [76, 77], 5q [75, 76, 78], 19 [75], 1p [79], 16p (overlap 
with IBD1)[80], and 3p [72] with specific identifiable CD risk factors [72, 77, 81]. In 
particular, risk alleles/haplotypes have been defined for the IBD1 (NOD2/CARD15) [70, 
82], IBD3 (HLA) [83] and IBD5 (5q cytokine cluster) [78]. Several other regions show 
great promise for containing additional IBD loci, particularly chromosomes 2q, 3q, 4q, 7, 
11p, and Xp each with suggestive evidence of linkage [84].  
These findings are summarized in Figure 3.  
A.2.5. Candidate gene studies in CD 
Most genetic studies in CD have concentrated on a candidate-gene approach. In 
candidate-gene studies, the frequency of allelic variants of candidate genes – usually 
variants encoding proteins believed to be involved in pathogenesis – are compared 
between cases and matched controls (case control analysis), or by investigating intra-
familial association/linkage (family-based studies). A number of candidate genes have 
been explored, but few have been validated and/or replicated. Of relevance to CD is the 
study by Ogura et al. who conducted a candidate gene approach and succeeded in 
revealing the role of NOD2/CARD15 gene in susceptibility to CD [74], at the very same 
time as Hugot et al. in France was publishing his linkage findings [70]. Research around 
NOD2/CARD15 gene is based on the assumption that the gene product of this gene, i.e. 
CARD15, is involved in the regulation of nuclear factor kappa-B (NF-kappaB) activation 
in response to bacterial endotoxins and hence may alter signalling pathways of the innate 
immune system [85]. Altered immune regulation is thus an important feature in the 
incriminated pathology of CD and genes thought to play a role in the regulation of innate 
immune response, mucosal integrity and apoptosis became subsequently primary 
candidates in the search for susceptibility genes in CD. Candidate gene studies have 
further led to the identification of several other susceptibility genes, including DLG5 
[86], as well as novel organic cation transporter (OCTN) 1 and 2 [87], and NOD1 
(CARD4) [88]. 
Overall, the candidate-gene approach has however proven to be difficult in confirming 
CD susceptibility genes. For instance, using a candidate gene approach, Peltekova et al. 
identified two genes, i.e. OCTN1/2 genes (i.e. IBD5 locus) that may confer susceptibility  
to IBD [87]. Nonetheless, due to tight linkage disequilibrium across the IBD5 locus and 
the wealth of candidate genes in the region [89], subsequently, it has been very difficult 
to identify with certainty the causative mutations in this region. Similarly, earlier studies 
of association with genes such as the DLG5 [86], PXR1 [90] and MDR1 [91] have not 
been consistently replicated in subsequent studies [92, 93]. A number of reasons could 
contribute to non-replication of candidate gene studies. Foremost is perhaps inadequate 
power and the tendency for early positive studies to be false-positive. On the other hand 
however, failure to replicate may be due to genetic heterogeneity, gene-environment 
interactions and phenotype heterogeneity. Some evidence for the latter comes from 
studies that have shown that the effects of the DLG5 gene may be different among males 
and females (please see below). Similarly, it is also more and more apparent that certain 
genes may affect specific clinical phenotypes of CD and lack of stratification for them 
may result in non-replication of earlier findings. This is in particularly apparent for early-
onset CD (see below). For example we have recently shown that the MDR1 gene was not 
associated with overall risks for CD (Krupoves et al, 2008, in press), however 
associations were apparent with colonic CD and inflammatory disease, highlighting the 
need to investigate and assess lack of replication of candidate-gene studies.  
A.2.6. Genome-wide association studies (GWAS) in CD 
There is increasing evidence that GWAS represent a powerful approach to the 
identification of genes involved in complex genetic traits [94]. In essence, GWAS 
compare the frequency of alleles and genotypes between cases and related or unrelated 
controls on a genome-wide scale, thus creating a comprehensive unbiased method to 
identify candidate genes.  
 With respect to CD, access to GWAS has not only managed to identify new 
susceptibility loci [95-99] but more importantly implication of these loci is suggestive of 
novel mechanisms of disease susceptibility, as shown in a study conducted by the 
Wellcome Trust Case Control Consortium (WTCCC) [100-102]. As such, in one of the 
first GWAS, Duerr et al., by using the Illumina HumanHap300 Genotyping BeadChip 
(i.e. over 300,000 single nucleotide polymorphisms, SNPs) and a study population of 
non-Jewish, European ancestry patients with ileal CD and non-Jewish controls, reported 
strong association between variants in the IL23R receptor gene and CD susceptibility 
[95]. In addition to being highly significant and replicable, both in case-control and case-
parent designs [95, 103], these data also provide insight to the importance of the IL23 
pathway in CD pathogenesis. 
To further advance gene discovery, Barrett et al recently combined data from the 
three genome-wide scans, i.e. The National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK) IBD Genetics Consortium [99], WTCCC [100] and the 
Belgian-French IBD Cohort Study [97] studies on CD (a total of 3,230 cases and 4,829 
controls) and carried out replication in 3,664 independent cases with a mixture of 
population-based and family-based controls. The results strongly confirmed 11 
previously reported loci and provide genome-wide significant evidence for 21 additional 
loci. Included among these are compelling functional candidates such as STAT3, JAK2 
and IL12B, whereas others, such as CDKAL1 and PTPN22, highlight potentially 
intriguing contrasts between genetic susceptibility to CD and other complex disorders - 
viz. type I [104] and II [105, 106] diabetes and rheumatoid arthritis [107]. 
 More recently, in the only GWAS focussed on the pediatric population, 
Kugathasan et al in a North American GWAS (647 CD and 4,250 matched controls) 
identified two previously unreported CD susceptibility (protective major allele was risk-
conferring) loci (20q13 and 21q22, respectively). Although the exact genes could not 
been identified, based on the LD structure surrounding the identified SNPs, genes such as 
the TNFRSF6B and PSMG1 are considered to be implicated [108]. 
Findings from GWAS to date and as they relate to CD are summarized in Table 
III.  
Although GWAS provide valuable clues to the pathogenesis of complex traits and 
there is growing focus on this approach, there are certain aspects related to GWAS for 
which considerable challenges remain. One such challenge relates in fact to the capacity 
of GWAS to provide a relatively unbiased examination of the entire genome for common 
risk variants; their weakness is that in doing so, these studies cannot clearly distinguish 
between the signal from true risk variants and the statistical noise from the vast numbers 
of markers that aren't associated with disease. To separate true signals from noise, 
researchers have to set a high threshold that a marker needs to exceed before it is 
accepted as a likely disease-causing candidate. That reduces the problem of false 
positives, but it also means that any true disease markers with small effects are lost in the 
background noise. Furthermore, most efforts at replication have concentrated on the 
signals for which the statistical evidence is strongest; whereas, some susceptibility loci 
with modest effect sizes might also benefit from further exploration in the context of their 
biological plausibility. As it stands, by increasing the numbers of samples in their disease 
and control groups, researchers are trying to dial down the statistical noise from non-
associated markers until even disease genes with small effects stand out above the crowd. 
As the cost of genotyping is decreasing steadily such an approach will become more and 
more feasible; however, the logistical challenge of collecting large numbers of carefully-
ascertained patients will always be a serious obstacle. This is because most published 
GWAS feature case-control designs (Table III) and thus concerns inherent to this type of 
design, i.e. selection bias, misclassification bias, and population stratification§, remain.  
One other important aspect is related to the fact that current genome scan technology rely 
heavily on the "common disease, common variant" (CDCV) assumption, which states 
that the genetic risk for common disease is mostly attributable to a relatively small 
number of common genetic variants. However, some fraction of the genetic risk of 
common diseases will be the result of rare variants, and findings from GWAS in a variety  
                                                 
§ Current GWAS have been dominated by subjects of Western European ancestry, and our understanding of 
genetic risk variants in non-European populations is almost non-existent 
of diseases have failed to provide unambiguous support for the CDCV hypothesis [109]. 
Whatever the proportion of variance that turns out to be explained by rare variants, 
current GWAS technologies have lower power to unravel it. Increasing sample sizes may 
be beneficial, but the inability of current chips to tag rare variation will still remain a 
problem [110]. The solution will be higher-density SNP chips incorporating lower 
frequency variants identified by large-scale sequencing projects; however, such 
approaches will have diminishing returns: as chip manufacturers lower the frequency of 
the variants on their chips, the number of probes that will have to be added to capture a 
reasonable fraction of total genetic variation will increase exponentially, with each new 
probe adding only a small increase in power. 
 
In summary, all the above approaches have led to the identification of several 
susceptibility genes for CD, with NOD2/CARD15, IL23R and ATG16L1 being the most 
important. Furthermore, the resulting genetic knowledge has provided important insights 
into the pathophysiology of CD and is stimulating future research. In parallel, the 
researchers’ attention also focused on genotype–phenotype association considering that at 
least in adults the genes identified so far via GWAS seems to be associated with ileal CD 
rather than other forms of CD. In the next section we highlight genotype-phenotype 
correlations relevant to CD and also describe findings pertinent to CD in children.  
A.2.7. Genotype-phenotype correlations in CD 
It is generally accepted that adults and children with CD do not share the same 
disease phenotype. A interesting difference that exists between early onset and late onset 
IBD is a male preponderance reported in paediatric CD [9, 14, 20], while female 
preponderance is only seen among patients diagnosed in adolescence (13–19 years) 
[111], in accordance with the overall higher incidence of CD in females. Pediatric onset 
CD also appears to be associated with less isolated ileitis compared with adult onset CD 
[19-23]. Furthermore, in comparison to cohorts of adult patients, at diagnosis children are 
more often closer to disease initiation and earlier in the process of chronic intestinal 
inflammation [16]. Taken together, it seems likely that paediatric CD represents a 
specific group of patients with particular phenotypic appearance (and perhaps also drug 
responsiveness) that might be driven by different mechanisms – in which different genes 
may be involved, and/or different host responses - in children versus adults, such as 
decreased ileal susceptibility or increased susceptibility to purely colonic and/or pan-
enteric disease (ileum + colon + upper tract). The genotype-phenotype characteristics of 
CD that we are reviewing here include gender, location of disease, and disease behaviour. 
A.2.7.1. Gender 
Although men and women share most genetic information, they have dramatically 
different disease susceptibilities that go beyond the expected gender-specific diseases. 
Gender was shown to influence susceptibility to nearly all common diseases that affect 
both men and women, including atherosclerosis and diabetes and their preceding risk 
factors, e.g. hyperlipidemia, insulin resistance, inflammation [112]. It has been generally 
accepted that endocrinologic differences are involved in the sexual asymmetry of 
complex disease; however, specific molecular mechanisms of such hormonal effects have 
not been elucidated yet.  
As it pertains to complex diseases, recent studies investigating key factors in lipid 
metabolism (e.g. apolipoprotein E – APOE) and obesity (e.g. perilipin – PLIN) revealed 
that the interplay between genes, gender, and environmental factors may modulate 
disease susceptibility. For example, in the Framingham Heart Study, complex 
interactions have been shown between a promoter polymorphism at the apolipoprotein 
A1 gene, gender and dietary polyunsaturated fatty acid intake that modulate plasma 
concentrations of high-density lipoprotein cholesterol [113]. The gender-APOE-disease 
interaction was also supported by another study testing the hypothesis that ischemic heart 
disease differs as a function of APOE genotype in women and men [114]. Of particular 
relevance are also the gender-dependent associations found between common 
polymorphisms at the PLIN locus and obesity risk that has been replicated in several 
populations around the world [115, 116]. Gender effects in complex disease susceptibility 
have been reported also in auto-immune disorders; for instance, female specific linkage 
to chromosomes 2, 6 and 11 was observed in osteoarthritis [117]. 
In the particular context of CD, a better understanding of the significance of specific 
disease-associated genetic polymorphisms in the context of gender may be of critical 
importance. In 2002, Fisher et al decided to re-analyse their genome search data [59], 
with stratification of families by the sex of affected individuals, to identify potential 
excess allele sharing specific to males or females. To this end, the authors revealed that 
the major histocompatibility region on chromosome 6p, referred to as IBD3, showed 
evidence of male-specific linkage with a maximum LOD score of 5.9 in CD male-
affected families. Regions on chromosomes 11, 14 and 18 also showed strong evidence 
of linkage in male-affected families but not in female-affected families. No evidence of 
sex-specific linkage was found in the IBD1 or IBD2 candidate regions of chromosomes 
16 and 12 [118]. 
Of particular relevance are the findings by Stoll et al, who in 2004 described an 
association between CD and DLG5 variants. In particular, a certain variant, i.e. R30Q, 
was found to be associated with CD in a German family cohort. The authors replicated 
the R30Q association with CD in a European case-control cohort and found a non-
significant over-transmission of the 30Q allele in patients with CD in a German/UK 
family cohort [86]. While Daly et al managed to replicate only partially these findings 
(one of two case-control cohorts and in a family cohort) [119], other subsequent studies 
failed to replicate the association of DLG5 30Q with CD [120-126]. Only recently, 
Friedrichs et al, by examining gender-stratified data from the case-control cohorts 
showing association in the initial two DLG5 studies [86, 119], was able to reveal that the 
DLG5 30Q allele was a risk factor for CD in men but not in women. The authors 
managed to replicate these findings by genotyping the R30Q mutation in two additional 
control samples, i.e. a sample of 190 male and 271 female participants from Germany 
and in a newborn sample of 301 male and 299 female infants from the United States 
(US). For all three samples (viz. combined control cohort, the German population sample 
and the US sample) the DLG 30Q allele frequency was significant lower in male than in 
female subjects [127]. Subsequently, other independent studies confirmed that DLG5 
R30Q variant is a female-specific protective factor in pediatric onset CD [128, 129]. In 
our pediatric cohort, we have observed that the DLG5 R30Q variant was not associated 
with overall susceptibility for CD, nor were there gender differences in risk (Amre et al, 
2008, submitted). On the other hand, however we observed that other variants in the 
DLG5 gene conferred risks for CD only among females. 
Although gender differences are not uncommonly found in susceptibility to complex 
diseases and, as previously mentioned, it has been generally accepted that endocrinologic 
and lifestyle differences underlie this observation, the presence of the male-female allele 
frequency differences in the newborn sample may suggest that these differences can be 
due to prenatal processes rather than selection later in life. Additional studies are required 
to further elucidate gender-specific risks related to the DLG5 gene. 
A.2.7.2. Location and disease behaviour 
Defining the initial location of CD is essential for a number of reasons. In general, 
there is stability of anatomic location over the course of the disease [30]. Besides, certain 
disease locations, as suggested by Farmer et al [130] over 30 years ago and confirmed 
more recently by Oostenbrug et al [131], are associated with a particular clinical course. 
Patients with ileocolonic location and those with perianal involvement, for example, 
often suffer a more complicated course than those with disease localization in the 
terminal ileum or colon only. Furthermore, upper gastrointestinal location is less often 
complicated by fistulization [132]. Third, by considering perianal disease separate from 
internal fistulization, the Montreal Classification recognizes the independent courses of 
these 2 entities [133]. Treatment regimens, prognostication, clinical trials, and genotype–
phenotype studies can all be confounded by the failure to recognize this distinction.  
The location of disease in most studies prior to the adoption of the Vienna 
followed by the Montreal classification divided location into small bowel and/or colon. 
Both Vienna and Montreal classifications identifies the disease site as one of four 
locations: upper gastrointestinal, ileal, ileocolonic and colonic. Behaviour in both 
classifications is divided into non-stricturing, non-penetrating (inflammatory), structuring 
and penetrating [32, 33].  
Variability in disease location is an important characteristic of CD. Incidentally, it has 
been suggested that CD is not a single disease, but a spectrum of diseases, with disease 
location and behaviour key element distinguishing individual cases. It is unclear why 
certain individuals would have predilection for disease in a certain location of the GIT or 
present with either inflammatory or non-inflammatory disease. It is however interesting 
that, several studies investigating the concordance rates and phenotypes in multiplex 
family studies demonstrated patterns of concordance for disease location and behaviour 
in CD pointing to inherited familial phenotypes [62, 134-136]. More recent studies that 
were mainly  driven by the observation that disease location can be a strong predictor 
/determinant of disease progression [137] (i.e. small bowel involvement may predict 
early stricturing and the anoperineal location is showing more penetrating complications, 
respectively), have shown that interactions of susceptibility and modifying genes can also 
influence the specific features of disease location, behaviour, and complications. Studies 
investigating NOD2/CARD15 variation and disease localization have shown very 
consistent findings. For instance, six independent studies, each of more than 200 CD 
patients, have shown that the presence of NOD2/CARD15 mutations is associated with 
the ileal form of CD [34, 138-142] and stenosis [138, 140], although it is not clear 
whether this is a primary association [34] as ileal disease and stricture formation are not 
independent [143]. One possible explanation of the association between NOD2/CARD15 
variation and ileal involvement rests with the overexpression of NOD2/CARD15 gene in 
the Paneth cells of the terminal ileum [144]. It is possible that partial or complete lack of 
protein function may lead to loss of the ability of Paneth cells to respond to bacterial 
components. With respect to the latter association, a meta-analysis of 42 study cohorts 
found a modest over-representation of the three common NOD2/CARD15 variants (viz. 
SNP 8, 12, 13) among CD patients with stricturing disease behaviour [145]. However, 
this observation needs to be viewed with caution, as for any given patient with CD the 
clinical phenotype regarding stenosis evolves over time, while disease location may 
change to a lesser extent in time [30, 137]. Thus, it is generally accepted that high-risk 
alleles may influence primarily the disease location and the location in itself can be a 
strong predictor /determinant of disease progression, i.e. small bowel involvement 
predicting early stricturing and anoperineal location showing more penetrating 
complications, respectively. Nonetheless, additional data is still required to demonstrate 
such assumptions.  
As for other phenotypic associations, the strong evidence of linkage of markers at 
the IBD3 locus on chromosome 6p21 to CD provided the impetus to research on the 
major susceptibility genes located in this region. The evidence for linkage was shown to 
be strongest in the vicinity of the major histocompatibility complex (MHC), which, given 
its central role in the immune response, has long been considered an excellent candidate 
locus for CD. While an independent association of DRB1*0701 and Cw*0802 with CD 
was reported, the classic autoimmune haplotype A1-B8-DR3 was specifically associated 
with colonic disease [34]. More so, in Canadian cohorts, HLA DRB1*0103 was found to 
be associated with the colonic form of CD [146].  
As it pertains to the perianal location of the disease, there is evidence of association with 
the IBD5 genotype [147] and another study showed significant association with the DLG 
rs2165047 mutation carriership in a pediatric population [148]. 
As previously mentioned, the most consistent difference in phenotype in children 
versus adults is in disease distribution; notably, a colonic predilection in early-onset CD. 
Since both the intestinal microbiota as well as the mucosal immune system are still under 
development in children, researchers speculate that the contributions of innate immune 
defects to the pathogenesis of CD are inversely related to the age of disease onset [149]. 
Based on this hypothesis that CD results from aberrant mucosal immune responses to 
environmental factors such as commensal bacteria and based on the relatively short 
exposure time to environmental factors in children, genetic mutations that either enhance 
the susceptibility for or protect from these pathogenic responses are thought to play an 
increasing role in early onset disease. However, evidence in support of this and further 
investigating candidate genes with mutations that are likely to present more frequently in 
childhood and lead to colitis-predominant CD is currently scarce, with two studies 
reporting on the frequency of association between previously identified genetic variants 
and pediatric CD [35, 148] and only one study identifying a candidate gene for the 
colitis-predominant disease of childhood. In the latter, Sun et al revealed that the cytosine 
insertion mutation 3020insC mutation in the NOD2/CARD15 gene was significantly 
more common in their pediatric population than in patients with CD (26% versus 11% of 
the alleles).  The genotype-phenotype analysis further showed that the patients with at 
least one of the six CARD15 disease-associated mutations had a high risk of 
inflammation located in the terminal ileum and ascending colon. More so, in 10 of 19 
patients with two mutations, intestinal resection surgery was necessary because of 
structuring [35]. These findings were complemented by those by De Ridder et al who 
reported a higher than expected by chance occurrence of two genetic variants, viz. 
polymorphisms 3020insC in NOD2/CARD15 and SNP rs3792876 in SLC22A4/5, in 
patients with pediatric-onset CD than in patients with adult-onset CD. Polymorphisms 
3020insC in CARD15 and SNP rs2165047 in DLG5 were also found to be associated 
with specific phenotypes in this pediatric-onset CD cohort [148]. Further supporting 
evidence is provided by Levine et al who described an association between a 
polymorphism in the TNF promoter and isolated colitis with an increased likelihood of 
pediatric onset disease in an Israeli cohort by comparing the prevalence of the 
polymorphism to an adult cohort [22]. The latter also published a recent study that 
investigated if the age-related colitis pattern noticed in younger children with CD is 
determined by genotype, by differences in colonic or ileal susceptibility, or due to an age-
related variability in NOD2/CARD15 mutations. Although NOD2/CARD15 mutations 
were previously shown to be associated predominantly with ileal involvement [150], the 
authors found increased colonic susceptibility in patients with early-onset disease 
carrying these mutations. The most striking finding was a significantly higher prevalence 
of isolated colitis, but not colonic involvement, in NOD2/CARD15 wild-type patients, 
which presented most commonly in early childhood and declined with age. This trend for 
more colitis lasted until age 11. Together, these findings demonstrate yet again that 
pediatric onset CD may be characterized by different genes that predispose to early onset 
and isolated colitis [25]. Studies evaluating other candidate genes or loci in pediatric 
cohorts have failed to show a predominance of early age of onset or a colitis-predominant 
phenotype [123, 151]. 
In many of these studies, analyses of disease localization is complicated by variation in 
clinical classification schemes and by changes in disease behaviour with time [12], which 
renders the overall available data inconsistent. These observations highlight the need for 
independent replication in adequately powered studies, ideally using a different 
genotyping technology. 
Although assigning disease phenotype may be difficult, this represents a critical step in 
determining the successful outcome of genetic association studies, as was shown in a 
group study that demonstrated that the erroneous assignation of disease phenotype may 
lead to a 40% loss of power in linkage studies [152].  
A.2.8. Gene-gene interactions  
An important goal of human genetics is to identify DNA sequence variations or 
polymorphisms in human genes that confer an increased risk to particular diseases. This 
is a difficult challenge for common, complex multifactorial diseases such as CD that are 
likely the result of interactions between multiple environmental and genetic factors [153-
156]. In respect to the latter, evidence of interaction between established CD risks alleles 
has been found. For example, a complex pattern of gene-gene interaction between DLG5 
and NOD2/CARD15 [86] as well as IBD5, ATG16L1, IL23R, and NOD2/CARD15 risk 
alleles [157] has been described. While progress in elucidating gene-gene and gene-
environment interactions in the ethiopathogenesis of CD are clearly underway, such 
interactions are difficult to detect and characterize using traditional parametric statistical 
methods such as logistic regression because of the sparseness of the data in high 
dimensions. That is, when interactions among multiple variables are considered, there are 
many contingency table cells that have very few or no data points. This can lead to 
parameter estimates that have very large standard errors resulting in an increase in type I 
errors [158, 159]. In addition, detecting gene–gene (and/or gene environment) 
interactions using traditional procedures for fitting logistic regression models can be 
problematic leading to an increase in type II errors and a decrease in power. For example, 
forward selection is limited because interactions are only tested for those variables that 
have a statistically significant independent main effect. Those DNA sequence variations 
that have an interaction effect but not a main effect will be probably missed. With 
backward elimination, a complete model that includes all main effects and all interaction 
terms may require too many degrees of freedom. Stepwise procedures are more flexible 
than either forward selection or backward elimination but can also suffer from requiring 
too many degrees of freedom. In consequence, detecting interactions among variables is 
an increasingly recognized problem in human genetics [160]. To address concerns about 
inaccurate parameter estimates and low power for identifying interactions in relatively 
small sample sizes, a nonparametric and genetic model-free approach called multifactor 
dimensionality reduction or MDR that uses a data reduction strategy has been recently 
developed [161]. With MDR, multilocus genotypes are pooled into high risk and low risk 
groups, effectively reducing the dimensionality of the genotype predictors to one 
dimension. While evidence suggests that MDR is able to identify gene–gene interactions 
in the absence of any statistically significant independent main effects in simulated data 
[161, 162], in sporadic breast cancer [161], and in essential hypertension [160], no 
application of this tool in the study of CD has been yet reported. 
 
While continued progress has been made in identifying potential genetic risk 
factors, the equally important role of mechanistic pathways that are involved in the 
pathogenesis of CD remains quite elusive. 
A.3. Pathogenesis of CD  
Recently, substantial advances in the understanding of the molecular pathogenesis 
of CD have been made owing to three related lines of investigation. First, the 
identification of NOD2/CARD15 gene [70, 82] followed by several additional 
susceptibility loci, e.g. IBD5, IL23R and ATG16L1 [78, 87, 95-97, 99, 163] point to the 
importance of the GIT epithelial/mucosal barrier function and innate and adaptive 
immunity in disease pathogenesis. Second, efforts directed towards the identification of 
environmental factors implicate commensal bacteria or their products, as drivers of 
dysregulated immunity and CD. Third, murine models have helped unravel the 
pathogenesis of CD. Taken together, this evidence implies that alternative pathways 
involved in the innate or adaptive immunity exert feedback regulation that result in gut 
inflammation and disease.  
A.3.1. The role of microbes in the development of CD 
Accumulating evidence suggests that the dynamic balance between microbes, 
particularly commensal flora, and host defensive responses at the mucosal frontier has a 
pivotal role in the initiation and pathogenesis of chronic CD. Evidence supporting this 
hypothesis is provided by the observed therapeutic benefits of antibiotic treatment in a 
subgroup of CD patients and recent findings suggesting that probiotics can ameliorate the 
symptomatology of CD [164, 165]. Furthermore, the enteric flora of CD patients has been 
found more commonly than in control patient groups to include strains of certain 
pathogens, such as E. coli that are able to adhere to the epithelium, and with low 
frequency effect epithelial invasion [166, 167]. The importance of the flora is more 
directly supported by studies in a variety of murine strains in which ‘spontaneous’ 
chronic colitis seems to be entirely dependent on the presence of a luminal flora. Thus, 
colitis is not observed when mice are maintained in a germ-free state, but rapidly emerges 
when they are reconstituted with bacteria that are considered normal constituents of 
luminal flora [168, 169]. Furthermore, in some instances, it has been possible to induce 
colitis in a susceptible murine strain with a single species of normal bacteria [170]. These 
studies provide compelling evidence that the nature of the host defenses, rather than the 
biological properties of a luminal bacterial species per se, may determine the functional 
outcome of that interaction. 
Unfortunately, our understanding of the microbial flora itself is quite incomplete. 
Insights into the microbial–host interrelationships are hampered by both the limited 
knowledge of the diversity and complexity of the microbial flora and the limitation of 
available tools to delineate these characteristics.  
A.3.2. The role of mucosal homeostasis in the development of CD 
From comparative studies of germ-free and colonised animals, supported by in 
vitro data, intestinal flora clearly affects mucosal structure and function [171-173]. 
Barrier function is provided by anatomical features that physically impede penetration of 
macromolecules and intact bacteria. Several molecular features of the pre-epithelial 
barrier and structure of the epithelial tight junctions that comprise this physical barrier 
have been defined and it has become evident that these junctions are dynamically 
regulated in response to signalling molecules, in particular pro-inflammatory cytokines 
(i.e. TNF-alfa, IL-17, interferon-gamma, chemokines, etc) and the underlying immune 
cell network [174]. The importance of the epithelial barrier in disease predisposition is 
supported by the finding of abnormal intestinal permeability in some first-degree 
relatives with CD [175-178]. Expression analysis in human CD biopsies has 
demonstrated downregulation of junctional complexes, although the mechanisms 
involved are unknown [179]. A recent GWAS reported that 5p13.1, a CD locus contained 
within a 1.25-Mb gene desert, is associated with disease susceptibility and the associated 
alleles correlated with quantitative expression of the prostaglandin receptor EP4 
(PTGER4) [97]. PTGER4 is expressed in intestinal epithelial cells and regulates 
epithelial barrier functions; interestingly, PTGER4 knockout mice are susceptible to 
chemical-induced colitis [180]. 
The epithelium is in constant communication with luminal flora and the 
underlying dense network of innate and adaptive immune cells. Production of 
chemokines by the epithelium in response to pathogenic infection alerts the host to a 
breach in barrier function and directs the immune response to the site of infection [181]. 
More specifically, intestinal epithelial cells express Toll-like receptors (TLRs)**, Nod-
like receptors (NLRs)††, and other receptors for different chemokines and antibody-
specific Fc [182-184]. In this context, epithelial-cell-specific NF-kB activation or 
suppression seems to be a nodal point in the suppression and/or recruitment of immune 
responses in CD. Interestingly, some bacteria seem to be able to shortcut this process to 
minimize epithelial cell NF-kB activation [185]. Taken together, these observations 
highlight the importance of NF-kB signalling networks within the intestinal epithelium in 
sustaining normal mucosal homeostasis and in mediating pathogen-specific responses. 
In addition to the epithelial barrier, other specialized cells are interspersed along 
the crypt villus axis to enhance protection against microbes and promote repair. For 
example, Paneth cells reside in the base of the crypt where they secrete antimicrobial 
peptides, including the alfa-defensins. Some observations suggest that a reduction in 
Paneth cell alfa-defensins may contribute to the pathogenesis of terminal ileal CD in 
patients with mutant NOD2/CARD15 [186, 187].  
A.3.3. The role of the mucosal integrity in the development of CD 
The mucosal immune system is primed to detect bacteria and antigens at the 
mucosal surface and to drive an appropriate response. The response must be nuanced 
                                                 
** Toll-like receptors (TLRs) are a class of single membrane-spanning non-catalytic receptors that 
recognize structurally conserved molecules derived from microbes once they have breached physical 
barriers such as the intestinal tract mucosa, and activate immune cell responses. They are believed to play a 
key role in the innate immune system. 
†† The NOD-like receptors (NLRs) are cytoplasmic proteins that may have a variety of functions in 
regulation of inflammatory and apoptotic responses. Approximately 20 of these proteins have been found in 
the mammalian genome and include a subfamily called the NODs. Current understanding suggests some of 
these proteins recognize endogenous or microbial molecules or stress responses and form oligomers that 
activate inflammatory caspases causing cleavage and activation of important inflammatory cytokines such 
as IL-1, and/or activate the NF-kB signaling pathway to induce production of inflammatory molecules.  
 
 
between ‘tolerant’ and ‘active’ to distinguish between an innocuous commensal and 
pathogens, which can invade the epithelium and beyond. A number of sentinel cell 
populations in the intestinal mucosa continuously monitor luminal microbes. These 
include specialized microfold cells (M cells) that have the unique ability to sample and 
transport antigen from the GIT lumen (i.e. microbial products), which are further picked 
up by antigen-presenting cells. Peyer’s patches, isolated lymphoid follicles and the 
lamina propria work as inductive sites for the mucosal response, whereas the lamina 
propria functions as a recognition/effector site [188, 189]. Among the subsets of antigen-
presenting cells, myeloid-derived dendritic cells are the dominant subtype in the intestinal 
lamina propria and show considerable functional plasticity depending on the location, 
state of maturation, and stage of inflammation. In response to TLR ligands, the immature 
dendritic cells produce cytokines, such as IL-23, which contributes to development of 
intestinal inflammation in murine models of colitis [190, 191]. Recent studies also 
implicate IL-4, B-lymphocytes and enteric flora in dendritic-cell-mediated granuloma 
formation in states of chronic intestinal inflammation [192]. Consistent with a baseline 
state of hyporesponsiveness, intestinal macrophages show attenuated proliferation and 
chemotactic activity in response to either microbial ligands or host cytokines/chemokines 
despite possessing the molecular mechanisms to elaborate strong phagocytic and 
bactericidal responses [193]. Following an inflammatory signal, circulating macrophages 
migrate to the intestinal mucosa and these cells, unlike resident macrophages, express 
NLRs and TLRs capable of rapid response and functional chemotactic receptors. Direct 
support for the role of macrophages in the regulation of CD has been obtained from 
analysis of mice with selective transcription disruption in their macrophages [194]. The 
tumor necrosis-factor (TNF) produced by non-lymphoid cells, mostly macrophages, was 
found to be essential for the development of colitis using the adoptive T-cell model of 
colitis induction. Recent murine studies have also shown that depletion of macrophages 
prevents development of colitis, which otherwise occurs owing to unregulated production 
of IL-12 and IL-23 by macrophages [195]. 
Altogether, it seems clear that the innate immune system, considered being the 
first line of immune defence, evolved as a means to monitor the microbial environment 
and to limit infection by invasive organisms. Distinct classes of receptors, broadly 
expressed in many cell types, and that recognize microbial molecular patterns are central 
to innate immunity. To date, several TLRs and NLRs have been identified and 
characterized. Furthermore, mutations in both TLRs and NLRs have been found to be 
associated with CD, suggesting that each detection system is key for regulating mucosal 
homeostasis [196-199].  
Perhaps the most compelling evidence for the importance of microbial-mucosal 
interaction in the pathogenesis of CD was provided by the identification of 
NOD2/CARD15 as IBD1. The emerging genetic data have inspired intensive studies of 
NOD2/CARD15 biologic functions and these analyses have already substantively 
enhanced understanding of the signaling pathways coupling bacterial pathogens to the 
earliest phases of the host immune response [200, 201]. Expressed in Paneth cells, 
enterocytes, monocytes, macrophages, T cells, and certain subsets of dendritic cells, the 
NLR family member protein NOD2/CARD15 is an intracellular pattern-recognition motif  
that promotes host resistance towards bacterial muramyl dipeptide (N-acetylmuramyl-L-
alanyl-D-isoglutamine, also referred as MDP) [202].  
The mechanism by which NOD2-mediated functions contribute to intestinal 
immune homeostasis and how dysregulation of these functions in individuals with 
disease-associated NOD2/CARD15 polymorphisms contribute to the increased 
propensity to develop CD remain incompletely understood. However, collectively studies 
suggest that NOD2/CARD15 primarily functions in antibacterial immunity and that 
persistent bacterial survival might be a driver of persistent inflammatory responses in CD 
[144, 203, 204]. However, a more comprehensive understanding of the relationship 
between NOD2-dependent pathways and cellular processes for handling internalized 
bacteria is needed. 
A.3.4. The role of the autophagy mechanism in CD development 
As noted above, a working model of CD pathogenesis has evolved from a central 
focus on mucosal integrity to innate immunity. A constellation of findings, particularly in 
the last year, suggest a more focused orientation of that model on intracellular responses 
to low-level invasive bacteria. These include recent findings implicating alterations in 
autophagy and phagosomal function. Autophagy is a fundamental biological process 
defined as a cytoplasmic homeostasis pathway whereby cytoplasmic portions become 
sequestered by a membrane for delivery to lysosomes. In general, the autophagy pathway 
plays a part in protecting mammalian cells against various bacterial pathogens and the 
cytotoxic effect of bacterial toxins [205] represent a primary attempt to re-establish 
homeostasis and when autophagic capacity is overwhelmed apoptosis could be triggered. 
Bridging the innate and adaptive arms of the immune system, autophagy is also linked to 
adaptive immunity, both by the delivery of ligands via TLRs and NLRs to promote 
inflammation and by delivery of cytoplasmic antigen to the human leucocyte antigen 
(HLA) class II molecules for the cross-presentation necessary for immune recognition 
[206-208]. Recent studies have also demonstrated that autophagy plays an important role 
in clearance of apoptotic bodies [209]. Persistence of apoptotic bodies as a result of 
incomplete autophagy in complex tissues such as the intestinal mucosa in turn could 
contribute to persistent inflammation and autoimmunity seen in CD. 
The relevance to CD is highlighted by the recent GWAS discovery that a 
synonymous SNP in the auto-phagocytic gene ATG16L1 is associated with increased risk 
for CD [96, 99]. These findings have been subsequently replicated in pediatric onset CD 
as well [93]. ATG16L1 is broadly expressed in the intestinal epithelium, M cells, CD4/8 
T cells, B1 cells and memory B cells. In addition, preliminary data have implicated 
ATG16L1 in host responses to intracellular bacteria [99]. Subsequently these findings 
were confirmed by a second study, part of the WTCCC GWAS [210]. The latter also 
directed attention towards a second autophagic gene for CD susceptibility – the IRGM 
gene. Specifically, studies reveal that IRGM is required for mycobacterial immunity and 
may have an analogous role in the granulomatous response often observed in CD [211, 
212]. Future studies will need to systematically determine the functional implications of 
disease variants in a cell- and tissue-specific context.  
A.3.5. The bridge between innate and adaptive immunity 
Although innate immune responses seem to be a prerequisite for the excessive 
activation of adaptive immunity, the latter is the more proximate driver of tissue damage 
that is manifest in CD patients. Adaptive responses are executed by a combination of 
resident and recruited cell populations. These comprise mucosal B cells producing 
immunoglobulins A and G, and a complex mixture of T cells that are dominated by a Th1 
phenotype in the case of CD (as opposed to Th2 phenotype for UC). Th1 development is 
triggered by microbes that stimulate production of specific cytokines, such as interferon-
gamma and IL-23 [213-215].  
Another CD4 T-cell lineage (Th17) has been described that is characterized by the 
production of the cytokine IL-17 and the development of which is promoted by IL-23 and 
suppressed by transcription factors required for both Th1 and Th2 cells [215, 216]. 
Although the precise mechanism by which IL-23 maintains Th17 responses in vivo is still 
not well understood, recent studies have shown that Th17 cell lineage commitment is 
driven by transforming growth factor-beta (TGF-beta) in the presence of pro-
inflammatory cytokines, whereas IL-23 seems only to be able to expand or maintain 
Th17 cell populations [217]. Recent studies have demonstrated that an IL23R coding 
variant is associated with reduced risk of CD [93, 95]. Further analysis suggests that there 
are multiple variants in the region independently associated with risk of CD and establish 
that IL23R signalling is central to the pathogenesis of the disease. In addition to its ability 
to support the development of Th17 cells, IL-23 induces the secretion of IL-17 by non-T-
cells in an inflammatory environment, and both T cells and monocytes serve as sources 
of increased expression in the mucosa of CD patients [174]. Recent data also suggest that 
IL-17 induces antimicrobial peptides and may regulate tight junction barrier formation 
[218]. Taken together, these data suggest that the IL-23 signalling pathway seems to 
function as a key conductor of innate and adaptive inflammatory responses in the 
intestinal mucosa [174]. 
An important conceptual development in the understanding of CD pathogenesis 
has been the more focused appreciation of the nature of the microbial–innate-immune-
response interaction during the transition from physiological to pathological intestinal 
inflammation. As highlighted above, achieving a thorough understanding may depend as 
much on more rigorous analysis of the complex dynamics of luminal microbial 
communities as on understanding of the host mucosal defence and response mechanisms. 
However, independent of the putative mechanism of disease, a characteristic 
feature of CD is uncontrolled and chronic inflammation in the GIT. Based on this fact, 
new formulations that target and inhibit leukotriene synthesis have been developed.  The 
first anti-leukotriene drug, zileuton, has recently been evaluated in CD and a significant, 
although insufficient, clinical response was obtained by a 70% inhibition of rectal LTB4 
synthesis [219]. Thus studying intrinsic pathways that lead to inflammation is likely to 
provide valuable insights into the pathogenesis of CD. 
The proposed mechanisms underlying the pathophysiology of CD are summarized 
in Figure 4.  
A.3.6. Inflammation and CD: mechanisms 
As reviewed above, many factors contribute to the complex course of 
inflammatory reactions. Microbiological, immunological and toxic agents can initiate the 
inflammatory response by activating a variety of humoral and cellular mediators. In the 
early phase of inflammation, excessive amounts of interleukins and lipid-mediators are 
released and play a crucial role in the pathogenesis of organ dysfunction. A widely 
studied pathway of inflammation is that mediated by eicosanoids, which are pro-
inflammatory signalling molecules.  
A.3.6.1. The role of eicosanoids in the pathogenesis of inflammation and 
CD 
Arachidonic acid (AA), the mother substance of the pro-inflammatory 
eicosanoids, is a normal constituent of cell-membrane phospholipids. Individuals living 
on a typical western diet have a large amount of AA acid in the cells. In particular, about 
25% of the fatty acid in platelets is constituted by AA, whereas the proportions in 
mononuclear cells (22%), neutrophils (15%), and erythrocytes (17%) are also high [101]. 
Cell-bound AA is converted to free AA by the action of phospholipase A2. Once it is 
released from membrane phospholipids in the course of inflammatory activation; the 
enzymes cyclooxygenase and peroxidase lead to prostaglandin H2, which in turn is used 
to produce the prostaglandins, prostacyclin, and thromboxanes; and the enzyme 5-
lipoxygenase (5-LO) leads to the production of leukotrienes (e.g. LTB4) via the 5-
lipoxygenase (5-LO) pathway [220] (Figure 5).  
The end-products of AA metabolism are dependent on the specific cell, and the 
activity, expression and amounts of these enzymes. The production of these derivatives 
and their action in the body are collectively known as the “arachidonic acid cascade”. 
Eicosanoids are thought to be implicated in the pathophysiology of inflammation 
because of their potent effects, in particular the effect of leukotriene B4 (LTB4), on 
vascular tone and permeability, mucus secretion, and leukocyte recruitment [221].The 5-
LO pathway by which LTB4 comes about becomes activated by various stimuli (i.e. 
dietary factors, immune complexes, bacterial peptides) that elicit a sequence of events 
starting with the translocation of arachidonate 5-lipoxygenase (ALOX5), a key enzyme, 
to the nuclear envelope. Here, ALOX5 transforms the released AA to the epoxide 
leukotriene A4 (LTA4), which can further undergo transformation by one or more of 
three possible fates depending on the cellular context: hydrolysis, conjugation with 
glutathione, or transcellular metabolism to generate bioactive eicosanoids [222]. In 
particular, the hydrolytic attack of LTA4 in pro-inflammatory cells by leukotriene A4 
hydrolase (LTA4H) enzyme present in the cytoplasm, and potentially in the nucleus, 
yields LTB4, a inducer of inflammation and a powerful mediator of leukocyte chemotaxis 
and adherence [220, 223].  Unknown transporters than facilitate efflux of LTB4 out of the 
cells. LTB4 can than act on target cells that can include epithelial cells, smooth muscle 
cells or endothelial cells by interacting with one of 2 receptors: LT-B1 and LT-B2. LT-
B1 is expressed primarily on leucocytes and is a high-affinity receptor whereas LT-B2 is 
expressed ubiquitously, but has a somewhat lower affinity for LTB4. Activation of the 
receptors leads to the activation of the Gq class of G proteins that subsequently result in a 
myriad of downstream effects. These include accumulation of virtually all subgroups of 
leukocytes to the site of inflammation, increasing the expression of adhesion molecules 
(thereby enhancing leukocyte adhesion to the microvasculature), and promoting cell 
motility that leads to transmigration of cells to the tissues. These cascades of events lead 
to the characteristic process of inflammation.  
The important role of LTB4 in the development and/or perpetuation of 
inflammation in CD is supported by several lines of evidence. In one of the earliest 
studies, Sharon et al (1984) examined the expression of LTB4 in CD patients. In the 
colonic mucosa of the patients they analyzed lipid extracts using high pressure liquid 
chromatography. They observed that the mucosa from CD patients contained 254 ng/g of 
LTB4 whereas that from normal subjects contained a significantly lower amount (5ng/g) 
[224]. In a subsequent study these authors observed that the chemotactic response in CD 
mucosa was blocked by anti- LTB4 sera and furthermore that the amount of chemotactic 
activity correlated with the high levels of LTB4 in the mucosa [225]. These observations 
were later confirmed by Lauritsen et al (1988) who demonstrated that LTB4 was elevated 
in CD patients in particular in those who had rectal ulcerations [226]. More recently, 
Schmidt et al (1995) also demonstrated higher levels of LTB4 in colonic mucosa of 
untreated and active CD patients [227]. In spite of the reported observations of elevated 
levels of LTB4 in IBD and CD patients, few studies have examined the expression of the 
enzymes/proteins involved in LTB4 synthesis in IBD. In one study, Hendel et al (2002) 
examined the mRNA expression of 5-LO in 21 patients with CD and 12 healthy controls. 
Using real-time polymerase chain reaction (RT-PCR) methods they reported non-
significant elevated trends in the levels of 5-LO mRNA expression in patients who had 
either active CD or quiescent CD as compared to controls [228]. More recently Jupp et al 
(2007), in a comprehensive examination of LTB4 synthesis pathway enzymes using 
immunohistochemistry reported a 3-fold higher number of cells staining for 5-LO, and a 
4-fold higher number of cells staining for LTA4H in colonic biopsies of patients with 
active CD as compared to healthy controls. In the small subset of CD patients (n=7), a 
higher number of cells stained for the LTA4H enzyme. They further examined whether 
frequencies of leukocyte counts in the biopsies were increased. They observed that there 
was an 18-fold higher mean count of neutrophils in active CD biopsies, a 4-fold increase 
in the mean number of eosinophils and a 3-fold increase in the mean number of 
macrophages. Consistent with these observations they reported strong correlations 
between neutrophils and cells expressing 5-LO and LTA4H in biopsies from CD patients 
[229]. These observations highlight that an abnormal prevalence of enzymes that co-
ordinate to synthesize LTB4 may be intimately linked to colonic tissue injury and 
inflammation in CD. It could thus be postulated that genetic variation in the synthesis and 
activities of these enzymes/proteins could underlie inter-individual differences in the 
production of LTB4 that could determine susceptibility for inflammation and CD.  
Because of the important role of LTB4 in inflammation, the AA metabolic 
pathway provides important target molecules for potential therapy of inflammatory 
disorders such as asthma, atherosclerosis, psoriases and CD. Clinical trials of CD patients 
using 5-LO inhibitors however, have been inconclusive [230-232]. The variability in 
clinical response may reflect variation in the numbers of inflammatory leukocytes 
expressing the 5-LO pathway in colonic mucosa, which in turn may be influenced by 
immunological and genetic factors [233]. The latter is supported by studies in particular 
in asthma where genetic variations in the ALOX5 enzyme were shown to determine 
variability in response to anti-leukotriene drugs [234-236].  
A.3.6.2. Genetic variation in genes involved in the 5-LO pathway and 
their potential role in CD  
As activation of LTB4 can trigger a cascade of downstream events leading to the 
inflammatory process its regulation is important in downgrading these responses. Such 
modulation can occur by the cellular expression of the 5-LO pathway, and/or the levels 
and activity of the enzymes involved in the 5-LO pathway, all of which may be under 
genetic control. There is currently no information on associations between genes coding 
for molecules within the LTB4 biosynthesis and/or regulation pathway and CD. However, 
there is evidence from studies among clinical phenotypes that have a significant 
inflammatory component suggesting that genetic variation in genes coding for 5-LO and 
CYP4F2 could be important. In the following section we briefly outline this literature.  
The ALOX5 gene that codes for 5-LO enzyme is situated on the long arm of 
chromosome 10 (10q11.2). The encoded protein, which is expressed specifically in bone 
marrow-derived cells, catalyzes the conversion of AA to LTA4. Mutations in the 
promoter region of this gene have been shown to affect mRNA associated levels, which 
can be further linked to increased mitochondrial damage and apoptosis [237]. Such 
alterations may lead to inflammation in animal models and in humans [238, 239] and 
diminished response to antileukotriene drugs in the treatment of asthma (e.g. zileuton) 
[240, 241]. In a recent study, Dwyer et al (2004) studied carotid artery intima-media 
thickness in relation to the polymorphisms in the promoter region of the gene, 
specifically the number of tandem repeats. Of 6 alleles, the most frequent allele, 
accounting for 80.5%, contained 5 of these tandem motifs. Variation in the tandem 
repeats (i.e. addition or deletion) was shown to be associated with atherosclerosis. Of 
particular interest the same authors also reported diet-gene interactions suggesting that 
dietary-omega-6 polyunsaturated fatty acids (viz. AA precursors) promoted whereas 
omega-3 fatty acids inhibited leukotriene-mediated inflammation and lead to 
atherosclerosis in their population  [242]. Similarly, there are suggestions that variants in 
particular the promoter region of the gene are associated with asthma or airway hyper-
responsiveness [241, 243, 244] indicating that the gene may be related to the 
inflammation characteristic of these diseases.  
At the level of the 5-LO pathway, other genes that can potentially affect 
inflammation are the genes that regulate the production of LTB4. LTB4 and some related 
eicosanoids are catalyzed/de-activated by the cytochrome P450 omega-hydroxylases 
(CYP-450) belonging to the CYP4F subfamilies, in particular the CYP4F2 enzyme. The 
CYP4F2 enzyme is an efficient LTB4 omega-hydroxylase, judging from its localization 
in human white blood cells and human liver and its substrate specificity, the Km‡‡ value 
for LTB4. Determination of the Km value allows comparing the specificity of different 
substrates for the same enzyme or the comparison of hydrolysis rates with different 
enzymes cleaving the same substrate. For a given substrate, a low Km value, as in the 
case of CYP4F2, is illustrative of high specificity [245]. The role of this enzyme is to 
metabolize LTB4 by omega-oxidation to 20-OH LTB4 and 20-COOH LTB4, essentially 
inactive products of LTB4 [246]. Of importance are also observations that CYP4F2 is 
involved in the omega-hydroxylation of AA thus potentially regulating the biosynthesis 
of LTB4 as well. Furthermore, studies have shown that it is also expressed in the intestine 
[247], thus signifying its potential role in deactivating both circulating as well as tissue-
specific LTB4.  
Thus, it can be postulated that the CYP4F2 enzyme is a key regulator of the 
negative-feedback mechanism that influences the actions of LTB4 in various tissues. The 
CYP4F2 enzyme is encoded by the CYP4F2 gene (NC_000019.8), part of a cluster of 
cytochrome P450 genes on chromosome 19 (i.e. 19pter-p13.11).  
                                                 
‡‡ Km = Specificity constant 
With regards to CYP4F2, three genome scans have revealed significant linkages 
to the chromosomal region where it is located (i.e. 19p) in different populations. Rioux et 
al (2000) using affected sib-pairs reported peak LOD scores§§ of 4.6 for IBD and 3.0 for 
CD at 19p in a Canadian population [75]. In their recent meta-analyses of 10 IBD 
genome scans among affected relatives, van Heel et al (2004) also reported significant 
linkage of CD to chromosome 19p [248]. Finally, Low et al (2004) carried out a linkage 
scan among UK Caucasians (affected sib-pairs) and confirmed linkage of CD to the 
19p13.2 region (peak multi-point linkage score of 1.59) [249]. Further support for the 
role of CYP4F2 in inflammation was provided by the study of Curley et al (2006). Based 
on the observation that celiac disease (i.e. another inflammatory disorder of the 
gastrointestinal system) shares two linkage regions with IBD, viz. on chromosome 5q31 
(CELIAC2 and IBD5) and 19p13 (CELIAC4 and IBD6) [75, 248, 250, 251], the authors 
hypothesized that genes situated on overlapping regions of chromosomes 5q31 and 
19p13.1 might be associated with susceptibility for both disorders, most probably by 
influencing inflammation in the gut. Further based on its role in inflammation and its 
location in the overlapping regions, CYP4F2 gene was thus chosen as one of the studied 
candidate genes. Two out of eight CYP4F2 tag-SNPs (selected according to their block-
tagging ability, replication status, allele frequency and SNP density) showed positive 
association with celiac disease in this unrelated case-control study, further supporting a 
putative role for this gene in gut inflammation [252]. 
Evidence for linkage to IBD on chromosome 19p was also used as an argument 
by Tello-Ruiz et al to conduct a screen for candidate genes [253]. However, none of the 
CYP4 family genes were considered for further investigation. 
Finally, a recent meta-analysis combining data from three GWA studies on CD (a 
total of 3,230 cases and 4,829 controls) and further replicated in 3,664 independent cases 
                                                 
§§ LOD stands for logarithm of the odds (to the base 10). A LOD score of three or more is generally taken 
to indicate that two gene loci are close to each other on the chromosome. (A LOD score of three means the 
odds are a thousand to one in favor of genetic linkage). 
 
with a mixture of population-based and family-based controls, identifies the 19p13 locus 
as a potential candidate region associated with CD [254]. 
In summary, LTB4 is crucial to the inflammatory process. Its role has been well 
demonstrated in a number of inflammatory diseases. Both in vitro and in vivo studies 
show that LTB4 expression is hampered in CD. Recent evidence highlights that 
enzymes/proteins in the LTB4 synthesis pathway are abnormally expressed in CD mucosa 
and the frequency of cells expressing these proteins was substantially higher. Although 
limited, genetic studies suggest in particular that the CYP4F2 gene could be linked to 
CD. Furthermore the ALOX5 gene is associated with susceptibility for other 
inflammatory diseases suggesting that it may play important roles in CD as well. 
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Figure 1 – Localisation and pathologic features of 
pediatric Crohn’s disease
 
Figure 2A - Age-specific incidence per 100,000 of Crohn’s disease
(CD) in five Canadian provinces, 1998-2000 
Legend: BC – British Columbia, AB – Alberta, SK – Saskatchewan, MB – Manitoba, NS – Nova Scotia
(from Bernstein, C.N. et al. « The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study » The 
American Journal of Gastroenterology 101 (7), 1559-1568)
 
Figure 2B - Age-specific prevalence per 100,000 of Crohn’s disease
(CD) in five Canadian provinces, 1998-2000
Legend: BC – British Columbia, AB – Alberta, SK – Saskatchewan, MB – Manitoba, NS – Nova Scotia
(from Bernstein, C.N. et al. « The Epidemiology of Inflammatory Bowel Disease in Canada: A Population-Based Study » The 
American Journal of Gastroenterology 101 (7), 1559-1568)
 
Figure 3 - Confirmed and suggested linkage intervals from genome
wide scans in Crohn’s disease (CD) with the potential candidate genes
coloured in red (significance levels defined by Lander and Kruglyak)
(from Noble C et al. Novel susceptibility genes in inflammatory bowel disease. World J Gastroenterol. 
2006 Apr 7;12(13):1991-9.)
 
Figure 4 – Hypothesized mechanisms underlying the pathogenesis of Crohn’s Disease (CD)
(1) A dysbalance of enteral bacteria changing epithelial barrier function or a primary barrier defect (2) allows bacteria an increased 
translocation across the epithelial barrier (3) challenging the mucosal immune system. Bacteria or bacterial wall compounds may enter 
macrophages/dendritic cells and bind to NOD2/CARD15 (4). In case of mutations with loss of function, no sufficient NF-kappa-B activation is 
achieved and the translocated bacteria cannot be quickly eliminated. 
An insufficient response will also occur if bacterial sensors (i.e. toll-like receptors) in the cell membrane are mutated (5). 
Another possibility is a mutation of NF-kappa-B itself (6) reducing protein expression of efficient translocation and inhibiting or delaying an 
immediate response. If the stimulus cannot be eliminated rapidly, antigen-presenting cells become activated and interact with Th1 cells. By 
expression of co-stimulatory molecules, which are normally downregulated, they induce T-cell proliferation (7) by secretion of Th1 stimulating 
cytokines such as IL-12, IL-23 or IL-18 to compensate the impaired innate immunity response. Insufficient activity of regulatory T-cells (8) 
could contribute to prolonged Th1 activity and chronicization of the inflammation. 
(from Rogler, G. Update in inflammatory bowel disease pathogenesis. Current Opinion in Gastroenterology 2004, 20:311–317)
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Table I – crohn’s disease (CD) Vienna and Montreal Classification 
 
 Vienna 
Classification 
Montreal 
Classification 
Reference (Gasche, Scholmerich et al. 
2000) 
(Silverberg, Satsangi et al. 
2005) 
A1 below 40 y A1 below 16 y 
A2 above 40 y A2 between 17 and 40 y 
Age at 
diagnosis 
(A) 
 A3 above 40 y 
L1 ileal L1 ileal 
L2 colonic L2 colonic 
L3 ileocolonic L3 ileocolonic 
Location 
(L) 
L4 upper L4 isolated upper disease* 
B1 non-stricturing, non-
penetrating 
B1 non-stricturing, non-
penetrating 
B2 stricturing B2 stricturing 
B3 penetrating B3 penetrating 
Behavior 
(B) 
 **  « p » perianal disease 
modifier 
 
*L4 is a modifier that can be added to L1–L3 when concomitant upper gastrointestinal 
disease is present. 
** "p" is added to B1–B3 when concomitant perianal disease is present. 
 
 
   
  
 
 
 
Table II. Summary of the large monozygotic (MZ) and dizygotic (DZ) 
twin studies to date. 
Population 
Monozygotic 
twins 
Crohn’s 
Disease 
(CD) 
Concordanc
e 
Dizygotic 
twins 
Crohn’s 
Disease 
(CD) 
Concorda
nce 
References 
Danish 5/10 0/27 (Orholm, Binder et al. 
2000) 
British 5/25 3/46 (Thompson, Driscoll et al. 
1996) 
Swedish 9/18 1/26 (Tysk, Lindberg et al. 
1988; Halfvarson, Bodin 
et al. 2003) 
European 20-50% >10% (Halme, Paavola-Sakki et 
al. 2006) 
 
 
 
 
Table III. Overview of the Genome-Wide Association Studies (GWAS) Performed to Date in IBD 
Location of 
the Centers 
Design No. of SNPs genotyped
Novel Gene 
Identified 
Other Genes 
Identified 
References 
Japan, UK Case-control  
(both screening and 
replication) 
72,738 TNFSF15 TNFSF8 (Yamazaki, McGovern 
et al. 2005) 
OCTN1/SLC22A4 Germany, 
UK 
Case-control (screening) + 
Trio (replication) 
19,779 ATG16L1 
NOD2/CARD15 
(Hampe, Franke et al. 
2007) 
Case-control (screening) + 
Trio (replication) 
308,332 
(Illumina, HumanHap300 
BeadChip) 
IL23R NOD2/CARD15 
10q21.1 "gene desert" 
(EGR2) 
PHOX2B 
NCF4 
North 
America 
Case-control (screening) + 
[Trio+ Case-control 
(replication)] 
308,332 
(Illumina HumanHap300 
BeadChip) 
FAM92B 
ATG16L1 
(Duerr, Taylor et al. 
2006) 
 
 
(Rioux, Xavier et al. 
2007) 
NOD2/CARD15 
IL23R 
Belgium Case-control (screening) + 
[Trio+ Case-control 
(replication)] 
 
 
 
308,332 
(Illumina HumanHap300 
BeadChip) 
 
5p13.1  
"gene desert" (PGER4) 
ATG16L1 
(Libioulle, Louis et al. 
2007) 
Table III. Overview of the Genome-Wide Association (GWA) Studies Performed to Date in IBD 
(CONT’D) 
Location of 
the Centers 
Design 
No. of SNPs 
genotyped 
Novel Gene 
Identified 
Other Genes 
Identified 
References 
(Wellcome Trust Case Control  
Consortium 2007) 
UK 
 
Case-control 
(screening) 
Case-control 
(replication) 
500,568 
(Affymetrix 
GeneChip 500K 
Mapping Array 
Set) 
IRGM 
NKX2–3 
PTPN2 
3p21 
1q "gene deserts" 
IL12B 
FLJ45139 
NOD2/CARD15 
IL23R 
ATG16L1 
IBD5 
(Parkes, Barrett et al. 2007) 
Mixed 
populations  
Meta-analysis 
Case-control and 
case-parent design 
(replication study) 
 
Focus on 526 
SNPs from 74 
distinct genomic 
loci  
 
PTPN22 
ITLN1 
IL12B 
CDKAL1 
CCR6 
JAK2 
C11orf30 
LRRK2 
MUC19 
ORMDL3 
STAT3 
ICOSLG 
IL23R 
ATG16L1 
MST1 
PTGER4 
IRGM 
TNFSF15 
ZNF365 
NKX2-3 
NOD2 
PTPN2 
 
(Barrett, Hansoul et al. 2008) 
Table III. Overview of the Genome-Wide Association (GWA) Studies Performed to Date in IBD 
(CONT’D) 
Location of 
the Centers 
Design 
No. of SNPs 
genotyped 
Novel Gene 
Identified 
Other Genes 
Identified 
References 
North America 
(pediatric IBD 
population) 
Case-control 
(both screening and 
replication) 
550,000 
(Illumina 
Human Hap550 
Genotyping 
BeadChip 
STMN3 
RTEL1 
TNFRSF6B 
ARFRP1 
ZGPAT 
LIME1 
ZBTB46 
IL23R 
NOD2 
HLA-DRB1 
PSMG1 
TNFRSF6B 
(Kugathasan and Cohen 2008) 
 
 
 
 
 
 
 
Section B. Rationale and hypothesis 
CD is considered a complex disease with contributions from genetic, 
environmental and immunological factors.  Evidence for genetic risk factors is now well 
established with respect to the NOD2/CARD15 gene. Although other specific genomic 
regions have been identified as playing an important role in CD, there is currently limited 
information on other susceptibility genes. The study of the leukotriene-generating 
pathway is of particular relevance, as it represents the final step in the pathogenesis of 
inflammation, a key process in CD. In addition to an aberrant innate and/or adaptive 
immune response, susceptibility to disease may reflect the inter-individual variability in 
the pathogenesis of inflammation, due to differences in the expression of genes that are 
involved in the pathway of leukotrienes production. Thus, of particular relevance are 
polymorphisms in genes that play an important role in this pro-inflammatory pathway. As 
such, both the ALOX5 gene that regulates the pathway upstream and was shown to have 
an important role in the pathogenesis of inflammation in chronic disorders, and the 
CYP4F2 gene, which is involved in the de-activation of LTB4 and is located in a region 
of significant linkage to CD, may be important candidate genes in the study of CD. In 
spite of the overwhelming support for a potential role of these genes in the pathogenesis 
of CD, no study has so far investigated these associations. In this study, we have 
hypothesized that DNA variants in the genes implicated in the 5-LO pathway, which 
plays a critical role in regulating the production of inflammatory leukotrienes, could 
modulate the risk for developing early-onset CD and can further influence the 
disease phenotype. In the context of our project, we have particularly focused on these 
two genes as potential candidates for CD, the ALOX5 and CYP4F2 gene, respectively, 
based on the available published evidence, as well as the critical points in which they 
intervene in the 5-LO pathway (upstream and downstream, respectively). 
 
 Objectives 
 
Based on this hypothesis, the primary objectives of this study were: 
1. In the first stage, to examine the associations between selected DNA variants in 
the ALOX5 and CYP4F2 genes and early-onset of CD; and, 
2. In the second stage of the study, to retest potential associations between DNA 
variants in the ALOX5 and CYP4F2 gene observed in the first phase of the study. 
 
In addition the secondary objectives included: 
1. To explore whether risk for CD associated with the CYP4F2 and ALOX5 genes 
were influenced by genomic imprinting mechanisms (parent-of-origin effect); 
2. To investigate whether the CYP4F2 and ALOX5 genes were associated with 
specific clinical phenotypes of CD such as gender, disease location and behaviour, 
and 
3. To determine whether interactions between the ALOX5, CYP4F2 and 
NOD2/CARD15 predisposed to early-onset CD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section C. Methods 
In order to address the two main objectives of this study, we implemented a 2-
phase approach. In the first phase, we explored associations between SNPs in the 2 
candidate genes and pediatric CD and in the second phase we investigated whether 
findings of potential associations detected in Phase 1 were replicated in an independent 
cohort. 
C.1. Study designs 
Case-control-studies, where sampling is conditional on the presence or absence of 
disease, are widely used in epidemiology for studying associations between disease and 
potential risk factors. In the current context, the risk factors are represented by 
alleles/genotypes in the candidate genes; i.e. the ALOX5 and the CYP4F2 genes. Some 
of the advantages in using this type of design are that it is a relatively inexpensive 
approach and the assessment of the “exposure” variables (i.e. genotypes) is quite 
straightforward. Yet, in the context of genetic studies using a case-control approach there 
are a few expressed concerns that can limit their validity. More specifically, from a 
practical standpoint, study participants, who typically provide data on exposures and 
other covariates, must also provide biologic material – usually blood, for genotyping 
purposes. Such samples are difficult to obtain, inventory and process. Concerns about 
potential abuses of genetic data and the procedure in itself (i.e. venopuncture to collect 
blood) may make genotyping healthy subjects that are used as controls and especially 
children hard to justify and recruit. The resulting low control participation can invalidate 
a study because controls who self-select to participate may not be representative of the 
base-population studied. An important concern regarding the use of unrelated cases and 
controls in association studies is that one cannot distinguish valid association due to 
linkage from spurious association due to confounding effects. One of the major 
confounders of importance in genetic association studies is population stratification, 
which occurs if the population from which the cases and controls were sampled consists of 
latent subpopulations, each with different variant allele frequencies and risks of disease. A 
spurious association due to this confounding effect will occur for any variant allele that is 
at an elevated frequency in the subpopulation with the greatest disease prevalence.  
In order to overcome the limitations of traditional case-control studies for 
studying genetic associations, non-traditional case-control designs have been proposed 
such as the case-sibling design [255] and the case-parent design [256]. In general, rather 
than using unrelated controls, these designs utilize familial controls. The use of family-
member case-control designs is appealing because family members have a common gene 
pool and hence the problem of population stratification is overcome by matching. From 
among the family-based case-control designs, the case-parent design has been most 
widely used. First introduced by Falk and Rubinstein (1987) to avoid spurious association 
from population stratification, they recommended collecting the parents of each case 
subject and using the non-transmitted parental alleles as a control sample. The key 
assumption is that transmission of alleles from parents to offspring follows Mendelian 
probabilities and that, for each parental mating type, the Mendelian genotype proportions 
persist among offspring until the ages at which the probands are studied [257]. In doing 
this, the cases and controls are matched in genetic ancestry and are therefore robust to 
population stratification.  
Based on this premise, Spielman et al. constructed a joint test of linkage and 
association, called the "transmission/disequilibrium test" (TDT) that attempts to identify 
preferential transmission of alleles from parent to affected child by use of a McNemar 
statistic [258]. A variant of the TDT, developed by Schaid and Sommer is a likelihood 
procedure for triads, called the "conditional on parental genotypes" (CPG) approach, that 
models the probability of an affected offspring's genotype conditional on parental 
genotypes as a function of the genotype relative risks (RRs) of the offspring. This CPG 
likelihood approach allows flexible modeling of the genotype RRs, which can be 
estimated using standard maximum-likelihood procedures [259].  
More recently, Nagelkerke et al. advocated an approximate analysis that, although 
having the advantage of being easily conducted by use of standard logistic-regression 
software, makes the strong assumptions of Hardy-Weinberg equilibrium (HWE), random 
mating, and a multiplicative model of allele effect on disease [260]. A modified, power-
preserving version of the Nagelkerke et al. likelihood-based approach was introduced by 
Epstein et al. shortly thereafter, to allow for more-flexible modeling of allele effects and 
less-restrictive assumptions about the distribution of parental mating types and genotypes 
[261].  
The sampling of parental controls is often more difficult and more expensive than 
that of unrelated controls, since studies must identify and sample the two parents of an 
affected subject. Many parents may not be available for analysis, because of death, refusal 
to participate, or false paternity. In his approach, Epstein et al. also addressed the issue of 
missing information. This generalized approach can also accommodate in the analysis 
triad samples with missing parental data, by inferring the missing genotypes based on the 
observed parental genotype data. In such instance, the statistical method used is an 
expectation-maximization (EM) algorithm that allows the incomplete triads to contribute 
their information to the likelihood-ratio test without invalidation of the analysis. 
Simulation results also suggest that using likelihood estimates for cases missing one or 
both parents from the analysis can recover much of the power that would be lost if we 
were to exclude data from these incomplete triads from the analysis [261]. 
In addition to overcoming potential confounding due to “population 
stratification”, there are other advantages of using the case-parent design vis-à-vis the 
traditional case-control design. One advantage is that it enables more efficient study of 
haplotype-based risks in addition to genotype-based risks. Studying haplotype-based risks 
is considered more powerful for the detection of potential candidate genes [262]. The 
latter is also possible using the traditional case-control design. However, in the absence of 
genotype information from the parents, it is not possible to accurately determine for 
homozygotes the “phase” of the transmitted allele, and hence haploytpes have to be 
inferred statistically. Although, many methods based on the EM algorithm have been 
proposed to infer haplotypes in case-control data [263], the accuracy of these estimations 
is less than optimal and can lead to biased inferences. A second advantage of the case-
parent design is that it enables the estimation of imprinting effects (i.e. parent-of-origin 
effects) that cannot be estimated using the case-control design. Although the case-parent 
design provides numerous advantages, there are also some inherent limitations. First and 
foremost is the inability to determine the independent effects of “non-genetic” risk factors 
and subsequently its inability to control for potential confounding from such “non-
genetic” variables besides ethnicity.  
For the present study, we took advantage of the strengths of both types of design, 
thereby also exerting some control over their limitations, by implementing a 2-phase 
design. In the first phase (exploratory phase), we implemented the case-parent design 
[264-266]. Using this design we examined associations between the targeted candidate 
genes and susceptibility for CD for estimating genetic risks (including haplotype effects) 
(Objective 1) and for determining parent-of-origin effects (secondary objective), i.e. 
imprinting. In the second phase (replication study, Objective 2), we employed a case-
control study on a separate subset of pediatric CD cases (same phenotype), to confirm 
potential associations observed in the exploratory phase. The cases from both Phase 1 and 
Phase 2 were then combined to investigate gene-gene interactions (secondary objective), 
whether gender modified the associations between the study genes and CD (secondary 
objective) and whether the study genes were associated with specific clinical phenotypes 
of CD, i.e. disease location and behaviour (secondary objective). Details are provided 
below. 
C.2. Study population 
The study was implemented at three pediatric gastroenterology centers across 
Canada Ste. Justine’s Hospital (HSJ) in Montreal, the Children’s Hospital of Eastern 
Ontario (CHEO) in Ottawa and British Columbia’s Children’s Hospital (BCCH) in 
Vancouver. These three centers are the main pediatric IBD treatment centers in the 
respective metropolitan areas and are expected to cover the majority of the early-onset 
IBD population in their respective catchment areas. 
C.3. Exploratory approach (Phase 1) 
The case-population for the case-parent study was represented by patients 
diagnosed before age 20 and that were being followed up for treatment and management 
at the three study hospitals mentioned above. These included both prevalent (Montreal) as 
well as new cases (Montreal, Ottawa, Vancouver). For non-genetic studies, selecting 
incident cases are ideal in order to avoid biases (such as reverse causality, survival bias, 
migration bias etc.) inherent when using prevalent cases. For genetic studies however, as 
the exposure of interest is fixed (genotype) and established prior to the outcome, 
including prevalent and incident cases is not a concern. CD patients that were undergoing 
follow-up during 2003-2007 were invited and recruited for the study – Appendix 1.  
The majority of the cases originated from HSJ in Montreal (n=127, 79.4%), 
whereas 17 (10.6%) were from CHEO (Ottawa) and 16 (10%) from BCCH (Vancouver). 
A total of 160 complete trios (i.e. a trio is formed by a case and both its parents) were 
recruited for the first phase of our study.  
Overall the diagnosis of CD was based on standard clinical, endoscopic, 
radiologic and histopathological criteria [267, 268]. These included: (i) the presence of 
characteristic small bowel involvement with or without obstructive symptoms secondary 
to stenosis or stricture; (ii) deep linear ulcers, cobblestoning and discontinuous 
inflammation at endoscopy; or, (iii) patchy transmucosal chronic inflammation with 
granulomas on biopsy specimens. For cases whose diagnosed was unclear, confirmation 
was acquired after a minimum follow-up of 12 months. Clinical phenotypes of the cases 
were characterized at diagnosis – Appendix 2.  
A web-based clinical database of information from the medical charts of IBD 
patients diagnosed and managed at the three study centers was created. The information 
included location and extent of disease, and disease behavior. Information on type of 
medications administered, their doses and duration, and surgical interventions was also 
extracted and maintained. Clinical phenotypes were classified according to the Vienna 
classification [32] and subsequently updated by the Montreal Classification [33] - Table I 
(Page 10).  
The parents of the cases were contacted and invited to participate in the study. 
Only parents who reported being the biological parents of the child were included. In 
addition, only those trios where both parents were available were included. No other 
major exclusion or inclusion criteria were imposed.  
In order to recruit the children and their parents the following strategy was 
utilized. For HSJ, a comprehensive list of all patients undergoing follow-up was 
established in coordination with the gastroenterologists. The gastroenterology outpatient 
clinics of HSJ maintain a list of all such patients. In order to include potential cases 
missing from these lists, the gastroenterologists were asked to prepare a list of patients 
that they currently followed-up. After acquiring these lists, the medical charts of all the 
patients were screened to first confirm that the patient had been diagnosed with IBD and 
with CD after at least 1 year of follow-up. In addition to prevalent cases, cases newly 
diagnosed during the time period of the study (2003-2007) were also included. As most 
patients clinically suspected of having IBD undergo endoscopy, all patients who on 
endoscopy were suspected of having CD were temporarily listed as potential subjects. 
Once the initial diagnosis was established (~1 month after endoscopy), these subjects 
were listed for recruitment.  
For both prevalent and newly-diagnosed cases, the permission of the 
gastroenterologist was acquired to contact the patient (as required by the Ethics 
Committee at HSJ). At the next scheduled visit of the patient, the parents/guardians were 
approached and invited for participation. For those patients (usually prevalent subjects 
with long-standing disease) for whom a clinic visit was not scheduled for in the near 
future, the contact information of these patients was sought. A letter describing the 
modalities of the study was sent to these families and they were informed that a research 
co-ordinator would subsequently contact them for soliciting participation. Approximately 
10 days subsequently, the parents (usually the mother) of the patients were contacted by 
phone. Details of the study were explained and upon preliminary agreement to 
participate, a short socio-demographic questionnaire and consent forms were mailed to 
their residence. Alternatively, for newly-diagnosed patients who were approached in the 
clinics, the study details were explained in the clinic and consent acquired.  
At BCCH (2004) and CHEO (2006-2008) only newly-diagnosed patients were 
recruited. The same strategy utilized for newly diagnosed patients at HSJ was 
implemented at these centers.  
C.4. Replication study (Phase 2) 
In order to examine whether potential associations observed in the Phase 1 study 
(i.e. case-parent study) withstood replication, a case-control study was carried out.  
C.4.1. Cases 
Cases for this study were those recruited at two pediatric gastroenterology clinics, 
one in Montreal (HSJ) and the other in Ottawa (CHEO). For this phase of our study, a 
total of 225 pediatric CD cases were included in the analyses.  
The same criteria for diagnosis as was implemented in the exploratory phase were 
implemented in the replication study. The cases for the replication study were selected 
by-and-large independent of the case-parent study. The case population nonetheless 
included those cases who were initially recruited as part of the first phase of the study, 
but for whom one or both parents were not available (~23 cases) – Appendix 1. It would 
have been ideal to randomly split the cohort of available cases and implement the 
exploratory and replication studies. However, our replication study was planned 
subsequent to the findings in the exploratory phase and hence practical limitations 
precluded the use of random methods. Nonetheless we believe that the selection factors 
involved in the exploratory and replication cohorts were similar (and not influenced by 
the exposure under study) and are unlikely to influence the validity of the findings in a 
major way.  
C.4.2. Controls 
One of the main challenges in carrying out a genetic study in children and when 
implementing the case-control design is selection of healthy population-based controls. 
As these controls are expected to provide DNA, the response rates could be low and low 
rates could invalidate the representativeness of the controls and the study-base principle. 
In order to overcome the latter limitations many investigators select as controls healthy 
adult controls. The rationale for the selection of adult controls for pediatric genetic 
studies is that the gene pool is not expected to change in one generation and hence the 
distribution of the genes under study among adults is likely to represent the distribution 
of the genes in that among healthy children. However, it has been shown that the gene 
pool in successive generations could be altered if the population structure gets altered. 
Immigration, inbreeding and emigration if present in successive generations than the gene 
pool in children would likely differ from those among individuals in the previous 
generation (adults).  
When selecting controls for our pediatric cases, in order to ensure 
representativeness of the genes under study we decided to recruit controls from different 
sources. One source of controls was children visiting the orthopaedic departments of the 
study hospitals. At both study hospitals, computerized listings of all patients visiting the 
Acute Trauma Centers (ATC) of the orthopaedic departments are maintained. We utilized 
this source for selection of controls. Based on the sampling frame we selected as controls 
children who were diagnosed with minor traumas (viz. fractures). In addition, all controls 
that were concurrently diagnosed with immune mediated diseases such as asthma, 
juvenile diabetes, celiac disease etc. were excluded. Whenever possible we selected 
controls such that there was more than 1 control per case. To enhance sample size and 
population representativity we also invited the siblings of the orthopaedic controls to 
participate in the study.  
In order to further ensure the representativeness of the control population and also 
to examine whether adult controls were appropriate for pediatric genetic studies we 
included as controls a population of adult controls that were being recruited for an 
ongoing genetic epidemiology study at the Montreal study center. The study explores the 
population genetics of a founder effect in the Saguenay-Lac-Saint-Jean region in North 
Quebec. As part of the study genetic material is collected and banked. We utilized this 
source in order to acquire the requisite adult controls for the study. As an additional 
source of controls we included umbilical cord samples from a birth cohort that is 
currently being assembled at HSJ – Appendix 1.  
For the orthopaedic controls (selected for cases recruited at Ottawa and Montreal) 
the same procedures were implemented. A research co-ordinator at each center based on 
information provided by the computerized listing sent a letter to the potential control (in 
most cases the mother) informing them in brief about the study and intimating them on 
their possibility of being contacted to solicit participation. One week after the letter was 
mailed to them, the potential participants were contacted over phone to solicit their 
participation. Details on the study objectives were provided. If verbal consent was 
obtained, an appointment was scheduled during their subsequent visit to the orthopaedic 
clinic. If a visit was not scheduled than a study kit (comprising of the consent form, brief 
socio-demographic questionnaire and a kit for collecting saliva) was mailed to the 
participants. If a clinic visit was scheduled, the participants were approached at the clinic, 
consent taken and information required for the study collected.  For the adult controls, 
DNA samples that were housed in DNA bank of the respective investigators was 
provided to us. Similarly, umbilical cord samples were provided by an investigator (and a 
co-investigator in the present study) responsible for establishing the DNA bank of the 
birth cohort at HSJ.  
A total of 330 controls (i.e. 225 orthopaedic controls; 20 controls from the birth 
cohort, and 85 healthy individuals) were selected for the replication phase of our study. 
Further details on the control population are presented in Table XIV (Results section).  
C.5. Genetic information 
C.5.1. Biological material 
In order to extract DNA, either peripheral blood (PB) samples or saliva were 
acquired from all participants (i.e. cases, parents, and controls). For the cases, PB for 
research purposes was collected during the patients’ regular follow-up visit, at the same 
time as blood samples were to be acquired for diagnostic and follow-up purposes. If 
blood samples were not being collected, than saliva was collected using ORAGENE 
KITS® (DNA Genotek Inc., Ottawa, Canada). A research coordinator demonstrated how 
the saliva was to be collected. For the parents and the controls either blood or saliva was 
collected. For subjects (cases and parents) who were not scheduled for a follow-up visit, 
the ORAGENE KITS® were mailed to them. The families were contacted by phone to 
verbally explain the procedure for collecting the saliva samples. Weekly reminders were 
made by telephone to ensure that samples were collected and mailed back to the study 
center (i.e. HSJ in Montreal). Participants were also advised to contact our study 
coordinator if they had any queries related to the provision of the study material.  
All study material (i.e. questionnaires and biological samples) were coded 
pairwise to maintain the anonymity of the participants.    
C.5.2. DNA extraction and genotyping 
The DNA in saliva comes from buccal epithelial cells and white blood cells found 
in the oral cavity. The ORAGENE® kits are extremely user-friendly and only require 
collecting saliva via expectoration. In addition to its effectiveness and non-invasiveness, 
this method provides high quality DNA of large quantity. These kits enhance the 
acceptance level by subjects and are an efficient alternative to collecting DNA from 
blood samples [269-271]. On receipt the kits were kept stored at 4ºC pending DNA 
extraction, according to the manufacturer’s protocol. Subsequently, DNA extraction was 
performed according to the extraction methods provided by the manufacturer 
(http://www.dnagenotek.com).  
For PB samples, DNA extraction was carried out using commercially available 
kits, i.e PUREGENE DNA® isolation kit (Gentra Systems, Minneapolis, USA) according 
to their validated methods (http://www1.qiagen.com/literature). Extracted DNA was 
subsequently quantified by spectrophotometer (NanoDrop Technologies, Delaware, 
U.S.A.), transferred on 96-well plastic plates and kept frozen (-80ºC) pending 
genotyping.  
Genotyping was done using the GenomeLab Sequenom technology which is 
based on a newly developed genotyping assay termed iPLEX for use with the Mass 
ARRAY® platform. Briefly, a primer extension assay is used to perform highly 
multiplexed genotyping of single nucleotide polymorphisms (SNPs) present in genomic 
DNA amplified by a multiplex PCR. The assay uses matrix-assisted laser desorption 
ionization time-of-flight mass spectrometry to accurately measure the masses of short 
oligonucleotide primers extended by a single dideoxynucleotide. The multiplexed 
genotyping assays rely on the natural molecular weight differences of DNA bases. By 
careful analysis of primer composition complementary to the target, or by judicious 
addition of one or more non-complementary 5' bases to the genotyping primers, mass 
spectra of interleaved genotyping products can be generated with no ambiguity in allele 
assignment [272]. This assay is specifically designed for high-throughput SNP 
genotyping and can also accommodate certain insertions/deletions.  
The GenomeLab™ Sequenom Genotyping System offers multiple advances 
including: flexible and efficient assay design (i.e. 96% success rate), improved call rates 
(i.e. 85%) and accuracy (i.e. error rate is less than 0.5%) and, significantly reduced cost 
per genotype (i.e. below 5 cents per genotype). Genotyping was performed using the 
high-throughput facilities at the McGill University Genome Quebec Innovation Center in 
Montreal (http://www.genomequebecplatforms.com/mcgill/home/index.aspx).   
C.5.3. Selection of SNPs in the CYP4F2, ALOX5 and NOD2/CARD15 
genes 
SNPs are the commonest variations across genes and genomes. On average, about 
40-50 SNPs can be found per gene. Since many of these SNPs can be in linkage 
disequilibrium (LD)***, information acquired from genotyping a few relevant SNPs can 
provide information on neighbouring SNPs. That means that if a causal polymorphism is 
not genotyped, we can still hope to detect its effects through LD with polymorphisms that 
are typed. Statistical approaches for identifying these “tag”-SNPs are well developed.  
We used the approach proposed by Carlson et al [273]. In brief, this method is 
based on LD between SNPs. By re-sequencing the gene in a random sample of subjects, 
SNPs are identified. Subsequently using a defined threshold for LD (i.e. r2=0.80 or more) 
and specifying the minimum allele frequency (MAF) of interest (i.e. 10%, for example), 
SNPs in LD with each other are grouped into subsets, called bins. Those SNPs with the 
highest LD with other SNPs in the bin are identified (or tagged) after an iterative process 
using a greedy algorithm. The tagged-SNPs are the ones that are genotyped. Only 1 
tagged-SNP needs to be selected per bin. The set of SNPs so selected are good 
representatives of the un-assayed SNPs.  
Besides being cost-effective, with relatively stringent LD specification, more than 
80% of the haplotypes existing in the population can be resolved, enabling the study of 
haplotype-based associations. Public databases are now available that provide raw 
sequencing data for different genes among different populations that can be utilized for 
identifying tag-SNPS. Using the LDSELECT® program (http://pga.gs.washington.edu), 
14 tag-SNPs in the 2 candidate genes were identified (Appendix 3), when using 
genotyping data available for European Caucasians for genotyping. To identify the latter, 
we used the Seattle SNP public database (http://pga.gs.washington.edu) that provides 
information on SNPs prevalent in populations of European descent and enables 
                                                 
*** Linkage disequilibrium is a term used for the non-random association of alleles at two or more loci, not 
necessarily on the same chromosome. 
 
identification of tag-SNPs based on implementation of the Carlson et al algorithm [273]. 
The tag-SNPs were derived from DNA samples of unrelated parents (23 samples) that are 
part of the Centre d'Etude du Polymorphisme Humain (CEPH) repository, which is also 1 
of the populations included in the HAPMAP project (www.hapmap.org). These samples 
are of Utah, USA, residents with ancestry from northern and western Europe. Three of 
these 23 samples are of subjects with French pedigrees. 
As for the selection of the SNPs in the NOD2/CARD15 gene, we used publicly 
available information. The caspase-activation and recruitment domain gene 15 (i.e. 
NOD2 or CARD15 gene) has been identified as the candidate gene on the IBD1 
susceptibility locus (on chromosome 16q12) and confers risk for development of CD 
[82]. Its 1,040 amino acids are structured into four distinct domains: two N-terminal 
CARDs, a central nucleotide-binding and oligomerization domain (NBD or so-called 
NACHT domain), and a C-terminal leucine-rich repeat (LRR) domain [274]. Three 
variants within the LRR were initially described to be associated with CD [70]. The three 
main variants are highly disease specific [70, 275, 276], are located in the distal third part 
of the gene, and are respresented by two missense point mutations [2104C>T 
(rs17860491) and 2722G>C (rs17860492)] and a frameshift mutation [3020insC 
(rs17860493)] resulting in nonconservative variations of the protein (respectively, 
R702W, G908R, and 1007fs). Altogether, these three disease susceptibility alleles 
represent 82% of the mutated chromosomes in CD [140]. These three disease 
susceptibility variants in the NOD2/CARD15 gene, identified as SNP8, SNP12 and 
SNP13, were genotyed in the cases (combined) and the controls. Genotyping was carried 
out using the SEQUENOM platform at the McGill University Genome Quebec 
Innovation Center in Montreal. In our sample population, individuals were categorized 
into NOD2+/NOD2-, depending on whether they carried any one of the three disease 
susceptibility variants. 
C.5.4. Quality control and evaluation of genotyping errors 
The genotyping process involved a stringent protocol for maintaining the quality 
of the results acquired. Evaluation of genotyping errors was carried out by examining 
Mendelian transmission patterns (case-parent design) and testing for HWE (case-parent 
and case-control designs). As the distribution of alleles among the alleles non-transmitted 
from parents to the child (pseudo-controls) is considered to be a measure of the 
population-allele frequency, for the case-parent study HWE was evaluated among the 
pseudo-controls formed by the complete trios. Thus for each trio, the allele not 
transmitted from the mother and father (i.e. a pair of alleles) were used as pseudo-
controls. For the case-control design HWE was evaluated among the controls.   
As departures from Mendelian transmission patterns could be due to false 
paternity or genotyping errors, distinguishing between these would be important. Douglas 
et al. (2002) have proposed algorithms to enable identifying whether Mendelian 
inconsistencies are likely the result of false paternity. In general, for every 100 families 
that are genotyped for ~20 SNPs, with expected genotyping error rates of ~5%, false 
paternity is likely to exist when for any family there are more than 6 inheritance 
inconsistencies (i.e. inconsistencies for 6 SNPs) [274].  
We applied a modified version of these algorithms to our trio samples to detect 
and exclude families demonstrating false paternity. In the absence of false paternity, 
departures from Mendelian transmissions were considered due to genotyping errors. The 
SNPs that demonstrated departures from Mendelian transmissions (i.e. >5% of the 
families) and that deviated from HWE (i.e. p<0.01, accounting for the number of SNPs 
being genotyped) were considered candidates for replacement with other tag-SNPs.   
In addition, to assess the reproducibility of the genotyping techniques, 20% of the 
samples were randomly re-genotyped for all the SNPs [275].  
C.6. Sample size and power 
C.6.1. Phase 1 - sample sizes for case-parent design  
For estimating main effects using the case-parent design, the following parameters 
were assumed: (1) allele frequencies between 10%-50%; (2) power of 80%; (3) an alpha 
level of 0.05 and, (4) relative risks between 1.5 and 2.0. Appendix 4a outlines these 
power calculations. Based on the above parameters, it was estimated that between ~150-
200 trios would be required to detect the expected risks with sufficient power assuming 
either a multiplicative or a dominant model. For most SNPs, power under the recessive 
model would not have been achievable unless very high relative risks were assumed. Our 
aim was thus to have sufficient power to detect risks based on either the multiplicative or 
dominant model while assuming modest risks for disease. 
C.6.2. Phase 2 - sample sizes for case-control design  
The case-control study was designed subsequent to observed findings of the case-
parent study (exploratory study). To confirm the observed associations between the three 
SNPs identified in the exploratory study, 225 cases were available. We anticipated 
selecting 1-2 controls per case (average case-control ratio of 1.5).  As the case-control 
design was carried out subsequent to the findings of the case-parent design, most of the 
parameters for estimating power were known. Based on these parameters (allele 
frequencies for the three CYP4F2 SNPs (rs1272, rs3093158, rs3093145) of, 22%, 35% 
and 45% respectively, odds ratios ranging from 1.5 to 4.0 (based on either the 
multiplicative or dominant model, 1 sided p-values of 0.05 and power=0.80), the 250 
cases (x ~1.5 controls) would have more than 80% power to detect significant 
associations if present – Appendix 4b. 
As the estimation of interaction effects, parent-of origin effects and genotype-
phenotype relationships were the secondary objectives and exploratory in nature, no pre-
hoc sample size estimations were made. In order to enhance power however, for 
investigating gene-gene interactions, gender-gene and gene-phenotype interactions, we 
combined the cases from the exploratory and replication studies and compared them with 
the controls selected for the replication study.  
Power estimations were made using the QUANTO® software (free download 
from http://hydra.usc.edu/gxe).  
C.7. Statistical analyses 
C.7.1. Disease models 
For complex traits, such as CD, the mode of inheritance is unknown. In our study, 
we modeled disease risks assuming three potential modes of inheritance of CD: 
multiplicative, dominant or recessive. When a dominant model is considered, it is 
assumed that carriers of either 1 or two risk alleles have the same risk for disease. 
Alternatively, in the recessive model, it is assumed that individuals have to carry both 
risk alleles in order to express disease and that those carrying 1 allele have the same risks 
as those not carrying any variant allele (wild-type homozygotes). An alternative 
perspective to analyse case control data is by estimating allelic risks. This method breaks 
down genotypes to compare the total number of alleles in cases and controls (or 
pseudocontrols), regardless of the genotypes from which these alleles are constructed. 
This analysis provides the most powerful method of testing under a multiplicative genetic 
model, where risk of developing a disease increases by a factor r for each risk allele 
carried: risk r for heterozygotes and r2 for high-risk homozygotes.  
C.7.2. Case-parent design (Phase 1) 
C.7.2.1. Independent effects of SNPs and haplotypes 
Genotyping data was checked for deviation from Mendelian transmission and 
departures from HWE prior to analysis. For single marker analyses we used the CPG 
approach developed by Schaid and Sommer [259, 276]. The method does not require the 
assumption of HWE and similarly can model, in addition to the multiplicative model of 
inheritance, other possible models such as recessive, and dominant enabling the selection 
of a model that best fits the data.  
Genotype relative risks, corresponding 95% confidence intervals and p-values were 
estimated for each SNP in the 2 candidate genes.   
In addition to single SNP analysis, we also carried out haplotype analyses using the 
methods described by Purcell et al (2007) [277]. These methods are extensions of recent 
methods described by Schaid et al (2002) [278]. A weighted maximum likelihood model 
was utilized to account for the potential ambiguity in the individual’s statistically-inferred 
haplotypes. For H number of haplotypes, two types of basic tests were carried out. A ‘H’ 
number of separate, 1 degree of freedom (df) tests of each specific haplotype compared to 
all others; and a single omnibus H-1 df test, jointly testing all haplotypes. Both parents 
were phased separately. Assuming independence between paternal and maternal 
chromosomes and based on basic Mendelian laws the probability of each offspring phase 
consistent with the observed offspring genotypes and parental phase were estimated. The 
contribution to the likelihood from each individual was parametrized using logistic 
regression and maximum likelihood was used to estimate the regression coefficients.  
In addition to the above 2 tests (i.e. omnibus and haplotype-specific test including 
all haplotypes), we also carried out haplotype analysis including only those SNPs that 
showed significant association in the single SNP analysis. All haplotype analyses were 
carried out using the WHAP® software developed by Purcell et al. [277] - 
http://pngu.mgh.harvard.edu/~purcell/whap/future.shtml. 
C.7.2.2. Parent-of-origin effects 
Parent of origin effects were examined by applying the TDT to data stratified 
according to whether the variant allele was transmitted from either the father or mother. 
Differences in transmission between parents were assessed using the z-test and p-values 
were estimated. Analysis was carried out using the TDT parent-of-origin feature in 
PLINK®  - http://pngu.mgh.harvard.edu/purcell/plink/. 
C.7.3. Case-control study (Phase 2) 
The major objective of the case-control study was to confirm the findings of 
association in the exploratory study. For this study all SNPs that were significantly 
associated at the allelic or genotypic level (individual SNP analysis) with CD in the 
exploratory study (case-parent design) at p≤0.10 were subjected to replication.  
Initial univariate analysis was carried out to study the distribution of the 
genotypes and alleles among cases and controls. Allelic associations and genotype 
associations were investigated. For allelic associations odds ratios and respective 95% CI 
were estimated. Genotype associations were evaluated by applying chi-square tests to the 
3 x 2 contingency table. Further analysis was carried out using unconditional logistic 
regression. Three different models of inheritance were examined: (i) model where the 
risks for heterozygotes and variant homozygotes were considered distinct, (ii) a recessive 
model, and (iii) a dominant model. The different models were examined using the 
Akaike’s Information Criteria (AIC), which is a proposed measure of the goodness of fit 
of an estimated statistical model [279]. Models with the lower AIC were considered to 
best fit the data. Each SNP was examined in separate models. Odds ratios and respective 
95% CI were estimated. 
Haplotype analyses were carried out using the methods described by Purcell et al 
(2007) [280]. For ‘H’ number of haplotypes, two types of basic tests were carried out. A 
‘H’ number of separate, 1 degree of freedom (df) tests of each specific haplotype 
compared to all others; and a single omnibus H-1 df test, jointly testing all haplotypes. 
All haplotype analyses were carried out using the WHAP® software developed by 
Purcell et al. [280] - http://pngu.mgh.harvard.edu/~purcell/whap/future.shtml. 
C.7.4. Examining gene-gene interactions  
To assess gene-gene interactions, we combined the case population from the 
exploratory study as well as that from the replication study.  
Assessing gene-gene interactions using moderate sample sizes may limit the 
power to detect important interactions. In addition considering the multiple numbers of 
tests that are carried out, required adjustment for multiple testing can further limit power. 
These limitations are more so in parametric methods such as logistic regression wherein 
at higher dimensions the data becomes sparse. High-dimensional contingency tables lead 
to many cells with no or small number of data points leading to large standard errors and 
thus high type-1 errors. Similarly in parametric methods genes that do not have 
independent effects are usually not selected (for e.g. in step-wise logistic regression) and 
hence their contribution to gene-gene interactions is likely to be missed. In order to 
overcome these limitations, data reduction strategies such as multi-factor dimensionality 
reduction (MDR) have been proposed [280, 281] to detect gene-gene interactions in the 
presence or absence of main effects in case-control studies in human genetics [161, 282]. 
MDR is a non-parametric genetic model-free approach wherein multi-locus genotypes are 
grouped into “high-risk” and “low-risk” groups thus reducing the N-dimensional space 
into one dimension. This is achieved through a stepwise process. In step 1, an exhaustive 
list of n combinations of genetic loci to evaluate from the list of all variables is created. 
Next, each of the n combinations is arranged in contingency tables in k-dimensional 
space with all possible combinations as individual cells in the table. Then, the number of 
cases and controls for each locus combination is counted. In step three, the ratio of cases 
to controls within each cell is calculated and each genotype combination is labeled as 
“high-risk” or “low-risk” of the phenotype of interest based on comparison of the ratio to 
a threshold. The threshold used is dependent on the ratio of cases and controls within the 
data set. If the ratio within a multifactor combination is above that seen in the data, it is 
labeled as “high-risk” and if it is below, it is labeled “low-risk”. This step compresses 
multidimensional genotype data into one dimension with two classes. The new multi-
locus variable is evaluated for its effectiveness in discriminating between the presence 
(case) and absence (control) of disease using cross-validation and permutation testing. 
Because the MDR algorithm is using permutation distribution for significance testing, 
correction for multiple testing is unnecessary. Using simulated data, it has been shown 
that MDR methods have much greater power than traditional methods such as logistic 
regression and classification and regression trees (CART) in detecting gene-gene 
interactions and particularly detecting genes that do not have main effects [283].  
In our exploratory study, we examined gene-gene interactions between three 
SNPs in the CYP4F2 gene (that were suggestive of associations in the exploratory study), 
four SNPs in the ALOX5 gene, and the three disease susceptibility variants (SNP8, 
SNP12 and SNP13) in the NOD2/CARD15 gene. For the NOD2/CARD15 gene, 
individuals were categorized into NOD2+/NOD2-, depending on whether they carried 
any one of the three disease susceptibility variants, as previously explained. The entire 
data were randomly classified into two subsets (9/10 and 1/10) with the larger subset 
(9/10) being the training sample and the smaller subset (1/10) providing the testing 
sample. The MDR procedure was run in both the training and the testing samples and the 
accuracies of the model were examined. The procedure was run 10 times (i.e. 10 cross 
validations). The results for the 10 cross-validations were averaged to acquire the testing 
accuracies or prediction errors (which is 1-testing accuracy). Based on the procedure the 
best model (based on the testing accuracy), separately for each order of interaction (i.e. 
best models for a 2, 3, 4 order interaction etc.) is identified. In order to limit over-fitting 
of the data that can occur with high-order interactions (viz. 4) we restricted our analysis 
to 2 and 3 order interactions.  
Significance of testing accuracies of the models selected using the MDR 
procedure was estimated based on permutation methods. In order to carry out the 
procedure, the case/control labels of the study data were randomly permutated to create 
1,000 data sets. The same MDR models were re-run on the 1,000 permuted data sets and 
the testing accuracies of the best models were sorted in ascending order. The p-value for 
an observed model was the proportion of times the best testing accuracy of the permuted 
data was higher than the observed testing accuracy. Thus if the testing accuracy of the 
observed model was 0.59 than a p-value of 0.05 would indicate that 5% of the testing 
accuracies from the 1,000 permuted data sets were higher than the observed testing 
accuracy. As the permutation process is carried out using the same procedures and same 
models utilized in the MDR procedure, the acquired p-values are automatically adjusted 
for multiple testing [281]. 
All analyses were carried out using the MDR version 2.0 (open-source software) 
and related utilities (MDR-permutation testing) (http://sourceforge.net/projects/mdr/). 
C.7.5. Examining gender-gene and genotype-phenotype associations 
Gender-gene interaction analysis was restricted to the CYP4F2 gene. Only 1 SNP 
in the CYP4F2 gene withstood replication and hence gender-gene interactions with this 
SNP were tested (viz. rs3093158). Cases from both the exploratory and replication 
studies were combined and compared to the unrelated controls, i.e. 385 cases versus 330 
unrelated controls. Interaction analysis was carried out by fitting a logistic regression 
model including the CYP4F2 genotype (coded according to a dominant model), gender 
and an interaction term involving the genotype and gender to the binary outcome (case-
control status). Significant interactions were deemed to be present when the interaction 
term was statistically significant at the 5% level.  
The two main phenotypes of CD, disease location and disease behaviour at 
diagnosis were the phenotypes evaluated in the study. Both a case-based analysis and a 
case-control analysis wherein the allele frequencies within a particular phenotype was 
compared with that among controls was carried out. The case-only analysis was based on 
the combined set of cases (160 plus 225), whereas the case-control analysis was based on 
the combined set of cases (i.e. 385) versus the unrelated controls (i.e. 330). Based on the 
Montreal classification disease location is categorized as L1±L4 (i.e. ileal with or without 
upper tract involvement); L2±L4 (i.e. colonic with or without upper tract involvement) 
and L3±L4 (i.e. ileo-colonic with or without upper tract involvement) – Table I (Page 
10). For the purpose of the analysis, we combined patients who had ileal disease (with or 
without upper tract or colonic involvement) i.e. L1±L4 and L3±L4, as pure colonic 
disease is expected to differ genetically from ileal disease. For disease behaviour, the 
phenotype according the Montreal Classification is: B1±B4 (i.e. inflammatory with or 
without perianal involvement), B2±B4 (stricturing with or without perianal involvement) 
and B3±B4 (penetrating with or without perianal involvement) – Table I (Page 10). As 
B2 and B3 represent non-inflammatory disease we combined these two categories for the 
analysis. 
In the case-based analysis, genotype associations were examined by using a chi-
square test (2 df) applied to the 2 x 3 contingency tables. Allelic associations were 
examined by applying a chi-square test to the frequency distribution of the variant allele 
in the case-chromosomes versus that among the control chromosomes (1 df). For the 
latter analysis, odds ratios and respective 95% CI were estimated. For the case control 
analysis, the allele frequencies within each phenotype were compared with that among 
controls using chi-square tests. Odds ratios and 95% CI were estimated.  
C.7.6. Linkage disequilibrium (LD) analysis 
We also evaluated the pair-wise LD between SNPs in the two candidate genes. 
Among the measures that have been proposed to evaluate LD, the two most important are 
D’ and r2 [284]. The first measure, D′ is sensitive to even a few recombinations between 
the loci since the most recent mutation at one of them. 
However, the literature emphasizes the exponential decay over time of D′ between linked 
loci under simple population genetic models, but stochastic effects may suggest that this 
theoretical relationship is of limited usefulness. A disadvantage of D′ is that it can be 
large (indicating high LD) even when one allele is very rare, which is usually of little 
practical interest. The second measure of LD, r2 reflects the statistical power to detect 
LD. Therefore, a low r2 corresponds to a large sample size that may be required to detect 
the LD between the markers. If, for example, disease risk is multiplicative across alleles, 
and HWE holds, r2 between a marker and a causal SNP gives the sample size that would 
have been required to detect the disease association by directly typing the causal SNP, 
relative to the sample size required to achieve the same power when typing the marker. 
For our study, both measures of LD, i.e. D’ and r2 were estimated. LD was 
determined both for the case-parent study [among the alleles not-transmitted to the index 
case (pseudo-controls)] and the case-control study (in controls). 
All analyses were performed by STATA version 8.0 (http://www.stata.com/). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Section D. Results 
 All figures and tables in the Results section are presented at the end of this section 
(Pages 82 -106). 
D.1. Case-parent design 
D.1.1. Demographic and clinical data 
As mentioned above, the cohort for the study was established based on CD cases 
(prevalent and newly-diagnosed) from HSJ (Montreal) during 2003-2007, cases newly 
diagnosed during 2004 at BCCH and those newly diagnosed during 2006-2007 at CHEO.  
A total of 160 complete trios (i.e. a trio is formed by a case and both its parents) were 
recruited. 
The majority of the cases (n=127, 79.4%) were enrolled at HSJ (Montreal), 
whereas 17 (10.6%) were from CHEO and 16 (10%) from BCCH. From among the 160 
patients with CD, 85 were boys (53.1 %) and 75 were girls (46.9%). Mean age at 
diagnosis was 11.8 years (SD = 3.3), ranging from 3 to 20.3 years (1 patient who was 
diagnosed just subsequent to completing 20 yrs was retained). All the patients were 
Caucasian. Disease was phenotypically classified on the basis of its location [terminal 
ileum (L1), colon (L2), ileocolon (L3), upper gastrointestinal tract (L4)] and behaviour 
[nonstricturing nonpenetrating (B1), stricturing (B2), penetrating (B3)]. The Montreal 
classification of CD clinical phenotypes was implemented. The demographic and clinical 
characteristics of the CD patients are shown in Table IV. 
At diagnosis, the majority of the patients had ileo-colonic disease (i.e. 57.5%) and 
had inflammatory behavior (i.e. 88.8%).  
D.1.2. Genetic analyses 
In order to carry out a comprehensive assessment of the role of the ALOX5 and 
CYP4F2 genes we utilized the haplotype-based gene-tagging approach previously 
described. Using an r2 cut-off of 0.80 for linkage disequilibrium (LD) between any 2 
SNPs, and setting the minimum allele frequency (MAF) to 10% we identified the set of 
SNPs that predicted >80% of the haplotypes formed by the gene. The location of the 
fourteen SNPs, i.e. ten in the CYP4F2 gene and four in the ALOX5 gene, is illustrated in 
Figures 6 and 7, respectively. Table V-A and B shows the primers utilized for 
genotyping the 14 tag-SNPs in both settings, i.e. case-parent and case-control design. 
The chromosomal and gene locations of the SNPs are shown in Table VI.  
In order to meet one of the main objectives of the study, i.e. to screen for 
associations between DNA variants in the ALOX5 and CYP4F2 genes and early-onset of 
CD, we implemented a case-parent design. Using this setting, fourteen tag-SNPs, 10 in 
the CYP4F2 gene and 4 in the ALOX5 gene, were genotyped among 182 trios. Overall 
the genotyping success rate was ~99%. Genotyping was successful for all three members 
of 179 trios. Based on published recommendations, approximately 20% of the DNA 
samples were genotyped in duplicate for all the 14 SNPs [278]. Samples that were not 
reproducible for any SNP were excluded from the analysis. This resulted in the exclusion 
of 3 additional trios, leaving 176 complete trios available for further analysis.   
When patterns of Mendelian inheritance were examined, ten trios showed 
deviation from Mendelian patterns across more than 4 SNPs, suggesting that the 
deviations were due to mis-paternity. These trios were excluded. A further 6 trios showed 
deviations for 1-4 SNPs. These deviations were regarded as potentially due to genotyping 
errors and these trios were also excluded from further analysis leaving 160 trios for 
statistical analysis.  
For the complete trios conforming to Mendelian patterns of inheritance, tests for 
deviation from HWE were carried out among the alleles not-transmitted to the case 
(pseudo-controls). All 14 SNPs were in HWE - Table VII.  
Further statistical analysis of the data was thus based on 160 complete trios 
(Table VIII). 
We also established the presence of linkage disequilibrium between SNPs in the 
two study genes among the alleles not-transmitted to the index case (pseudo-controls). 
Table IX (a and b) show the pair-wise LD structure for SNPs belonging to the two 
candidate genes (D’ and r2 measures).  
The maximum LD for gene CYP4F2 was observed between SNPs rs1272 and 
rs3093198 (r2=0.060). A r2 of 0.56 was observed between SNPs rs1272 and SNP 
rs2016503. In general the LD between most of the pair-wise LD was low. This was 
expected as the selection of tag-SNPs using the Carlson algorithm was based on an r2 of ≥ 
0.80 between SNPs, hence none of pair-wise r2 were ≥=0.80.  
D.1.2.1. Single marker analyses 
Single marker analysis was carried out using the CPG method implemented in the 
SCOUT® software (http://www.genetics.emory.edu/labs/epstein/software/scout/). Three 
models of inheritance, i.e. dominant, multiplicative and recessive, were examined.  
The results of the single marker analyses for CYP4F2 gene in complete trios are 
presented in Table X.  
From, among the 10 SNPs for the CYP4F2 gene, significant associations (p<0.05) 
assuming either the multiplicative, recessive or dominant models of inheritance were 
observed for SNPs rs3093158 (OR=4.02, pdom= 0.00003), rs1272 (OR=3.10, pdom =0.04), 
and with rs3093145 (OR=1.76, pdom =0.017). 
The results of the single marker analyses for ALOX5 gene are shown in Table 
XI.  
None of the four SNPs in the ALOX5 gene were significantly associated with CD 
assuming any model of inheritance.   
D.1.2.2. Haplotype analyses 
By using regression-based methods, we further examined whether haplotypes 
formed by the tag-SNPs in the CYP4F2 and ALOX5 were associated with CD.  
For CYP4F2 haplotype analyses, we included first all ten biallelic markers in our 
analysis. The ten SNPs formed eight haplotypes (i.e. H1-H8) in the population.  
Table XII shows the haplotype descriptions, their frequency, and the p-value of a 
regression-based analysis of the association between each haplotype and CD.  
Two haplotypes – H6 (6%) and H7 (5%), respectively - showed significant 
associations with CD (p=0.05 and 0.001, respectively). An omnibus test examining 
overall haplotype associations was also significant (p=0.035).  
Subsequently, we performed haplotype analyses using the three SNPs, which 
showed significant associations when using the multiplicative, recessive or dominant 
model in the single marker analysis (i.e. rs3093158, rs1272, and rs3093145). These three 
SNPs formed four haplotypes (i.e. H11-H14). When tested individually, significant 
associations were observed with two haplotypes (i.e. H11 and H14, respectively) that 
account for approximately 60% of potential haplotypes (p=0.045 and 0.004, 
respectively). The corresponding omnibus test for haplotype association showed strong 
evidence for association with CD (p=0.007).  
D.1.2.3. Parent-of-origin analysis  
Recent findings suggest that parent-of-origin effects may be at play in CD. These 
observations provided the impetus to explore such effects in the present study. Table 
XIII contains the results of the parent-of-origin analysis in the 10 SNPs of the CYP4F2 
gene. In the parent-of-origin analysis, the TDT was applied separately to trios where the 
risk allele was transmitted to the child from the father and to trios where the transmission 
occurred from the mother. There seems to be an indication of association with disease, 
when the risk allele of two SNPs was transmitted from the fathers (rs1272: p=0.07; 
rs3093158: p=0.02). However, the z-test comparing the differences in transmission by 
parent was not significant for any of the 10 SNPs suggesting that there were no parent-of-
origin effects. Interestingly, the rs3093158 SNP shows similar associations irrespective if 
the risk allele is transmitted from the father (p=0.02) or the mother (p=0.07), suggesting 
that this SNP may be associated with CD, irrespective of the parent-of-origin effects. 
D.2. Case-control design  
In order to address the second objective of the study, i.e. to confirm the findings 
from the case-parent analyses, as well as to explore gender-gene and gene-gene 
interactions, we implemented a case-control design, whereby we analyzed the three tag-
SNPs in the CYP4F2 gene that were found to be significantly associated (i.e. p<0.05) 
with CD in the screening phase (i.e. case-parent design) in a separate cohort of CD cases 
(N=225) and controls (N=330). 
D.2.1. Demographic and clinical data  
The cases and controls for the case-control design originated only from HSJ and 
CHEO. For this phase of our study, a total of 225 CD cases and 330 controls were 
included in the analyses.  
The majority of the cases (n=173, 76.9%) were recruited from HSJ (Montreal), 
whereas 52 (23.1%) were recruited from CHEO (Ottawa). From among the 225 patients 
with CD, 138 were boys (61.3 %) and 87 were girls (38.7%). Mean age at diagnosis was 
12.4 years (SD = 3.4), ranging from 3 to 21 years. All the patients were Caucasian.  
At diagnosis, the majority of the patients had ileo-colonic disease, L3 (i.e. 56%) 
and had inflammatory behavior (i.e. 84.8%). From HSJ, 282 (84.4%) controls were 
recruited, whereas 48 controls (14.6%) were recruited from CHEO. Among the controls, 
there was a preponderance of males (n=199, 60.3%). The mean age of the controls was 
10.6 years (SD=7.2).   
The demographic and clinical characteristics of the CD patients versus the 
controls are shown in Table XIV. 
D.2.2. Genetic analyses (replication study) 
Cases and controls were genotyped using the same methods as in the case-parent 
design. A full description of the primers used is presented in Table VI.  
The results of the case-control analysis are presented in Table XV (A, B, and C). 
From among the three SNPs that suggested associations in the screening study, 
associations were replicated with SNP rs3093158 in the Phase 2 study. Significant 
genotype associations (uncorrected p=0.03, one-sided) were noted. After applying the 
standard Bonferroni correction for multiple testing, this genotype association however did 
not withstand correction (corrected p=0.09). When a dominant model was examined, 
individuals carrying 1 or more of the common variant in this SNP were at elevated risks 
for CD (OR=1.94, pdom=0.023) even after correction for multiple testing– Table XV-B.  
There was no evidence for association between SNPs rs1272 and rs3093145 in the 
case-control setting. 
The results of the haplotype analyses in the case-control study are presented in 
Table XVI. The three SNPs in the CYP4F2 gene formed 4 haplotypes (H1-4). The 
frequencies of these haplotypes in the cases versus the controls are presented in the same 
table. One of the haplotypes, i.e. H4, was found to be significantly associated with CD 
(p=0.02). 
D.3. Combined analyses 
D.3.1. Combining results from the case-parent and case-control 
analyses 
This entire experiment, i.e. a multistage approach, must be viewed as the result of 
both stages for valid statistical inference. This entire experiment, i.e. a multistage 
approach, must be viewed as the result of both stages for valid statistical inference. 
According to Skol (2006), a joint analysis is more powerful than treating the second stage 
as a stand-alone replication sample [288]. In order to gauze the significance of these 
results, we combined the findings of the case-parent and case-control designs by using a 
likelihood-based approach described by Epstein et al [288]. In short, Epstain et al 
developed combined tests of association that are based on the likelihood of Nagelkerke et 
al. that looks for overlap in CIs for the separate relative risks parameters [260]. In 
contrast to the latter, the method proposed by Epstein et al applies selection procedures, 
such as the Akaike information criteria (AIC), Bayesian information criteria, or 
backwards selection to formalize hypothesis testing and model selection. Backward 
selection can be used by starting with the richest possible model and removing 
parameters after hypothesis testing. Under the assumption that at least one hypothesis is 
rejected, the appropriate parameters can be constrained and the model can be refit. This 
procedure is repeated until no additional hypotheses about parameters can be rejected. 
Using simulated as well as real data, the authors demonstrated that this single combined 
association approach has improved power over statistical methods that analyze triads and 
unrelated subjects separately. Direct comparison of the genotype distribution among triad 
parents with that of unrelated controls is recommended since allele-frequency differences 
between the two samples may induce bias and therefore the information from these two 
sources cannot be safely combined.  
More specific, the SCOUT software conducts a joint association analysis of triads 
and unrelated controls using a version of the CPG approach that is augmented to allow 
for unrelated control information. First, the program will run an unconstrained analysis 
that estimates the RR parameter from the triad information (RR1) and the control 
information (RR0), as separate parameters. Second, the program will run an analysis that 
constraints RR1=RR0 but estimates the RR parameter from the data. Finally, the program 
will run a null association analysis that constraints RR1=RR0 =1. Using results from these 
three analyses, SCOUT then constructs and evaluates likelihood-ratio statistics for testing 
two hypotheses of interest. The first hypothesis is H0: RR1=RR0, which is a test for 
assessing whether the controls can be safely combined with the triads for association 
analysis. Rejection of H0 suggests that the two samples cannot be combined, so inference 
should be based on the CPG analysis of the triads only. The second hypothesis tested is 
H0: RR1=RR0=1, which is a test of association between SNP and disease. 
Performing this analysis in our data set, based on the multiplicative model, the 
combined p-value was 5.01 x 10-3 and under the dominant model, 1.51 x 10-4. After 
applying a standard Bonferroni correction for multiple testing (for 3 SNPs), the adjusted 
p-values were 1.5 x 10-2 and 4.53 x 10-4 respectively. 
D.3.2. Gender-gene interaction 
A significant difference in gender distribution between early-onset and adult CD 
has been noted. Although endocrinologic differences are considered to underlie the 
sexual asymmetry of distribution, to date, no specific molecular mechanisms of such 
hormonal effects have been elucidated. In the context of our study, investigating the 
interaction between gender and risk alleles might provide additional insight into the 
pathogenesis of CD. 
Based on the logistic regression analysis applied to the data from the combined 
cases from phase 1+2 (N=385 cases) versus the unrelated controls (M=330 controls), 
Table XVII presents the result of the interaction between the rs3093158 in the CYP4F2 
gene with gender. No significant interaction was observed. 
D.3.3. Gene-gene interaction 
Both CYP4F2 and ALOX5 genes play a critical role in the eicosanoids pathway. 
ALOX5 is the enzyme responsible for initiating the process whereas CYP4F2 is involved 
at the termination of the pathway that leads to production of inflammatory mediators such 
as leukotrienes. On the other hand NOD2/CARD15 is known to be the key gene involved 
in innate immunity. We thus postulated that interactions between these three genes could 
modulate the inflammatory process and a combination of variants in these genes may 
impact disease. The location of the tag-SNPs that were analyzed and their frequencies in 
the unrelated controls is presented in Table XVIII.  
To investigate the joint effects between the three genes, we applied MDR methods 
to the combined cases-unrelated control data (Table XIX). 
In the MDR analysis, when two-factor models were fit involving the 8 SNPs (3 
CYP4F2, 4 ALOX5 and NOD2), a model including SNP rs3093158 (CYP4F2) and 
NOD2 had the highest testing accuracy (0.5806) and the highest cross-validation success 
(the same model was identified as the best model in 8 of 10 cross-validations). This 
model was statistically significant on permutation testing (P-value between 0.004-0.005). 
Similarly when three-factor models were examined the model including the CYP4F2 
SNP rs3093158, the ALOX5 SNP rs2115819 and the NOD2 gene was identified as the 
best model. This model was statistically significant (P-value between 0.006-0.007). These 
analyses indicate that although the ALOX5 gene did not appear to have any independent 
effects on the risk for CD, in combination with CYP4F2 and NOD2 it contributes 
significantly to risk for CD.  
D.3.4. Case-only analyses for genotype-phenotype association 
Location and disease behaviour have been shown to be two important 
determinants of clinical management and outcome. Patients with ileocolonic location and 
those with perianal involvement, for example, often suffer a more complicated course 
than those with disease localization in the terminal ileum or colon only. While certain 
locations may predict clinical outcomes, it is yet unclear why certain individuals would 
have predilection for disease in a certain location. In addition, a consistent difference in 
phenotype in children versus adults in disease distribution has been noted. Based on these 
observations, a secondary objective of this study was to study associations between the 
validated SNPs and disease phenotypes. Table XX contains the case-based analysis of 
association between CYP4F2 SNP rs3093158 with CD disease location and behaviour in 
Canadian children (viz. combined case population, N=385 CD cases). No significant 
impact of the studied SNP on disease location and/or behaviour was observed. 
 
 
 D.3.5. Case-control analysis for genotype-phenotype association 
After combining all cases (i.e. 160 cases from the screening study + 225 cases 
from the replication phase), we performed a case-control analysis wherein the CYP4F2 
SNP rs3093158 allele frequencies in the CD cases was compared with that among the 
unrelated controls (M=330).  Consistent with the previous analysis, no significant impact 
of the studied SNP on disease location and/or behaviour was observed. The results of this 
analysis are presented in Table XXI.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromosome: 19
Location: 19pter-p13.11 
CYP4F2
rs1272 (NT_011295.10)
Chromosome position: 15850040
ttccggacctagata[C/G]tgacgaaggtagc
rs2016503 (NT_011295.10)
Chromosome position: 15866185
CCAGGAGAAGTAAA[C/T]CATGGGCCATTTCTG 
rs2108622 (NT_011295.10)
Chromosome position: 15851431
AGGGTCCGGCCACA[C/T]AGCTGGGTTGTGAT
rs2074900 (NT_011295.10)
Chromosome position: 15857820
GTGCTTTGCAAG[A/G]TGGTACAGGA
rs2074902 (NT_011295.10)
Chromosome position: 15869099
GAATGAGTAAGA[C/T]GCCTCCTCTGCT
rs3093144 (NT_011295.10)
Chromosome position: 15863297
attgtggcaaaggttttgc[A/G]aagtatctaggatttt
rs3093145 (NT_011295.10)
Chromosome position: 15862852
ggactacctcccC[A/C]AAAACAGGGATATTTTTG 
rs3093158 (NT_011295.10)
Chromosome position: 
15861166ATGTCAGATGAAAG[A/G]ATTTGAACTTGATTAA 
rs3093193 (NT_011295.10)
Chromosome position : 15852914
ctgtatagtattccatc[C/G]tgtggctgtttatctaa
rs3093198 (NT_011295.10)
Chromosome position : 15851048
CAAGTTCCAGCTCTC[C/T]TTCCCTCACCTCCTCTGGAG
Figure 6 –Physicalmap CYP4F2 on 
Chromosome 19 and positioning of the 
SNPs
 
ALOX5
rs2291427 (NT_033985.6)
Chromosome position: 45256230 
TGTTCTCAGAGTCAGT[A/G]ATGCCCCTAAAGGAAGA
rs2115819 (NT_033985.6) 
Chromosome position: 45221095 
GGGATGGAAAGGGT[C/T]TTCTTAAGCAAAGGA
rs3780901 (NT_033985.6) 
Chromosome position: 45237382 
GGCTCCTTGTTCATC[C/T]TGACACATGAGGAG
rs10751383 (NT_033985.6) 
Chromosome position: 45257998 
CTGCATCACTCAG[A/C]AGCCGGGATCGG
Figure 7 –Physicalmap ALOX5 on Chromosome 10 and positioning of the SNPs
Chromosome: 10; Location: 10q11.2 
 Table IV. Demographic and clinical characteristics of the CD 
Patients in the case-parent design (N=160) 
NO. OF CASES 
N=160 
Age at diagnosis 
Mean (SD)                      11.8 (3.3) 
Gender (%) 
Females                             75 (46.9)  
Males                                 85 (53.1) 
Study site (%) 
Montreal                         127 (79.4) 
Ottawa                              17 (10.6) 
Vancouver                        16 (10.0) 
Clinical characteristics (at diagnosis) At diagnosis 
Disease location*(%)  
Ileum with or without upper digestive tract, L1+/-L4 22 (13.7) 
Colon with or without upper digestive tract, L2+/-L4 46 (28.7) 
Ileum and colon with or without upper digestive tract, L3 +/-L4 92 (57.5) 
Disease behaviour* n (%)  
Inflammatory B1 +/- p‡ 142 (88.8) 
Stricturing B2 +/- p 13 (8.1) 
Perforating B3 +/- p 5 (3.1) 
*according to Montreal classification 
‡ perianal modifier 
 
Table V-a – List of primers used to detect the 10 tag-SNPs in the CYP4F2 gene 
 Position 
Referenc
e SNP 
Sen
se 
Abbreviation Flanking Sequence 
F rs1272_CG_F ACGTTGGATGCACATACCACGAAATTCACC 1
. 
15850040 rs1272 
R rs1272_CG_R ACGTTGGATGGGGATGGTGAAAATGTTCCG 
F rs3093198_CT_F ACGTTGGATGCAACCCAACCGTACTCTATG 2
. 
15851048 
rs309319
8 R rs3093198_CT_R ACGTTGGATGGACATTGTAGATGGTCCAAG 
F rs2108622_CT_F ACGTTGGATGCATCAGTGTTTTCGGAACCC 3
. 
15851431 
rs210862
2 R rs2108622_CT_R ACGTTGGATGCTCTAGGAGCCTTGGAATGG 
F rs3093193_GC_F ACGTTGGATGGTGATGAGACTAGTGATCCC 4
. 
15852914 
rs309319
3 R rs3093193_GC_R ACGTTGGATGGCCACATACACATTGATGGG 
F rs2074900_GA_F ACGTTGGATGATCTCTTTAGGCTCACGGTC 5
. 
15857820 
rs207490
0 R rs2074900_GA_R ACGTTGGATGAGTGGTCTCTCCTGGGTCCT 
F rs3093158_AG_F ACGTTGGATGTCCCTTCCTCAATCACCTTC 6
. 
15861166 
rs309315
8 R rs3093158_AG_R ACGTTGGATGGTAGAAGGGAGCTTCATGTG 
F rs3093145_CA_F ACGTTGGATGCACATGGCATTGTTTCTGGC 7
. 
15862852 
rs309314
5 R rs3093145_CA_R ACGTTGGATGAGGACTCAACGAAGGACTAC 
F rs3093144_AG_F ACGTTGGATGAGGAGTCTCTCGTCCTTCTG 8
. 
15863297 
rs309314
4 R rs3093144_AG_R ACGTTGGATGGGGAAGAATTGTGGCAAAGG 
F rs2016503_CT_F ACGTTGGATGCCACCTTTCCCCTAGAGTTC 9
. 
15866185 
rs201650
3 R rs2016503_CT_R ACGTTGGATGATCAGAGACACAGGGATTGG 
F rs2074902_CT_F ACGTTGGATGTACGAGGCTTAGGGAGTGG 
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rs207490
2 R rs2074902_CT_R ACGTTGGATGGTAGGCACCTCACAGAAATG 
 
 
 
 
 
 
Table V-b – List of primers used to detect the 4 tag-SNPs in ALOX5 gene 
 
Position 
Referenc
e SNP 
Sen
se 
Abbreviation Flanking Sequence 
F rs2115819_CT_F ACGTTGGATGTGTTGCTTTTGCCACAGGAG 1. 452210
95 
rs21158
19 R rs2115819_CT_R ACGTTGGATGTTTGTGTAACACTGGGATGG 
F rs3780901_CT_F ACGTTGGATGAGAGGCCTTTGTGAGTACTG 2. 452373
82 
rs37809
01 R rs3780901_CT_R ACGTTGGATGGGCAACTTCCAGCAGTACAC 
F rs2291427_AG_F ACGTTGGATGGCTCCTAGCTGTTTTCTTCC 3. 452562
30 
rs22914
27 R rs2291427_AG_R ACGTTGGATGGATCACTGACATCCCACAGG 
F rs10751383_CA_F ACGTTGGATGTGAGCTTGTGAGTGTGTCTG 
A
L
O
X
5
 
 
L
O
C
A
T
I
O
N
 
1
0
q
1
1
.
2
 
4. 
452579
98 
rs10751
383 
  
R rs10751383_CA_R ACGTTGGATGTGTTGTGTGCTCAGGTGAGG 
 
 
 
 
 
  
 
 
 
 
Table VI - Location of the tag-SNPs in CYP4F2 and ALOX5 genes 
 
Gene/SNP 
Chromosomal 
location 
Gene location 
CYP4F2 Chromosome 19pter-p13.11 
1. rs1272 15850040 3’-utr 
2. rs3093198 15851048 intron 12 
3. rs2108622 15851431 exon 11-
coding-ns 
4. rs3093193 15852914 intron 9 
5. rs2074900 15857820 exon 9-coding-
ns 
6. rs3093158 15861166 intron 7 
7. rs3093145 15862852 intron 5 
8. rs3093144 15863297 intron 5 
9. rs2016503 15866185 intron 3 
10. rs2074902 15869099 intron 2 
ALOX5 – Chromosome 10q11.2 
1. rs2115819 45221095 intron 2 
2. rs3780901 45237382 intron 4 
3. rs2291427 45256230 intron 8 
4. rs10751383 45257998 intron 9 
 
 
 
Table VII - Frequency distribution of the tag-SNPs in CYP4F2 and 
ALOX5 in the informative cases and the pseudo-control(s)  
(formed by the non-transmitted alleles, one pseudo-control 
versus all three pseudocontrols) belonging to the complete 
trios (N=160). 
Gene 
Minor Allele Frequency 
(MAF) (%) 
CY4F2 
Chromosome 
Location 
19pter-p13.11 
Position  
SNP 
Cases 
(N=160) 
Pseudo-
control(s) 
(1/3) 
HWE-p-
value (1/3)* 
15850040 rs1272 29.4 23.9/22.8 0.28/0.90 
15851048 rs3093198 35.6 28.3/27.9 0.28/0.75 
15851431 rs2108622 43.5 28.4/29.1 0.46/0.72 
15852914 rs3093193 42.0 36.9/36.7 0.18/0.71 
15857820 rs2074900 35.9 29.5/30.0 0.14/0.26 
15861166 rs3093158 32.0 38.0/35.5 0.98/0.24 
15862852 rs3093145 52.2 44.2/46.2 0.24/0.60 
15863297 rs3093144 34.9 14.7/17.0 0.91/0.92 
15866185 rs2016503 26.6 17.1/16.8 0.87/0.80 
15869099 rs2074902 32.3 17.8/17.8 0.18/0.27 
ALOX5 
Chromosome 
Location 
10q11.2 
SNP Cases 
Pseudo-
control(s) 
(1/3) 
HWE-p-
value (1/3)* 
45221095 rs2115819 50.4 49.6/49.3 0.35/0.29 
45237382 rs3780901 38.5 32.1/31.8 0.92/0.48 
45256230 rs2291427 28.0 28.8/28.7 0.53/0.93 
45257998 rs10751383 39.0 41.0/42.0 0.82/0.38 
* Examined among the pseudo-controls (1 or 3) 
  
 
 
 
 
Table VIII - Distribution of case-parent families in the study. 
 
Case-parent 
families 
Trios 
Total 
number of participants 
 
Recruited 
 
182 546 
After successful 
genotyping 
179 537 
After testing for 
reproducibility 
176 528 
After testing for 
Mendelian 
inheritance 
160 480 
 
 
 
 
 
  
 
 
Table IX-a – Linkage disequilibrium (LD) measures D’/r2   values for SNPs in CYP4F2 gene  
(case-parent design) 
CYP4F2 
 rs1272 rs3093158  rs3093193 rs3093198  rs2016503 rs2108622 rs2074900 rs2074902 rs3093145 rs3093144 
rs1272 0.24          
rs3093158 0.94/0.45 0.38         
rs3093193 0.90/0.15 0.37/0.05 0.37        
rs3093198  0.86/0.60 0.66/0.27 0.93/0.20 0.28       
rs2016503 0.92/0.56 1.00/0.34 0.86/0.09 0.88/0.41 0.17      
rs2108622 0.94/0.11 1.00/0.24 0.87/0.52 0.96/0.14 1.00/0.08 0.28     
rs2074900 0.84/0.09 0.90/0.21 0.82/0.16 0.88/0.13 0.91/0.07 0.81/0.11 0.29    
rs2074902 1.00/0.07 1.00/0.13 0.93/0.33 1.00/0.08 1.00/0.04 1.00/0.55 0.76/0.05 0.18   
rs3093145 0.80/0.16 0.88/0.37 0.33/0.05 0.45/0.06 0.78/0.10 0.17/0.01 0.85/0.39 0.96/0.16 0.44  
rs3093144 0.74/0.03 0.84/0.07 0.38/0.04 0.15/0.01 0.51/0.01 0.44/0.08 0.97/0.07 1.00/0.04 1.00/0.22 0.15 
Off-diagonal elements are estimates of D’/R-squared; Diagonal elements are relative frequencies of allele 2 
 
 
  
 
 
 
Table IX-b – Linkage disequilibrium (LD) measures D’/r2   values for SNPs in ALOX5 gene  
(case-parent design). 
 
ALOX 5 
 rs3780901 rs2291427 rs10751383 rs2115819
rs3780901  0.32    
rs2291427 0.64/0.35 0.29   
rs10751383 0.61/0.25 0.81/0.38 0.41  
rs2115819    0.23/0.03 0.21/0.02 0.48/0.16 0.50 
 Off-diagonal elements are estimates of D’/R-squared; Diagonal elements are relative frequencies of allele 2 
 
 
 
 
Table X -  Association between CD and SNPs in the CYP4F2 gene. 
Conditional on parental genotype analysis, N=160 trios. 
 
Chromosome 
Location 
19pter-p13.11 
SNP Relative Risk AIC 95% CI p-value 
1. 15850040 rs1272 
Multiplicative 
Recessive 
Dominant 
 
1.29 
1.14 
3.10 
 
546.50 
547.82 
544.11 
 
0.87-1.91 
0.73-1.79 
1.00-5.00 
 
0.20 
0.56 
0.04* 
2. 15851048 rs3093198 
Multiplicative 
Recessive 
Dominant 
 
0.95 
0.94 
0.95 
 
609.39 
609.42 
609.41 
 
0.67-1.35 
0.43-1.89 
0.62-1.47 
 
0.790 
0.853 
0.83 
3. 15851431 rs2108622 
Multiplicative 
Recessive 
Dominant 
 
1.21 
1.08 
1.34 
 
651.48 
652.66 
651.07 
 
0.86-1.69 
0.56-1.98 
0.86-2.11 
 
0.27 
0.81 
0.20 
4. 15852914 rs3093193 
Multiplicative 
Recessive 
Dominant 
 
0.99 
1.08 
0.93 
 
680.96 
680.85 
680.86 
 
0.73-1.41 
0.66-2.08 
0.60-1.44 
 
0.933 
0.738 
0.73 
5. 15857820 rs2074900 
Multiplicative 
Recessive 
Dominant 
 
1.03 
0.94 
1.07 
 
621.46 
621.46 
621.39 
 
0.74-1.43 
0.44-1.87 
0.71-1.61 
 
0.86 
0.86 
0.76 
6. 15861166 rs3093158 
Multiplicative 
Recessive 
Dominant 
 
1.63 
1.34 
4.02 
 
635.46 
641.98 
630.72 
 
1.17-2.30 
0.89-2.03 
1.82-6.5 
 
3.5 x 10-3* 
0.15 
2.7 x 10-4* 
7. 15862852 rs3093145 
Multiplicative 
Recessive 
Dominant 
 
1.35 
1.11 
1.76 
 
704.13 
707.55 
702.10 
 
0.99-1.86 
0.68-1.80 
1.10-2.90 
 
0.057 
0.662 
0.017* 
  
8. 15863297 rs3093144 
Multiplicative 
Recessive 
Dominant 
 
1.32 
1.00 
1.44 
 
493.35 
495.29 
492.76 
 
0.89-1.97 
0.32-2.67 
0.92-2.30 
 
0.16 
0.99 
0.11 
9. 15866185 rs2016503 
Multiplicative 
Recessive 
Dominant 
 
1.35 
1.29 
2.38 
 
448.53 
449.24 
448.78 
 
0.86-2.17 
0.77-2.16 
0.61-4.2 
 
0.19 
0.32 
0.23 
10. 15869099 rs2074902 
Multiplicative 
Recessive 
Dominant 
 
1.21 
1.05 
1.30 
 
521.92 
522.86 
519.91 
 
0.82-1.78 
0.40-2.43 
0.82-2.10 
 
0.33 
0.92 
0.27 
  
 
 
Table XI - Association between CD and SNPs in the ALOX gene. 
Conditional on parental genotype analysis, n=160 trios. 
 
 
Chromosome 
Location 
10q11.2 
Position 
SNP 
Relative 
Risk 
AIC 95% CI 
p-
value 
1. 45221095 rs2115819 
Multiplicative 
Recessive 
Dominant 
 
1.00 
0.91 
1.11 
 
710.72 
710.54 
710.54 
 
0.73-1.36 
0.55-1.44 
0.69-1.78 
 
0.99 
0.67 
0.68 
2. 45237382 rs3780901 
Multiplicative 
Recessive 
Dominant 
 
0.99 
1.41 
0.82 
 
645.22 
644.00 
644.45 
 
0.71-1.37 
0.76-2.54 
0.54-1.27 
 
0.93 
0.27 
0.39 
3. 45256230 rs2291427 
Multiplicative 
Recessive 
Dominant 
 
0.96 
1.12 
0.89 
 
611.44 
611.38 
610.71 
 
0.70-1.35 
0.57-2.10 
0.60-1.39 
 
0.83 
0.74 
0.61 
4. 45257998 rs10751383 
Multiplicative 
Recessive 
Dominant 
 
1.00 
0.94 
1.09 
 
711.80 
711.76 
711.68 
 
0.74-1.38 
0.58-1.51 
0.68-1.77 
 
0.94 
0.81 
0.72 
 
 
 
 
 
  
 
 
 
Table XII - Association between CD and haplotypes of CYP4F2  
tag-SNPs in the case-parent design (N=160 trios) 
 *Frequency in the study population 
 
 Omnibus test p-value:  
 All haplotypes= 0.035, 3 SNP haplotype=0.007 
SNP (Location) 
 RS
12
72
 (1
58
50
04
0)
 
R
S3
09
31
98
 (1
58
51
04
8)
 
R
S2
10
86
22
 (1
58
51
43
1)
 
R
S3
09
31
93
 (1
58
52
91
4)
 
R
S2
07
49
00
 (1
58
57
82
0)
 
R
S3
09
31
58
 (1
58
61
16
6)
 
R
S3
09
31
45
 (1
58
62
85
2)
 
R
S3
09
31
44
 (1
58
63
29
7)
 
R
S2
01
65
03
 (1
58
66
18
5)
 
R
S2
07
49
02
 (1
58
69
09
9)
 
FR
EQ
U
E
N
C
Y
* 
P-
V
A
LU
E 
H1 G C C G A A A G T T 0.30 0.80 
H2 G C T C G A C G T C 0.19 0.26 
H3 C C C G G G C G C T 0.15 0.16 
H4 G C T C G A A A T T 0.12 0.64 
H5 C T C G G G C G T T 0.07 0.61 
H6 G T C G G A A A T T 0.06 0.05* 
H7 G C C C G G C G T T 0.05 0.001* 
H8 G C C G G G C G T T 0.05 0.57 
H11 G     A A    0.48 0.045* 
H12 C     G C    0.22 0.21 
H13 G     A C    0.19 0.31 
H14 G     G C    0.11 0.004* 
Table XIII – parent-of-origin effects analysis examining all ten snps in the cyp4f2 gene.  
Analysis based on N=160 complete trios. 
 
CHR 
19pter-p13.11 
Position 
SNP A1:A2 T:U_PAT 
CHISQ_ 
PAT 
P_PAT T:U_MAT 
CHISQ_ 
MAT 
P_MAT Z_POO P_POO 
1. 15850040 
rs1272 
 
2:1 20:33 3.19 0.074 25:25 0 1 -1.25 0.21 
2. 15851048 
rs3093198 
 
2:1 27:34 0.80 0.37 
35:31 
 
0.24 0.62 -0.99 0.32 
3. 15851431 
rs2108622 
 
2:1 35:32 0.13 0.71 
38:26 
 
2.25 0.13 -0.82 0.41 
4. 15852914 
rs3093193 
 
2:1 35.5:39.5 0.21 0.64 
35.5:30.5 
 
0.38 0.54 -0.76 0.44 
5. 15857820 
rs2074900 
 
2:1 38.5:35.5 0.12 0.73 31.5:32.5 0.015 0.90 0.33 0.74 
6. 15861166 
rs3093158 
 
2:1 27.5:47.5 5.33 0.021 
26.5:41.5 
 
3.31 0.069 -0.28 0.778 
7. 15862852 
rs3093145 
 
2:1 51:39 1.60 0.20 
40:28 
 
2.12 0.145 -0.27 0.785 
8. 15863297 
rs3093144 
 
2:1 30.5:24.5 0.65 0.41 
25.5: 
17.5 
1.49 0.22 -0.38 0.70 
9. 15866185 rs2016503 2:1 13:22 2.31 0.13 
18:20 
 
0.105 0.745 -0.88 0.382 
10. 15869099 
rs2074902 
 
2:1 27.5:25.5 0.075 0.78 
29.5:20.5 
 
1.62 0.20 -0.72 0.47 
Table XIV. Demographic and clinical characteristics of the CD Patients 
(N=225) and controls (N=330) in the case-control design. 
CASES 
N=225 
CONTROLS 
N=330 
P-
value
Age at diagnosis 
Mean (SD)                      12.4 (3.4) 
Age at diagnosis 
Mean (SD)                      10.6 (7.2) 
 
0.005
Study site (%) 
Montreal                       173 (76.9) 
Ottawa                             52 (23.1) 
Study site (%) 
Montreal                       282 (84.4) 
Ottawa                            48 (14.6) 
 
 
0.01 
Gender (%) 
Females                               87 (38.7) 
Males                                138 (61.3) 
Gender (%) 
Females                             131 
(39.7) 
Males                                199 
(60.3) 
 
0.81 
 
Type 
Orthopedic + siblings    225 (68.1) 
Birth cohort                      20 (6.1) 
Healthy adults                  85 (25.8) 
CD cases - clinical characteristics (at diagnosis) 
Disease location* N=225  N (%) 
Ileum with or without upper digestive tract, L1+/-L4 40 (17.8) 
Colon with or without upper digestive tract, L2+/-L4 59 (26.2) 
Ileum and colon with or without upper digestive tract,  
L3 +/-L4 
126 (56.0) 
Disease behaviour* N=224 (%) 
(The disease behaviour of 1 patient could not be appropriately 
identified) 
N (%) 
Inflammatory B1 +/- p‡ 190 (84.8) 
Stricturing B2 +/- p‡ 22 (9.8) 
Perforating B3 +/- p‡ 12 (5.4) 
*according to Montreal classification 
‡ perianal modifier 
 
 
 
 
 
 
 
Table XV-a – allelic and genotype associations between the rs1272 
dna variant in the cyp4f2 gene and cd.  
Analysis based on the case-control study a  
(n=225 cd cases; m=330 controls). 
 
Chromosome 
Location  
19pter-p13.11 
Position 
SNP 
Cases 
N=225 (%) 
Controls 
M=330 (%) 
Odds ratio 
(95% CI) 
P-value AICb 
G 350 (77.8) 514 (77.9) 
C 100 (22.2) 146 (22.10) 
1.00 
(0.74-1.35) 
0.48* N/A 
CC 10 (4.4) 23 (7.0) Reference 0.13* 
GC 80 (35.6) 100 (30.3) 
1.84 
(0.83-4.1) 
0.13* 
GG 135 (60.0) 207 (62.7) 
1.50 
(0.69-3.2) 
0.30 
752.63 
Recessive Model 
0.89 
(0.63-1.26) 
0.52 752.98 
CYP4F2 
rs1272 
(15850040) 
Dominant Model 
1.61 
(0.75-3.45) 
0.22 751.83 
 
aThe actual number of cases and controls per SNP can vary according to the genotyping call 
rates; bAkaike Information Criteria; * 1-sided p-value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XV-b– allelic and genotype associations between the 
rs3093158 dna variant in the cyp4f2 gene and cd. Analysis based on 
the case-control study a 
(N=225 cases; m=330 controls) 
 
Chromosome 
Location 
19pter-p13.11 
Position  
SNP 
Cases 
N=225 (%) 
Controls 
M=330 (%) 
Odds ratio 
(95% CI) 
P-value AICb 
C 307 (68.9) 430 (65.2) 
T 139 (31.2) 230 (34.8) 
1.18 
(0.91-1.54) 
0.10* N/A 
TT 18 (8.1) 48 (14.5) Reference 0.03* 
TC 103 (46.2) 134 (40.6) 
2.05 
(1.12 - 3.73) 
0.019 
CC 102 (45.7) 148 (44.9) 
1.84 
(1.01 - 3.34) 
0.046 
745.89 
Recessive Model 
1.04 
(0.74 – 1.46) 
0.84 749.74 
CYP4F2 
rs3093158 
(15861166) 
Dominant Model 
1.94 
(1.09 – 3.43) 
0.023 744.24 
 
aThe actual number of cases and controls per SNP can vary according to the genotyping call 
rates; bAkaike Information Criteria; * 1-sided p-value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XV-c– allelic and genotype associations between the 
rs3053145 dna variant in the cyp4f2 gene and cd. Analysis based on 
the case-control study a 
(n=225 cases; m=330 controls). 
 
Chromosome 
Location 
19pter-p13.11 
Position  
SNP 
Cases 
N=225 (%) 
Controls 
M=330 (%) 
Odds ratio 
(95% CI) 
P-value AICb 
G 239 (53.1) 356 (54.1) 
A 211 (46.9) 302 (45.9) 
1.04 
(0.81-1.33) 
0.74 N/A 
GG 62 (27.6) 95 (28.9) Reference 0.94 
GA 115 (51.1) 166 (50.5) 
1.06 
(0.71-1.58) 
0.77 
AA 48 (21.3) 68 (20.7) 
1.08 
(0.66-1.76) 
0.75 
754.24 
Recessive Model 
1.04 
(0.69-1.58) 
0.85 752.33 
CYP4F2 
rs3053145 
(15862852) 
Dominant Model 
1.07 
(0.73-1.56) 
0.73 752.25 
 
aThe actual number of cases and controls per SNP can vary according to the genotyping call 
rates; bAkaike Information Criteria; * 1-sided p-value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Table XVI - Association between CYP4F2 haplotypes and risk for CD 
in children. Analysis based on the combined case-control data 
(n=225 cases, m=330 controls) 
 
 
 * P <0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CYP4F2 SNP (LOCATION) 
 RS
12
72
 (1
58
50
04
0)
 
R
S3
09
31
58
 (1
58
61
16
6)
 
R
S3
09
31
45
 (1
58
62
85
2)
 
MAJOR 
ALLELE 
FREQUENCY 
IN CASES 
MAJOR 
ALLELE 
FREQUENCY 
IN CONTROLS 
P-
VALUE 
H1 C A A 0.48 0.46 0.42 
H2 G G C 0.21 0.22 0.85 
H3 C A C 0.21 0.19 0.30 
H4 C G C 0.09 0.13 0.02* 
 
 
 
 
 
 
 
 
 
 
 
Table XVII – Interaction between CYP4F2 SNP rs3093158 and gender 
in Canadian children with CD. Finding based on the logistic 
regression analysis applied to all cases (N=385) and the controls 
(M=330). 
 
Odds ratio (95%CI) 
SNP Model 
Females Males 
Interaction 
Odds ratio  
(p-value) 
Dominant† 
2.31 
(1.03-5.20) 
2.33 
(1.21-4.48) 
1.00 (0.98) 
CYP4F2 
rs3093158 
Additive↑  1.11 
(0.78-1.60) 
1.31 
(0.97-1.74) 
1.17 (0.51) 
 
† Based on coding the homozygous common genotype=0 and the heterozygous and 
homozygous rare genotypes as 1; * P ≤ 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XVIII - Location of the tag-SNPs in CYP4F2 and ALOX5 genes and 
their frequencies in the unrelated controls (case-control data). 
Gene/ 
Chromosomal location  
SNP Polymorphism 
Minor allele 
frequency in the 
unrelated controls 
CYP4F2 Chromosome 19pter-p13.11  
1. 15850040 rs1272 G/C 22.1% 
6. 15861166 rs3093158 C/T 34.8% 
7. 15862852 rs3093145 G/A 45.9% 
ALOX5 Chromosome 10q11.2  
1. 45221095 rs2115819 A/G 44.0% 
2. 45237382 rs3780901 C/T 34.8% 
3. 45256230 rs2291427 A/G 32.4% 
4. 45257998 rs10751383 A/C 46.4% 
NOD2/CARD15 Chromosome 16q21  
1. 49303427 
rs2066844  
(SNP8) 
C/T 8.5% 
2. 49314041 
rs2066845 
(SNP12) 
G/C 1.8% 
3. 49321282^49321283 
rs5743293 
(SNP13) 
insC 4.5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XIX - Interactions between CYP4F2, ALOX5 and NOD2 genes. 
Findings based on applying the multifactor dimensionality Reduction* 
to the combined case population (n=385) versus unrelated controls 
(m=330). 
 
Model 
Training 
accuracy 
Testing 
Accuracy 
Cross-
validation 
P-value** 
rs3093158 
(CYP4F2), 
NOD2/CARD15 
0.5989 0.5806 8/10 <0.005 
rs3093158 
(CYP4F2), 
NOD2/CARD15, 
rs2115819 
(ALOX5) 
0.6196 0.5795 9/10 <0.007 
 
* Subjects with 1 or more variants of the three NOD2/CARD15 SNPs (SNP8, SNP12 and 
SNP13) were designated as NOD2+, and those with none as NOD2- 
** Based on 1000 permutations 
 
 
 
 
 
 
 
 
 
 
 
Table XX - Case-based analysis of association between CYP4F2 SNP 
rs3093158 with CD disease location and behaviour in Canadian 
children. Findings based on the combined set of cases (n=385). 
Disease location 
SNP Variant 
Ileal* Colonic 
Odds 
ratio 
(95% CI) 
P-value 
C 160 (29.9) 63 (31.5) 
T 374 (70.0) 137 (68.5) 
1.07 
(0.74-
1.54) 
0.69 
CC 9 (9.0) 16 (6.0) 
CT 45 (45.0) 128 (47.9) 
TT 46 (46.0) 123 (46.1) 
 0.57 
Disease behaviour 
 
Variant 
Inflammatory Non-
inflammatory** 
Odds 
ratio 
(95% CI) 
 
P-value 
C 441 (69.8) 68 (68.0) 
T 191 (0.30) 32 (32.0) 
1.09 
(0.67-
1.74) 
0.72 
CC 144 (45.6) 24 (48.0) 
CT 153 (48.4) 20 (40.0) 
C
Y
P4
F2
 r
s3
09
31
58
 
TT 19 (6.0) 6 (12.0) 
 
0.23 
 
* includes ileal disease with or without colonic involvement 
** Includes structuring and/or penetrating disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table XXI - Case-control analysis of association between CYP4F2 
SNP rs3093158 with CD disease location and behaviour in Canadian 
children. Findings based on the combined set of cases (n-385) versus 
unrelated controls (m=330). 
Ileal* Colonic 
SNP 
Controls 
(%) 
Odds ratio 
(95% CI) 
P-value Odds ratio (95% CI) P-value 
1.25 
(0.97-1.61) 
0.07 1.16 (0.82-1.66) 0.38 
Inflammatory Non-inflammatory** 
rs
30
93
15
8 
(C
/T
) 
34.8% 
1.23 
(0.97-1.57) 
0.08 1.14 (0.71-1.84) 0.57 
 
* includes ileal disease with or without colonic involvement 
** Includes stricturing and/or penetrating disease 
 
 
 
 
 
 
 
 
 Section E. Discussion 
Our analyses based on the exploratory phase (case-parent design) implicated 
three genetic variants in the CYP4F2 gene in the etiopathogenesis of CD in children. 
Using the case-control design in Phase 2, association between 1 tag-SNP in the CYP4F2 
gene (rs3093158) and CD was successfully replicated. Furthermore, case-control analysis 
revealed that interactions between the CYP4F2, ALOX5 and NOD2/CARD15 genes 
could play an important role in disease susceptibility. There was no evidence for 
associations between CYP4F2 and gender or CYP4F2 and specific disease phenotypes. 
No parent-of-origin effects were obvious when studying the transmission of either the 
CYP4F2 and/or ALOX5 gene variants to affected children.  
CD is a multi-factorial disease with a strong genetic component. Few disorders in 
clinical medicine are associated with as much chronic morbidity as CD. The disorder is 
characterised by transmural inflammation that could affect any part of the GIT, and the disease 
relapses and remits throughout its course. For many patients, CD imposes a substantial 
personal burden, with unpredictable fluctuating symptoms, time off work, need for expensive 
drugs, or surgery and multidisciplinary care. This becomes more evident in early-onset of CD, 
which is marked by growth failure, higher disease severity and frequency of complications 
when compared to adult onset of disease [17]. With a prevalence of about 0.5% in Canada [1], 
CD also places a major burden on public health-care resources. 
In spite of a wealth of information that suggests that alternative pathways involved in 
the innate or adaptive immunity exert feedback regulation resulting in aberrant and chronic 
inflammation and disease, the exact mechanisms underlying the inflammatory process in the 
GIT are unknown. Considering chronic inflammation as a key point in disease development, 
we postulated that genetic variants that code for key enzymes involved in the metabolism of 
pro-inflammatory mediators, in particular eicosanoids, could play an important role in early-
onset disease susceptibility. More specifically, we targeted 2 candidate genes, the ALOX5 and 
the CYP4F2 genes that are intricately linked to the production of important inflammatory 
mediators, such as prostaglandins and leukotrienes that are known to trigger and maintain the 
inflammatory process.  
To our knowledge this is the first study that targeted mechanistic pathways of 
inflammation in order to elucidate the complex pathogenesis of CD. The focus of this study 
was the 5-LO pathway, a widely studied pathway of inflammation. Via the 5-LO pathway, 
arachidonic acid (AA) is transformed to biologically active pro-inflammatory mediators. The 
eicosanoid family of mediators includes prostaglandins, thromboxanes, and leukotrienes. 
Upon activation, the immediate product of 5-LO pathway is LTA4 (leukotriene A4), which is 
enzymatically converted into LTB4 (leukotriene B4) by LTA4 hydrolase. Biologically active 
LTB4 is metabolized by omega-oxidation carried out by specific cytochrome P450s (CYP4F), 
ultimately yielding the various eicosanoid metabolites. These metabolites have well-
established roles in many pathological processes, including recruitment and activation of 
neutrophils, thrombosis, inflammation and immunosuppression [221, 224, 289, 290], and 
disease-states (e.g. asthma, allergic rhinitis, idiopathic pulmonary fibrosis, atherosclerosis, 
atopic dermatitis, acne, ischemia-related organ injury, and IBD) [291]. 
Defects in expression of participating enzymes or genetic variation of their encoding 
genes may be involved in dysregulation of this pathway and susceptibility to inflammation. 
Prior evidence suggested a possible link between variants in these genes and inflammation. 
For instance, arachidonate 5-lipoxygenase is the key enzyme in leukotriene biosynthesis and 
catalyzes the initial steps in the conversion of AA to biologically active leukotrienes. This 
enzyme is encoded by the 5-LO gene (i.e. ALOX5 gene) that has been linked to 
atherosclerosis in mouse models and in humans [238, 239]. Recently, a tandem-repeat 
polymorphism in the promoter region of the ALOX5 gene was shown to be associated with 
carotid intimal-medial thickness, a measure of atherosclerosis [242, 292]. This polymorphism 
was also related with ALOX5 mRNA expression and leukotriene production, and with the 
response to anti-asthma treatments [240, 241].  
Another candidate gene of interest is CYP4F2, which is located in a region shown 
previously to be linked to IBD (i.e. 19p). A recent study by Curley et al. revealed that IBD and 
coeliac disease, another chronic inflammatory disorder of the gastrointestinal system, share 
two linkage regions: on chromosome 5q31 (CELIAC2 and IBD5), and 19p13 (CELIAC4 and 
IBD6). The same study revealed that the CYP4F2 gene showed a small effect on familial 
clustering of this disease, suggesting a putative role of this gene in disease pathogenesis [252]. 
Other studies investigating potential links between CYP4F2 and inflammation are presently 
lacking. 
As the onset and maintenance of inflammation is likely to be dependent upon AA-
derived prostaglandins and eicosanoids, genetic mutations in genes that encode for enzymes 
that are implicated in this pathway can tip the balance of this metabolic process.  Thus, we 
postulated that genes that code for enzymes within the pathway are likely to play important 
roles in the determination of susceptibility for inflammation and indirectly in the susceptibility 
for CD. Thus, individuals’ who are genetically susceptible by way of harbouring genes that 
negatively influence this pro-inflammatory metabolic pathway could be more likely to be at 
risk for CD.  
The main objective of this study was to examine whether the ALOX5 gene, which 
encodes for the 5-LO enzyme – a key enzyme in the 5-LO pathway, and in the CYP4F2 gene 
that encodes the cytochrome p450 enzyme, and which is specifically implicated in the omega-
oxidation of the biologically active LTB4, could be relevant to the development and 
perpetuation of inflammation in the gut. The CYP4F2 gene is located in chromosome region 
19p13.11. Three genome scans and a meta-analysis of GWAS have reported significant 
linkages to this region in different populations. Rioux et al (2000) using affected sib-pairs 
reported peak LOD scores of 4.6 for IBD and 3.0 for CD in a Canadian population [75]. In 
their recent meta-analyses of 10 IBD genome scans among affected relatives, van Heel et al 
(2004) reported significant linkage of CD to chromosome 19 [248]. Low et al (2004) carried 
out a linkage scan among UK Caucasians (affected sib-pairs) and confirmed linkage of CD to 
the 19p13.2 region (peak multi-point linkage score of 1.59) [249]. Finally, a meta-analysis of 
GWAS complemented by an independent replication study totalling 5,555 CD cases and 6,638 
controls, confirmed the association between CD and the 19p13 region (critical region 1.05-
1.15), i.e. RR=1.26 [254]. The location of the CYP4F2 gene in the region of significant 
GWAS signals adds further support to our observations that it may be an important candidate 
gene for CD.  
The exact mechanisms whereby variation in the CYP4F2 gene can predispose to CD 
can only be speculated on. As the CYP4F2 gene influences neutrophil migration, variants in 
the gene may alter this process and lead to a dysregulated response to inflammatory stimuli 
whereby there is excess neutrophil trafficking and chemotaxis to the intestinal epithelium. The 
latter could lead to a cascade of events that includes stimulations of pro-inflammatory 
cytokines that can sustain the inflammatory process. It has been reported that activated 
neutrophils have an effect on epithelial tight junctions that results in enhanced permeability 
[293] in the intestine, which could facilitate the influx of various commensals from the lumen 
leading to the recruitment of even more phagocytic neutrophils and thus to a perpetuation of 
barrier impairment and hence inflammation. When this balance in mucosal immune-system 
responsiveness is tilted towards an exaggerated or uncontrolled reaction against the 
commensal flora, CD may result. This is in line with a previous hypothesis that states that CD 
may be caused by genetic defects that produce exaggerated innate responses to the flora 
leading to excessive inflammation [294]. Concomitantly, genetic variants in the CYP4F2 gene 
may directly influence neutrophil migration, a feature usually associated with the innate 
immune response and thus create an environment in the gut mucosa that contributes to CD 
pathogenesis. There are a number of congenital conditions such as Glycogen Storage Disease 
type 1b [295], Chediak-Higashi syndrome [296]  and Leukocyte Adhesion Deficiency 
syndrome [297] that are associated with CD and all of these conditions have poorly 
functioning neutrophils. Furthermore, the use of a stimulator of neutrophils showed evidence 
suggestive of decreased CD activity [298]. 
Epidemiologic evidence suggests that in addition to genetic variation per se, epigenetic 
factors may play an important role in the pathogenesis of pediatric CD. In particular, findings 
such as: (i) the maternal effect in transmission of CD from affected parent to offspring; (ii) 
parental differences in the degree of genetic anticipation; and, (iii) discordance of 
monozygotic twins affected by CD, have provided strong support to this hypothesis. Because 
such parent-of-origin effects may be of pathogenic importance in CD, one of our secondary 
objectives was to explore if there were any differences in the transmission of the risk alleles 
from parents of one sex to children. In our case-population, no such preferential transmission 
was observed for the CYP4F2 gene. 
Assuming a key role played by the 5-LO enzymes in the pathogenesis of inflammation, 
it can be thought that alterations of several enzymes within this pathway would be more 
predictive of the outcome, i.e. CD, than either of them alone. Concomitantly, existing 
evidence underlines the importance of microbial-mucosal interaction in the pathogenesis of 
CD and the modulating role of NOD2/CARD15 gene in this process [200, 201]. We thus 
postulated that interactions between these genes (i.e. ALOX5, CYP4F2 and NOD2/CARD15) 
could modulate the inflammatory process and a combination of variants in these genes may 
impact disease. To test this hypothesis, we analyzed whether interactions between the 4 SNPs 
in the ALOX5 gene, 3 SNPs in the CYP4F2 gene and carriage of any of the 3 SNPs (SNP8, 
SNP12 and SNP13) in the NOD2/CARD15 gene were associated with CD. To study this 
interaction, we applied MDR methods to the case-control data. A three-SNP model that 
included the CYP4F2 SNP rs3093158, the ALOX5 SNP rs2115819 and the NOD2/CARD15 
gene was significantly associated with disease, suggesting that in combination these genes 
may have an impact on disease susceptibility. It is of interest to note that the ALOX5 SNPs 
were not independently associated with CD in our study. Nonetheless in the presence of 
variants in both the NOD2/CARD15 and CYP4F2 genes, it was found to impact disease. 
These observations are in line with the biologic process leading to CD wherein an interaction 
between innate immunity (CARD15) and acquired immunity (ALOX5, CYP4F2) is 
implicated.   
Rather than a unique disorder, CD is regarded as a collection of various inflammatory-
driven disorders of the GIT. Biological discrimination between various subgroups of CD 
patients led to a proposal for a phenotypic classification, which was taken up and further 
developed and evaluated by an international working group, leading first to the Vienna 
classification [32], followed by the Montreal classification [33] – Table I. Accordingly, CD is 
separated into three categories: age at diagnosis, location, and behaviour. Several teams have 
now tested these classifications in their databases and found that they are feasible and 
reproducible [30, 299, 300]. It is evident that variations in the human genome contribute to 
disease susceptibility and also shape the clinical phenotype. For instance, in addition to 
conferring risk to disease susceptibility, variation in the NOD2/CARD15 gene also it relates to 
ileal disease location, possibly through its selective expression in Paneth cells and regulation 
of antibacterial host defence [144, 301]. This state-of-knowledge prompted us to seek out any 
associations between the identified risk allele in the CYP4F2 gene (i.e. rs3093158) and disease 
location or behaviour. No significant impact of rs3093158 on disease location and/or 
behaviour was observed. However, these analyses were limited by power and need to be 
examined in larger samples. 
Another interesting phenotypic particularity of early-onset CD is a preponderance of 
male versus female cases.  In the context of our study, investigating the interaction between 
gender and the CYP4F2 risk allele was considered to be of interest in providing further insight 
into the pathogenesis of the disease. No significant interaction between gender and rs3093158 
was however observed. Given the relatively low power of a stratified gender-based analysis, 
larger studies would be required to detect gender-specific associations between CYP4F2 and 
CD, if any. 
Strengths and limitations of the study 
We carried out a two-phase candidate gene study, employing the case-parent design in 
Phase 1 and the case-control design in Phase 2, to examine the impact of genes within the 5-
LO pathway and risk for CD. To underline the significance of our results, the combined p-
value is highly suggestive of association with one SNP rs3093158 and CD (combined 
corrected pmultiplicative=0.015, combined corrected pdominant=4.53 x 10-4). In our context, we used 
a strict definition of a replication study, meaning that we explored a genetic association in the 
replication phase with (i) the same phenotype, (ii) only using the SNPs that were found to be 
significantly associated with CD in the first stage of our study, and (iii) the same direction of 
effects [302]. In general replication studies require investigations in populations that are 
independent of the original study. For our study, the replication case-population included cases 
that were initially recruited as part of the Phase 1 study, but for whom one or both parents 
were not available (i.e. incomplete trios, ~23 cases). So in some ways the replication 
population was not independently selected. Furthermore, the replication population of cases 
was a subset of a larger cohort (as the replication stage was planned subsequent to the findings 
in the Phase 1 of the study). However, as the selection factors that might have influenced any 
disparities between the two case-populations were similar and not under the influence of the 
exposure under study (i.e. genotypes), we believe that the possibility of them influencing the 
validity of the findings in a significant way is unlikely. In addition, other biases if any are 
likely to be limited as (i) the clinical characteristics at diagnosis of the patient population was 
by-and-large similar – Table XXII; (ii) the allele frequencies of the three CYP4F2 SNPs (i.e. 
rs3093158, rs1272, and rs3093145) were by-and-large similar within the pseudo-controls 
(case-parent design) and the unrelated controls (case-control study), indicating that both 
samples were generated from the same source population; and (iii) the major allele of 
rs3093158 seemed to be risk-conferring allele in both the exploratory and replication stages.  
By using the proposed case-parent approach in the Phase 1 study, the problem of 
population stratification inherent to the case-control design is completely eliminated by the use 
of non-transmitted alleles as controls. Also in using this approach, genetic associations are 
robust to confounding from non-genetic exposures under the principle of Mendelian 
randomization [303] whereby alleles are transmitted from parents to offspring randomly, 
simulating a randomized trial and thus ensuring that non-genetic factors are randomly 
distributed with genotype groups in the population. However, non-genetic exposures that are 
known risk factors for the disease of interest can confound genetic associations, if: [1] the 
genotype influences the exposure (e.g. possessing specific alleles in the alcohol 
dehydrogenase gene (ADH) prevents individuals from consuming alcohol, resulting in a 
negative correlation between the genotype and alcohol consumption. A study that examines 
association between the gene and heart disease would need to consider alcohol consumption as 
a potential confounder). [2] If the gene being studied, is in LD (or associated) with another 
gene that influences the exposure (in the example above, if ADH did not directly influence 
alcohol consumption but was associated with the aldehyde dehydrogenase (ALDH) gene that 
influenced alcohol consumption, alcohol consumption would be potential confounder).  
As previously mentioned, one of the main challenges, when implementing the case-
control design in a pediatric population, is the selection of healthy population-based controls. 
By using controls from three different sources (i.e. healthy children visiting the orthopaedic 
departments, healthy children from the general population, and healthy French-Canadian 
adults), we ensured that the control population was similar to the source population. Still, our 
case-control design could have been affected by potential confounding due to population 
stratification. In order to control for this, only Caucasian subjects were included. Nonetheless, 
there were differences in the magnitude of the associations between the risk alleles and CD in 
the case-parent study versus the case-control study, some of which could be attributed to 
subtle population stratification.  
We included both newly-diagnosed and prevalent cases in both our exploratory and 
replication stages. The possibility of selection bias influencing the results was considered. It is 
likely that some patients who had CD were missed, either because they were transferred to 
other hospitals (having crossed the age limit of 20 years) or died due to the disease. In respect 
to the former, the majority of our cases were diagnosed after 1988 and they are currently under 
follow-up in a pediatric hospital. Intentionally, we did not include in this study cases that were 
diagnosed before 1988 and who could have left the hospital. We also believe that it is unlikely 
that the distribution of alleles in the cases we possibly missed versus the ones we studied to be 
different. In respect to the latter, CD is not a fatal disease and therefore it is improbable that 
we missed cases because they died before being recruited. Another source of selection bias 
that might also affect the external validity of our study is the level of disease severity. In the 
beginning, mild cases of CD might get treated by family physicians. CD is a long-standing 
condition with periods of relapses and remittance and most of the patients (if not all) will be 
eventually referred to a gastroenterologist. If the disease has a spontaneous remittance, it 
probably means that it is not CD and the patient was misdiagnosed.  
The inclusion of incident/prevalent cases could influence the examination of genotype-
phenotype relationships. This is particularly true for diseases such as CD where the disease 
phenotype evolves over time. Thus the timing of ascertainment of the phenotype is important. 
Selection bias would be possible if for some cases phenotypes at diagnosis were included 
whereas for others phenotypes during disease course were considered. In order to avoid this 
we focussed on disease phenotype at diagnosis for all cases. At the same time with regards to 
susceptibility for a particular phenotype, it is the phenotype at diagnosis that is likely to be 
relevant for prevention/diagnosis.  
 Information bias, i.e. genotyping accuracy, needs to be considered for all genetic 
studies including ours. In using the GenomeLab™ Sequenom Genotyping platform, we 
ensured that our genotyping results were highly accurate (i.e. 96% success rate, 85% call rate, 
and error rate less than 0.5%). In addition, 20% of the samples were randomly re-genotyped 
for all the SNPs to ensure reproducibility. The reproducibility rate was >95%. As genotyping 
was carried out blinded to the case/parent/control status of the subject, misclassification bias if 
any, was further likely to be minimal.  
With regards to confounding, environmental factors by-and-large are unlikely to 
confound genetic associations. The only environmental factor that has been consistently 
associated with adult CD is smoking. There is limited evidence for smoking as a risk factor for 
pediatric-onset CD. Smoking is rare prior to age 10 and among those between age 11-15, the 
prevalence of smoking is approximately 15% (ref). CD is most common between ages 10-15 
and smoking may act as a trigger for disease. However, collecting information on smoking 
from adolescents is likely to be unreliable. On the other hand however, children exposed to 
passive smoke may be at higher risk. We have however shown that maternal smoking was not 
associated with pediatric CD [11], indicating limited support for smoking as a risk factor for 
pediatric-CD. Although environmental risk factors are unlikely to be major confounders in our 
study, it is possible that other genetic confounders might be responsible for the observed 
effect. For instance, genes that are in LD with CYP4F2, such as the neighbouring CYP4F3 
gene, may confound these associations. However, none of the CYP4F2 genes we studied (in 
particular SNP rs3093158 that was found to be associated with CD), are in LD with SNPs in 
the CYP4F3 gene suggesting that confounding due to LD may also be limited.  
We compared our findings of association with CYP4F2 gene with that of the WTCCC 
study [254] and that of Curley et al [252]. In the former, SNPs in and around the CYP4F2 
were not associated with CD. The WTCCC study however was exclusively based on adult CD. 
There is growing evidence that genetic susceptibility may be different in early- versus adult-
onset disease [18]. Similarly, it is not clear whether the genome-wide SNPs studied by the 
WTCCC provided adequate coverage of SNPs within the CYP4F2 region and also whether 
their study had sufficient power to capture modest associations. This is highlighted by findings 
from the meta-analyes of GWAS [254] that reported significant associations with SNPs within 
the region of the CYP4F2 gene.  
The Curley et al study (2006) revealed that 2 tag SNPs in the CYP4F2 gene were 
associated with risk for celiac disease in an adult Dutch celiac disease cohort. One of these 
SNPs, rs3093156, is in strong LD with rs3093145 (LD = 1.0), a SNP that was significantly 
associated with CD in our exploratory phase. Given that both celiac disease and CD are 
characterized by gut inflammation and therefore potentially share some genetic susceptibility, 
these observations imply that CYP4F2 may play an important role in gut inflammation that is 
characteristic of CD. As associations with SNP rs3093145 were not replicated in our case-
control study, certainly larger studies would be required to assess whether SNP rs3093145 is 
also associated with pediatric CD.  
Gene-gene interaction is a fundamental component of the genetic architecture of 
complex traits such as disease susceptibility. Interaction has been recognized for many years 
and has been described essentially from two different perspectives, biological and statistical 
[154]. Biological interaction, as defined by William Bateson in 1909, results from physical 
interactions among bio-molecules in gene regulatory networks and biochemical pathways at 
the cellular level in an individual. Statistical interaction, as defined by Fisher shortly thereafter 
(1918) in «The Correlation Between Relatives on the Supposition of Mendelian Inheritance», 
is deviation from additivity in a linear mathematical model that describes the relationship 
between multilocus genotypes and phenotype variation at the population level [304]. Gene-
gene interaction, along with other phenomena such as locus heterogeneity, phenocopy, and 
gene–environment interaction, is a major source of complexity in the mapping relationship 
between genotype and phenotype. As such, a need for research strategies that embrace, rather 
than ignore, this complexity has been described. In the current study, we addressed this 
necessity by implementing a recently developed non-parametric and genetic model-free data 
mining algorithm called MDR [283, 284]. With MDR, multilocus genotypes are pooled into 
high-risk and low-risk groups, effectively reducing the dimensionality of the genotype 
predictors to one dimension. The power of this strategy is the ability to analyze different 
selection methods and different construction algorithms leading to knowledge discovery from 
patterns of results across different strategies. The greatest challenge however rests with the 
interpretation of these models. Another important concern with conducting these analyses with 
a method such as MDR is that there may be a certain amount of important information 
potentially lost by limiting results to one best model. An interesting future direction would be 
to develop hypothesis testing methods that are able to identify a best set of statistically 
significant MDR models rather than a single best model.  
In this study we examined associations with 10 tag-SNPs in the CYP4F2 gene. Two of 
the tag-SNPs genotyped in the CYP4F2 gene were coding SNPs (rs2108622 and rs2074900). 
However, associations between them and CD were not evident. In contrast associations were 
noted with SNPs either in the intronic regions or in the 3’ utr regions of the gene. As these 
latter SNPs were in low LD (r2<0.80) with the coding tag-SNPs (else they would not be 
selected as tag-SNPs), it would be important to further assess putative risk-conferring SNPs in 
the gene.  
In this study, we were able to capture most of the newly diagnosed CD cases that 
presented at either one of the three major tertiary hospitals. Similarly, most cases diagnosed 
since 1995 and undergoing treatment were captured from the main study hospital in Montreal. 
Furthermore, the phenotypic distribution in both our case-parent and case-control setting was 
comparable to the published distribution of phenotypes in children with CD worldwide. Taken 
together, our findings could therefore by-and-large be generalised to the pediatric Caucasian 
CD population.  
Public health relevance 
The early-onset form of CD is of important concern. Firstly, it is becoming more and 
more apparent that CD incidence and prevalence among children and young adults is on the 
rise in Canada with rates approaching those in adults. Secondly, children with CD experience 
certain features unique to pediatric CD, more disease-associated morbidity and the long-term 
complications of this disease impact greatly on their physical and psychological well-being. 
Thirdly, it is not known whether potential risk factors contributing to the adult-onset CD 
similarly predisposes to the early-onset form of disease. Last, to date, the early-onset form of 
this disease has been insufficiently investigated. Research in the pathogenesis of pediatric CD 
has thus become of particular public health interest. Studying genetic susceptibility to CD in 
children is of particular relevance to the further understanding of the pathogenesis of this 
disease and implicitly to the pursuit of finding ways to prevent the development of this 
disease.  
Conclusions and future directions 
We observed that genes involved in the 5-LO metabolic pathway may be important to 
the pathogenesis of CD. It would be important to further examine these findings in a larger 
cohort of patients preferably in different geographical and ethnic populations. In parallel, 
investigating the presence of other functional SNPs in the gene by deep re-sequencing would 
be relevant. A more detailed assessment of the contribution of CYP4F2 variants to neutrophil 
recruitment and intestinal permeability that can be related to the development of inflammation 
associated with CD will be necessary. Fundamental studies to examine the expression of 
CYP4F2 in CD patients would be interesting. As the 5-LO inflammatory pathway is common 
to various other related disorders examination of associations of these diseases with variants in 
the CYP4F2 would be worthwhile. Of relevance would be also to identify other candidate 
genes in the 5-LO pathway and study their association (either independent or interactions) 
with CD. Our study findings indirectly suggest that imbalances in dietary fatty acids could 
impact the pathogenesis of CD. Future studies investigating interactions between dietary 
consumption of fatty acids, 5-LO pathways genes and risk for CD could provide insights for 
preventive or therapeutic interventions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table XXII - Comparison between the distribution of clinical  
 characteristics at diagnosis in the 2 case-populations    
(i.e. case-parent and case-control designs) versus the evidence 
from the published literature. 
Clinical Characteristics at diagnosis 
Case-
Parent 
Design (%)
Case-
Control 
Design 
(%) 
Published 
data for 
pediatric 
CD* (%) 
Disease Location  
Ileum with or without upper digestive tract  13.7 17.8 5.9 
Colon with or without upper digestive tract 28.7 26.2 36.3 
Ileum and colon with(out)  upper digestive tract 57.5 56 50.5 
Disease Behaviour  
Inflammatory  88 84.8 78.8 
Stricturing 8.1 9.8 7.7 
Perforating 3.1 5.4 8.4 
 
* after (Van Limbergen, Russell et al. 2008) 
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APPENDIX 1 
Crohn’s disease (CD) patients and controls  
recruitment and acquisition of clinical information
Phase 1 - Screening Study  
(case-parent design) 
Phase 2 - Replication Study 
(case-control design) 
Cases  Controls  
 
Pediatric case-population from:  
Hopital Ste. Justine (HSJ),  
British Columbia Children’s Hospital 
(BCCH), and 
The Children’s Hospital of Eastern Ontario 
(CHEO) 
Pediatric case-population from:  
Hopital Ste. Justine (HSJ),  
and 
The Children’s Hospital of Eastern 
Ontario (CHEO) 
Source population: 
1. Pediatric Orthopedic Departments – 
HSJ and CHEO; 
2. Healthy adults from Saguenay-Lac-
Saint-Jean region; 
3. Newborns. 
A. Identification of patients diagnosed with 
CD at the 3 hospitals: 
1. HSJ (2003-2007): incident + prevalent 
cases; 
2. BCCH (2004): incident cases; 
3. CHEO (2006-2007): incident cases. 
A. Identification of patients diagnosed 
with CD at the 3 hospitals: 
1. HSJ (2003-2007): incident + 
prevalent cases; 
2. CHEO (2006-2007): incident cases. 
Selection of controls: 
1. Children with minor traumas; 
2. Participants in a population genetics 
study at HSJ; 
3. Cord Blood Biobank at HSJ. 
B. Confirmation of diagnosis (minimal 
follow-up 12 months or latest diagnosis for 
new patients) 
 
B. Confirmation of diagnosis (minimal 
follow-up 12 months or latest diagnosis 
for new patients) 
 
Exclusions: 
1. Children with immune mediated 
diseases (asthma, juvenile diabetes, celiac 
disease etc); 
2. None; 
3. None. 
C. Acquired clinical information from 
medical charts and biological samples were 
collected. 
C. Acquired clinical information from 
medical charts 
Cascade recruitment of controls: 
1. Siblings of healthy children with minor 
traumas.  
D. Patients with Ulcerative Colitis (UC) 
and Indeterminate Colitis (IC) excluded 
D. Patients with Ulcerative Colitis (UC) 
and Indeterminate Colitis (IC) excluded 
E. Patients and parents contacted and 
invited for participation 
E. Patients contacted and invited for 
participation 
F. Information collection F. Information collection 
Information collection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 2 
 
Relevant clinical information acquired from  
Crohn’s disease (CD) patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CLINICAL INFORMATION FOR CROHN’S DISEASE (CD) PATIENTS 
 
Date completed: ______/_______/_______ 
  Day Month Year 
 
Study ID: ______________ 
Age: _______/_______ 
 Years   Months 
Sex: ____________ 
 
Diagnosis:  
Ulcerative Colitis :______  Crohn’s Disease______ Indeterminate colitis_____ 
Date of Diagnosis: ____/_____/_____ 
    Day   month year 
 
CLINICAL DATA 
 
Intestinal manifestations 
 
    Yes No Unknown 
Urgency    ____ ____ ____ 
Nocturnal diarrhea  ____ ____ ____ 
Incontinence   ____ ____ ____ 
Tenesmus   ____ ____ ____ 
Diarrhoea   ____ ____ ____ 
Abdominal pain   ____ ____ ____ 
Rectal bleeding   ____ ____ ____ 
Fistula: 
 Perianal   ____ ____ ____ 
 Enteroenteric  ____ ____ ____ 
 Enterocutaneous  ____ ____ ____ 
 Rectovaginal  ____ ____ ____ 
 Enterovesicular  ____ ____ ____ 
 Enterolabial  ____ ____ ____ 
 Other: ____________ ____ ____ ____ 
Fissure    ____ ____ ____ 
Internal abscess   ____ ____ ____ 
Perianal abscess   ____ ____ ____ 
Others __________________ ____ ____ ____ 
 _________________ ____ ____ ____ 
 
Extraintestinal manifestations 
 
  
Growth parameters Weight ____________% Height ________________% 
 
     
 
 
Yes No Unknown 
Skin 
Erythema Nodosum  ____ ____ ____ 
Pyoderma Gangrenosum  ____ ____ ____ 
Psoriasis    ____ ____ ____ 
 
Eyes 
Iritis    ____ ____ ____ 
Conjuctivitis   ____ ____ ____ 
Uveitis    ____ ____ ____ 
Episcleritis   ____ ____ ____ 
  
Musculoskeletal 
 
Arthritis    ____ ____ ____ 
Sacroileitis   ____ ____ ____ 
Arthralgia   ____ ____ ____ 
Ankylosing Spondylitis  ____ ____ ____ 
Clubbing   ____ ____ ____ 
 
Liver 
Viral hepatitis   ____ ____ ____ 
Sclerosing Cholangitis  ____ ____ ____ 
Autoimmune hepatitis  ____ ____ ____ 
Nonspecific elevated liver tests ____ ____ ____ 
Other _______________________ ____ ____ ____ 
 
Miscellaneous 
Gallstones   ____ ____ ____ 
Aphthae    ____ ____ ____ 
Nephrolithiasis   ____ ____ ____ 
Pouchitis   ____ ____ ____ 
Malnutrition   ____ ____ ____ 
Obstruction; site _____________ ____ ____ ____ 
Osteoporosis/Osteomalacia ____ ____ ____ 
Fatigue   ____ ____ ____ 
  
 
Disease location (Anatomic extent of disease) 
Oropharyngeal ___ Esophagus ____  Stomach  ____
  Duodenum ____ 
Jejunum ____  Ileum ____  Cecum ____  Ascending colon 
____ 
Transverse colon ____ Descending colon ____ Sigmoid colon ____ Rectum 
____ 
 
Perianal ____  Anal ____ 
 
 
Disease behavior 
Stricturing ____ (colon ____, small bowel ____)  UC-like ____ 
Internal perforating ____ (colon ____, small bowel ____) Perianal perforating ____ 
Non perforating/non stricturing ____ 
 
Disease activity 
    Yes No 
No activity   ____ ____ 
Mild activity   ____ ____ 
Moderate activity   ____ ____ 
High activity   ____ ____ 
Fulminate activity 
Laboratory data 
CBC with manual differentiation: WBC__________ Hgb________ MCV _______ PLT 
_______ 
 
ABS Polys _____________ ABS lymphs __________ 
 
CRP ______________  ESR _______________ Albumin ___________ 
 
Vit. B12 _____________ Vitamin D _____________ 
 
RBC folate _____________ Amylase ___________ Lipase ___________ 
 
ALT _____________ AST _______________ Total bilirubin ____________ 
 
Alkaline phosphatase _________ Iron __________ 
  
 
 
 
 
 
DIAGNOSTIC DATA 
 
Endoscopic studies 
 
    Disease Location 
Pr
oc
ed
ur
e 
D
at
e 
BX 
H
os
p 
O
P 
E S D J I C A
C 
T
V 
D
C 
S
C 
R P A 
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
(BX: Barium X-ray; OP: oropharynx; E: eosophagus; S: Stomach; D: Duodenum; J: Jejunum; 
I: ileum; C: caecum; AC: ascending colon; TV: transverse colon; D: descending colon; SC: 
sigmoid colon; R: rectum; P: perinanal; A: anal) 
 
Histopathologic studies 
 
 
 Disease Location 
Findings OP E S D J I C A
C 
TV D
C 
SC R P A 
CD compatible               
Granulomas               
UC compatible               
Indeterminate 
colitis 
              
(OP: oropharynx; E: eosophagus; S: Stomach; D: Duodenum; J: Jejunum; I: ileum; C: 
caecum; AC: ascending colon; TV: transverse colon; D: descending colon; SC: sigmoid 
colon; R: rectum; P: perinanal; A: anal) 
  
 
 
 
 
Radiologic studies 
 
 
    Disease Location 
Pr
oc
ed
ur
e 
D
at
e 
H
os
p.
 
Fi
nd
in
g 
O
P 
E S D J I C A
C 
T
V 
D
C 
S
C 
R P A 
                  
                  
                  
                  
                  
                  
                  
                  
                  
                  
(H: Hospital; OP: oropharynx; E: eosophagus; S: Stomach; D: Duodenum; J: Jejunum; I: 
ileum; C: caecum; AC: ascending colon; TV: transverse colon; D: descending colon; SC: 
sigmoid colon; R: rectum; P: perinanal; A: anal) 
 
 
 
 
MANAGEMENT DATA 
 
Surgery procedures 
 
 
# of IBD surgeries ________ 
Small bowel resection  with ileostomy ____ without ileostomy ____ 
Large bowel resection segmental with colostomy ____ segmental without colostomy 
____ 
   subtotal colectomy with colostomy ____ subtotal colectomy 
without colostomy ____ 
   total colectomy with colostomy ____ total colectomy with ileoanal 
pull-through ____ 
 
  
Stricturoplasties ____ 
Asbcess drainage ____ 
Indication  Bleeding ____ Perforation ____ Obstruction ____ Other ____ 
(____________________) 
 
Hospitalization 
 
Indication __________________________________________ 
Intervention _________________________________________ 
 
Initial medical management/Drug-related adverse events 
 
Allergies No ____  Yes ____  Specify 
_____________________ 
 
1. Mesalamine 
 
Asacol  Previous  ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose ________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
Pentasa  Previous  ____ , date started ____________ date stopped 
_________ dose ________ 
  Current ____ , date started ____________   dose ________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
Sulfasalazine Previous  ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose ________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
Balsalazide Previous  ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose ________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
Rowasa enema Previous  ____ , date started ____________ date stopped 
_________ dose ________ 
  Current ____ , date started ____________   dose ________ 
  
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
Rowasa suppository 
  Previous  ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose ________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
 
 
 
 
Corticosteroids  Never used steroids ____ 
 
Prednisone First course ____ , date started ____________ date stopped _________ 
dose ________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
  Second course ____ , date started ____________   dose 
________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
Third course ____ , date started ____________   dose 
________  Disease activity when steroids started: Mild      Moderate     
Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
  
   
Budesonide First course ____ , date started ____________ date stopped _________ 
dose ________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
  Second course ____ , date started ____________   dose 
________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
Third course ____ , date started ____________   dose 
________  Disease activity when steroids started: Mild      Moderate     
Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
 
Other steroid medication 
First course ____ , date started ____________ date stopped _________ dose ________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
  Second course ____ , date started ____________   dose 
________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
  
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
Third course ____ , date started ____________   dose 
________  Disease activity when steroids started: Mild      Moderate     
Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
 
Cortisone enema/foam 
First course ____ , date started ____________ date stopped _________ 
dose ________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
  Second course ____ , date started ____________   dose 
________ 
  Disease activity when steroids started: Mild      Moderate     Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
 If yes, date of surgery:  
 
Third course ____ , date started ____________   dose 
________  Disease activity when steroids started: Mild      Moderate     
Severe 
  Responded to steroids:   Yes   No 
Able to taper off steroids  Yes ____  No ____ 
Side effects No ____  Yes ____  Specify: 
____________________ 
Underwent surgery  Yes   No  
  
 If yes, date of surgery:  
 
 
Immunomodulator therapy 
 
Imuran  Previous ____ , date started ____________ date stopped _________ dose 
________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
6 MP  Previous  ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
  TPMT testing performed  Yes ____ No ____ 
 
Cyclosporine Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
MTX  Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
FK 506  Previous  ____ , date started ____________ date stopped 
_________ dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
Celcept/MMF Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  
  Side effects No ____  Yes ____ Specify: 
____________________ 
 
Infliximab Usage  Yes____ No____ 
  Date of infusion _______________ Improvement No____ Yes____ 
  Date of infusion _______________ Improvement No____ Yes____ 
  Date of infusion _______________ Improvement No____ Yes____ 
  Date of infusion _______________ Improvement No____ Yes____ 
  Date of infusion _______________ Improvement No____ Yes____ 
 
Antibiotics 
 
Metronidazole Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No____  Yes____  Specify: 
____________________ 
 
Ciprofloxacin Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No____  Yes____  Specify: 
____________________ 
 
Neomycin Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No____  Yes____  Specify: 
____________________ 
 
Pain medication  
  Name: ________________________________ 
  Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No____  Yes____  Specify: 
____________________ 
 
  
Anti-diarrheal medication 
  Name: ________________________________ 
  Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No____  Yes____  Specify: 
____________________ 
 
TPN  Yes____  No____ 
 
Enteral  
Nutrition Yes____  No____  Name 
________________________ 
 
Supplements Name (vitamins, herbs, probiotics) ______________________________ 
  Previous ____ , date started ____________ date stopped _________ 
dose ________ 
  Current ____ , date started ____________   dose 
________ 
  Side effects No____  Yes____  Specify: 
____________________ 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 3 
 
Tag – SNP selection sequence for  
CYP4F2 and ALOX5 genes 
 
 
 
 
 
 
 
 
 
 
  
 
Gene Name: CYP4F2 
Gene ID: 8529 
Chromosome 19: 15849833 - 15869884 (-) 
Allele Frequency Cutoff (%): 0 
R2 Threshold for Clusters: 0.8 
Minimal Genotype Coverage (%) of Snps to Be TagSnps: 85 
Minimal Genotype Coverage (%) of Snps to Be Clustered: 70 
Data Merging: common samples with combined variations 
Population: PGA-EUROPEAN-PANEL, Submitter: PGA-UW-FHCRC 
Bin Total Number of Sites 
Average Minor 
Allele 
Frequency 
Tag SNPs Other SNPs 
1 25 11 % 
rs2074902 
rs3093098 
rs3093173 
rs2006193 
rs2365178 
rs3093100 
rs3093103 
rs3093105 
rs3093106 
rs3093110 
rs3093112 
rs3093114 
rs3093115 
rs3093116 
rs3093120 
rs3093121 
rs3093122 
rs3093124 
rs3093128 
rs3093129 
rs3093134 
rs3093135 
rs3093160 
rs3093167 
rs3093180 
2 6 47 % 
rs1126433 
rs2074900 
rs3093097 
rs3093194 
rs3093195 
  
rs3093203 
3 6 39 % 
rs3093145 
rs3093148 
rs3093159 
rs3093170 
rs3093182 
rs3093156 
4 4 24 % 
rs1272 
rs758154 
rs3093184 
rs3093190 
 
5 4 5 % 
rs2215092 
rs3093150 
rs3093153 
rs3093224 
 
6 3 27 % 
rs3093158 
rs3093166 
rs3093168 
 
7 2 21 % 
rs3093193 
rs3093199 
 
8 2 7 % 
rs3093200 
rs3093204 
 
9 2 4 % 
rs3093220 
rs3093222 
 
10 1 0 % rs736089  
11 1 11 % rs2016503  
12 1 17 % rs2108622  
13 1 7 % rs2886296  
14 1 0 % rs3093093  
15 1 0 % rs3093094  
16 1 0 % rs3093095  
17 1 0 % rs3093096  
18 1 0 % rs3093099  
19 1 0 % rs3093101  
20 1 0 % rs3093102  
21 1 0 % rs3093104  
22 1 0 % rs3093107  
23 1 0 % rs3093108  
24 1 0 % rs3093109  
25 1 0 % rs3093111  
26 1 0 % rs3093113  
27 1 0 % rs3093117  
28 1 0 % rs3093118  
29 1 0 % rs3093119  
  
30 1 0 % rs3093123  
31 1 0 % rs3093125  
32 1 0 % rs3093126  
33 1 0 % rs3093127  
34 1 0 % rs3093130  
35 1 0 % rs3093131  
36 1 0 % rs3093132  
37 1 0 % rs3093133  
38 1 0 % rs3093136  
39 1 0 % rs3093137  
40 1 0 % rs3093138  
41 1 0 % rs3093139  
42 1 0 % rs3093140  
43 1 0 % rs3093141  
44 1 0 % rs3093143  
45 1 10 % rs3093144  
46 1 0 % rs3093146  
47 1 0 % rs3093147  
48 1 0 % rs3093149  
49 1 0 % rs3093151  
50 1 0 % rs3093152  
51 1 0 % rs3093154  
52 1 0 % rs3093155  
53 1 0 % rs3093157  
54 1 0 % rs3093161  
55 1 0 % rs3093162  
56 1 0 % rs3093163  
57 1 0 % rs3093165  
58 1 0 % rs3093171  
59 1 0 % rs3093172  
60 1 0 % rs3093174  
61 1 0 % rs3093175  
62 1 0 % rs3093176  
63 1 0 % rs3093177  
64 1 0 % rs3093178  
65 1 0 % rs3093179  
66 1 0 % rs3093181  
67 1 0 % rs3093183  
68 1 0 % rs3093185  
69 1 0 % rs3093186  
70 1 0 % rs3093188  
71 1 0 % rs3093189  
72 1 0 % rs3093191  
  
73 1 0 % rs3093192  
74 1 0 % rs3093196  
75 1 0 % rs3093197  
76 1 30 % rs3093198  
77 1 0 % rs3093201  
78 1 2 % rs3093218  
79 1 2 % rs3093219  
80 1 4 % rs3093223  
81 1 2 % rs3093225  
82 1 7 % rs3093226  
83 1 2 % rs3093227  
84 1 0 % rs3093142  
85 1 3 % rs3093221  
 
Variation Color code: 
splice-site 
coding-nonsynonymous 
coding-synonymous 
coding 
mrna-utr 
 
 
 
 
 
 
 
 
  
 
Gene Name: ALOX5 
Gene ID: 240 
Chromosome 10: 45189634 - 45261567 (+) 
Allele Frequency Cutoff (%): 0 
R2 Threshold for Clusters: 0.8 
Minimal Genotype Coverage (%) of Snps to Be TagSnps: 85 
Minimal Genotype Coverage (%) of Snps to Be Clustered: 70 
Data Merging: common samples with combined variations 
Population: AFD_EUR_PANEL, Submitter: PERLEGEN 
Bin Total Number of Sites 
Average Minor 
Allele 
Frequency 
Tag SNPs Other SNPs 
1 5 13 % 
rs3824613 
rs12783095 
rs17157728 
rs17157733 
rs17157736 
 
2 3 15 % 
rs745986 
rs11239501 
rs17444064 
 
3 3 2 % 
rs7077173 
rs7917687 
rs17157771 
 
4 2 43 % 
rs1369214 
rs2115819 
 
5 2 12 % 
rs1487562 
rs7080474 
 
6 2 32 % 
rs1565096 
rs17523178 
 
7 2 43 % 
rs3780901 
rs7090328 
 
8 1 2 % rs2228064  
9 1 6 % rs2288619  
10 1 42 % rs2291427  
11 1 2 % rs3780905  
12 1 38 % rs7080713  
13 1 0 % rs10128306  
  
14 1 48 % rs10751383  
15 1 0 % rs11239499  
16 1 0 % rs11239500  
17 1 0 % rs11239502  
18 1 0 % rs11239503  
19 1 0 % rs11239504  
20 1 38 % rs12264801  
21 1 0 % rs17153289  
22 1 0 % rs17157731  
23 1 0 % rs17157756  
24 1 0 % rs17157784  
25 1 4 % rs17522720  
 
Variation Color code 
splice-site 
coding-nonsynonymous 
coding-synonymous 
coding 
mrna-utr 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
APPENDIX 4 A+B 
A - Models of power calculations for the  
case-parent design 
B - Models of power calculations for the  
case-control only design 
 
 
 
 
 
 
 
 
  
Summary Table: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allele 
frequency 
Alpha Power Model 
Relative 
risk 
Trios 
required 
10% 0.05 80% Additive 2.0 141 
   Additive 1.8 203 
   Recessive 2.0 1587 
   Recessive 4.0 271 
   Dominant 2.0 175 
   Dominant 2.2 133 
20% 0.05 80% Additive 2.0 87 
   Additive 1.7 152 
   Recessive 2.0 448 
   Recessive 3.0 147 
   Dominant 2.0 130 
   Dominant 1.8 165 
30% 0.05 80% Additive 2.0 71 
   Additive 1.5 213 
   Additive 1.7 123 
   Recessive 2.0 233 
   Recessive 2.5 123 
   Dominant 2.0 130 
   Dominant 1.8 177 
50% 0.05 80% Additive 2.0 69 
   Additive 1.6 146 
   Recessive 2.0 129 
   Recessive 1.8 182 
   Dominant 2.0 189 
   Dominant 2.2 152 
  
Model # 1 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   
 Mode of inheritance:         Log-additive 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000121 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      141    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 2 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000117 
  
    RG:       1.8000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      203    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 3 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000119 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      175    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 4 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
  
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000123 
    RG:       2.2000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      133    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 5 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000101 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                     1587    bG=0       bG         ---- 
  
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 6 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000103 
    RG:       4.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      271    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
 
Model # 7 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
  
   Allele frequency:            0.2000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000144 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                       87    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 8 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.2000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000130 
    RG:       1.7000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      152    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
 
  
 
Model # 9 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.2000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000136 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      130    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 10 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.2000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000125 
  
    RG:       1.7000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      222    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 11 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.2000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000131 
    RG:       1.8500                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      165    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 12 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
  
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.2000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000104 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      448    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 13 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.2000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000108 
    RG:       3.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      147    bG=0       bG         ---- 
  
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 14 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.3000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000169 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                       71    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 15 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.3000 
  
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000132 
    RG:       1.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      213    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 16 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.3000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000146 
    RG:       1.7000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      123    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 17 
Outcome:                        Disease 
  
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.3000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000151 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      130    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 18 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.3000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000141 
    RG:       1.8000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
  
------------------------------------------------------------------ 
Gene                      177    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 19 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.3000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000109 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      233    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 20 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
  
   Mode of inheritance:         Recessive 
   Allele frequency:            0.3000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000118 
    RG:       3.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                       80    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 21 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.3000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000114 
    RG:       2.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      123    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
  
 
Model # 22 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.5000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000225 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                       69    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 17 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.5000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000156 
  
    RG:       1.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      195    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 18 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.5000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000169 
    RG:       1.6000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      146    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 19 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
  
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.5000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000175 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      189    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 20 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.5000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000190 
    RG:       2.2000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      152    bG=0       bG         ---- 
  
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 21 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.5000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000125 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      129    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
Model # 22 
Outcome:                        Disease 
Design:                         Case-parent 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 2-sided 
Gene 
   Mode of inheritance:         Recessive 
   Allele frequency:            0.5000 
  
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000120 
    RG:       1.8000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      182    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of case-parent trios required for the desired power 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Summary Table: 
 
Allele 
frequency 
Alpha (1-
sided) 
Power Model Relative 
risk 
Cases* 
22% 0.05 80% Additive 1.6 121 
   Additive 1.4 242 
   Dominant 2.0 175 
   Dominant 2.2 133 
35% 0.05 80% Additive 1.3 318 
   Additive 1.4 192 
   Dominant 1.6 203 
   Dominant 1.5 270 
45% 0.05 80% Additive 1.3 301 
   Additive 1.5 127 
   Dominant 2.0 130 
   Dominant 1.8 177 
*Based on a case-control ratio of ~1:1.5. The allele frequencies correspond to the following 
CYP4F2 SNPs: rs1272 (22%), rs3093158 (35%) and rs3093145 (45%), that were estimated in 
the pseudo-controls in the screening case-parent study. 
 
Dominant Model: 
Model # 1 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
  
    P0:     0.000100               *kp:     0.000119 
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      115    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 2 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000109 
    RG:       1.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      360    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
 
  
Model # 3 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.1000 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000113 
    RG:       1.7000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      203    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 4 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.2200 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000139 
  
    RG:       2.0000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                       87    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 5 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.2200 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000120 
    RG:       1.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      255    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
 
 
  
Model # 6 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.2200 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000123 
    RG:       1.6000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      190    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 7 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.4500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000135 
  
    RG:       1.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      328    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 8 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.4500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000156 
    RG:       1.8000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      164    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 9 
Outcome:                        Disease 
  
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.4500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000142 
    RG:       1.6000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      248    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Multiplicative Model: 
 
Model # 1 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.2200 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000138 
  
    RG:       1.8000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                       75    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 2 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.2200 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000128 
    RG:       1.6000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      121    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
 
 
  
Model # 3 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.2200 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000118 
    RG:       1.4000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      242    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 4 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.3500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000130 
  
    RG:       1.4000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      192    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 5 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.3500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000122 
    RG:       1.3000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      318    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
 
 
  
Model # 6 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.3500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000146 
    RG:       1.8000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      133    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 7 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.3500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000129 
  
    RG:       1.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      270    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 8 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Dominant 
   Allele frequency:            0.3500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000135 
    RG:       1.6000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      203    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
 
 
  
Model # 9 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.4500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000150 
    RG:       1.5000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      127    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
Model # 10 
Outcome:                        Disease 
Design:                         Unmatched case-control (1:1.5) 
Hypothesis:                     Gene only 
Desired power:                  0.800000 
Significance level:             0.050000, 1-sided 
Gene 
   Mode of inheritance:         Log-additive 
   Allele frequency:            0.4500 
Disease model                   Summary parameters 
    P0:     0.000100               *kp:     0.000129 
  
    RG:       1.3000                (*indicates calculated value) 
 
Parameter                   N    Null       Full       Reduced 
------------------------------------------------------------------ 
Gene                      301    bG=0       bG         ---- 
------------------------------------------------------------------ 
N is the number of cases required for the desired power 
The required number of controls is 1.5xN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
